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Introduction: Conventionally, irritable bowel syndrome (IBS) is subgrouped using 
predominant stool pattern, yet it is a complex disorder, with multiple biopsychosocial 
contributors. This thesis aimed to explore an alternative approach to subgrouping by 
incorporating factors beyond stool pattern alone. 
Methods: Two network meta-analyses, examining the relative efficacy of secretagogues 
for IBS-C, and of pharmacological therapies for IBS-D or IBS-M, respectively, were 
conducted to evaluate the merits of subgrouping people with IBS using stool pattern 
alone. A large cohort of people who self-identified as having IBS was recruited, and the 
clinical and psychological differences between individuals based on the Rome IV versus 
Rome III criteria were examined. In the same cohort, latent class analysis was used to 
derive new IBS subgroups by combining data on gastrointestinal symptoms and 
psychological health. Longitudinal follow-up was undertaken to assess the natural 
history and prognostic value of these new subgroups. 
Results: The efficacy of treatments for both IBS-C and IBS-D or IBS-M was modest 
overall, with little difference between individual drugs. In total, 1375 individuals who 
self-identified as having IBS were recruited. Individuals with Rome IV-defined IBS had 
significantly more severe symptoms and poorer psychological health, compared with 
those who only met the Rome III criteria for IBS. In both Rome IV and Rome III-
defined IBS, people could be divided into seven distinct subgroups defined by a pattern 
of gastrointestinal symptoms (diarrhoea-related, constipation-related, or mixed) and 
further differentiated by the presence of abdominal pain not relieved by defaecation, and 
by the extent of psychological comorbidity. Follow-up showed that people in clusters 
with high psychological burden at baseline had significantly more severe symptoms at 
follow-up, which had a greater impact on daily activities, received a significantly higher 
viii 
 
mean number of subsequent treatments, and were significantly more likely to consult a 
doctor than people in clusters with low psychological burden.  
Conclusions: Directing treatment according to predominant stool pattern alone results 
in modest outcomes at best. Additional factors, such as psychological health, may 
influence treatment response, and people with IBS can be divided into unique subgroups 
characterised by differences in gastrointestinal symptoms, extra-intestinal symptoms, 
and mood. Subgroups with higher psychological burden were predictive of a more 
severe disease course. Personalising treatment according to these novel subgroups, 
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Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder. It is a 
common condition, affecting 5-10% of people worldwide at any given time. The impact 
of IBS on the individual, in terms of their quality of life, and on healthcare services and 
society as a whole, in terms of economic costs, is substantial. A diagnosis of IBS is 
made using the Rome criteria. These are symptom-based criteria that define IBS 
according to a specific pattern of gastrointestinal symptoms reported by the patient; 
namely, the presence of abdominal pain related to defaecation, associated with a change 
in stool pattern. The predominant stool pattern reported is used to subgroup patients in 
order to guide treatment. The pathophysiology of IBS is complex and incompletely 
understood. Psychological comorbidity, psychological stressors, such as a history of 
trauma and abuse, and previous enteric infection have all been recognised as risk factors 
for developing IBS. Moreover, additional factors, such as genetics, dietary changes, 
alterations in the gut microbiome, and physiological mechanisms, such as visceral 
hypersensitivity, have been identified as playing a potential role in the pathogenesis of 
the condition. In recognition of the fact that IBS is a disorder with multiple 
biopsychosocial influences, recent revisions to diagnostic criteria have reclassified IBS 
as a disorder of gut-brain interaction. Treatment of IBS should start by providing the 
patient with a clear explanation about the condition using a sensitive and empathic 
approach to communication. Drug treatment is focussed on addressing a patient’s most 
troublesome gastrointestinal symptoms; antispasmodic drugs, laxatives, and 
antidiarrhoeals can all be used first-line, in addition to simple dietary and lifestyle 
changes, such as increases in fibre intake. If patients fail to respond to these, central 
neuromodulators, such as tricyclic antidepressants (TCAs), can be tried, and more 
recently a number of second-line drugs targeting abnormal stool pattern have been 
developed. Psychological therapies are also beneficial, but identifying who is most 
likely to benefit from these in everyday clinical practice is difficult, partly because 
3 
 
routine assessment of psychological comorbidity is not currently considered in the 
diagnosis or subgrouping of the condition. Consequently, other approaches to 
subgrouping patients, which incorporate factors beyond stool pattern, may better 
represent the complex, multifaceted nature of IBS, and facilitate a more personalised 
approach to treatment, with the potential to improve outcomes. 
This chapter will provide an overview of how the definition of IBS has evolved 
over time, including the concurrent development of symptom-based diagnostic criteria. 
The current practice of subgrouping people with IBS according to their predominant 
stool pattern will be examined in detail, and the grounds for exploring new approaches 
to subgrouping patients that look beyond gastrointestinal symptoms will be appraised in 
order to understand the rationale for conducting the body of work presented in this 
thesis. The epidemiology, natural history, and impact of IBS will be reported with a 
view to highlighting the importance of IBS to healthcare infrastructure and to society, as 
well as to individual patients with the condition. Risk factors for the development of 
IBS, and the pathophysiology of the disorder, will be summarised for the purpose of 
exploring which factors, in addition to gastrointestinal symptoms, could be incorporated 
into novel subgrouping models. Finally, the management of IBS will be evaluated in 
order to inform discussion of how new approaches to subgrouping people with IBS 
might be used to personalise treatment. 
1.1 Defining Irritable Bowel Syndrome 
The definition of IBS that is widely used in clinical and research practice today 
was first proposed by the Rome Foundation 30 years ago; however, the earliest 
descriptions of the disorder can be traced back to the observations of physicians made 
two centuries ago. Although our understanding of the epidemiology, pathophysiology, 
and treatment of this common gastrointestinal disorder has advanced considerably since 
that time, knowledge that has informed several revisions to the Rome Foundation 
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definition of IBS, it is striking that throughout its history, IBS has always been defined 
according to a specific pattern of gastrointestinal symptoms reported by the patient. 
1.1.1 Historical Context 
In his paper On Certain Painful Affections of the Intestinal Canal, published in 
1820, the physician Dr Richard Powell gave a description of a disorder characterised by 
the presence of abdominal pain and the passage of mucus per rectum. 1 At that time, the 
cause of such symptoms was generally attributed to intestinal inflammation, but Powell 
noted that “the most remarkable circumstance in the history of [these] cases was the 
production of an effect usually ascribed to inflammatory action without its previous 
existence”. 2 This observation appears to be the first recognition of a clinical situation in 
which a patient may report physical gastrointestinal symptoms in the absence of clear 
organic pathology. It is similar to Sir William Osler’s later description that the mucus 
was “closely adherent to the mucosa of the colon, but capable of separation without any 
lesion on the surface”. 3  
In a subsequent paper from 1859, published in The Lancet, Dr Andrew Clark of 
the London Hospital, described his experience of the “mucous disease of the colon”. 4 
He characterised this as a single disorder with three stages, although it is more likely 
from his descriptions that these stages, in fact, represented separate gastrointestinal 
diseases, including inflammatory bowel disease. The first stage, however, was a benign 
disorder, from which the patient “generally recovered”, akin to Powell’s earlier 
observations. Clark recommended treatment by removal of the mucus using laxatives or 
enemas, followed by a range of treatments to prevent recurrence. Some of these 
suggestions, such as the “application of cutaneous friction”, were almost certainly of 
little value. However, Clark also reported success with various therapeutic strategies 
that are still in use today, including dietary modification, with the exclusion of 
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vegetables and fruits, avoidance of caffeine and alcohol, daily exercise, and the 
regulation of the bowel with “astringents and tonics”.  
A more detailed case series describing this disorder, instead referred to as 
“membranous enteritis”, was provided by the American physician J. M. Da Costa, in his 
paper of 1871. 5 The cardinal features were, again, the presence of abdominal pain and 
the passage of mucus, but Da Costa elaborated further, describing a chronic disorder, 
with distinct exacerbations, that may, in more severe cases, be continuous. Moreover, he 
also noted that a change in bowel habit was a hallmark of the condition: “Between 
attacks the bowels are irregular, sometimes constipated, at others loose; and tenesmus is 
often complained of”.  
These 19th century observations were summarised by Sir William Osler as a 
disease called “mucous colitis” in his esteemed work of 1892, The Principles and 
Practice of Medicine. 3 Osler noted that the condition had a strong female 
predominance, with 80% of recorded cases affecting women. At the time, it was felt that 
the condition had a primarily psychological basis, with hysteria, hypochondriasis, and 
melancholia being frequently reported amongst sufferers, and “mental emotions and 
worry of any sort” being often cited as the trigger for an attack. A study of 60 cases of 
the disorder, published in The Lancet in 1905, also observed that it was frequently 
associated with many forms of neurosis, and therefore suggested that the nervous 
system might be implicated in its causation. 6 In addition, it was noted that the disorder 
was commoner in younger adults, and in those of higher socioeconomic class. Later 
accounts of “mucous colitis” by Bockus, Bank, and Wilkinson in 1928, 7 although 
different to Osler’s definition in terms of precise clinical characteristics, with 
individuals being primarily “constipated, dyspeptic, and exhausted”, 8 are nevertheless 
similar in their general description of symptoms occurring in the absence of organic 
colonic pathology. Indeed, they describe the rectal mucosa as having a “glistening, 
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glairy, shining, or lustrous” appearance at sigmoidoscopy, 7 descriptions recognisable as 
those of macroscopically normal colonic mucosa.  
By the 1920s, the concept of the spastic colon had emerged, characterised by 
abdominal discomfort or pain, in the absence of organic disease, the colon often 
palpable and tender. Dr John Ryle described 50 such cases in 1928, some of whom also 
reported the passage of mucus per rectum, including 11 individuals who were diagnosed 
as having mucous colitis. 9 Smoking, anxiety, menses, and defaecation were all 
identified as exacerbating the spastic colon, and Ryle also noted that a prior history of 
dysenteric infection was a predisposing factor in some individuals. It was Ryle’s 
opinion that spastic colon and mucous colitis were, in fact, the same condition, a view 
corroborated by another study published in the same year, which suggested that they 
resulted from dysfunction of the autonomic nervous system, possibly related to a 
specific personality disorder. 8 This was explored in detail by White, Cobb, and Jones in 
1939, in a case series of 60 patients with mucous colitis, in which they suggested that 
there was a close relationship between psychological factors and the onset of symptoms, 
mediated via the autonomic nervous system and cholinergic effects on intestinal smooth 
muscle. 10   
The 1920s also saw usage of the term “irritable colon” to describe a situation in 
which normal colonic motility was interrupted due to “a disturbance in the tonus and 
irritability of the musculoneural tissue”. 11 Using investigation with barium enema to 
observe patterns of colonic motility, Jordan and Kiefer identified irritable colon as the 
cause of symptoms in around one-third of patients seen in gastroenterology clinics, 
many of whom reported altered stool consistency. It was not until 1944, however, that 
the specific term “irritable bowel syndrome” was first coined, 12 and began to replace 
previous nomenclature.  
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1.1.2 Early Attempts to Classify Irritable Bowel Syndrome 
In 1962, Chaudhary and Truelove made an initial attempt to systematically 
classify patients with IBS, which they defined as pain of colonic origin, and disordered 
bowel habit, with either diarrhoea or constipation. 13 The passage of mucus per rectum 
might sometimes occur, but this symptom no longer featured as prominently as it had in 
earlier descriptions of the disorder. They conducted a retrospective analysis of 130 
patients who had received a clinical diagnosis of IBS following normal investigation 
with routine bloods, sigmoidoscopy, and barium enema to exclude organic disease. 
Around two-thirds were female, and many reported long-standing symptoms, 
sometimes in excess of 10 years’ duration, at the time of their diagnosis.  
Following a detailed analysis of the clinical features of this cohort, two main 
subgroups of the disorder were identified: those with spastic colon, and those with 
painless diarrhoea. All of the patients in the spastic colon group had abdominal pain, 
considered to be of colonic origin, and a variable bowel habit; sometimes stools were 
normal, and sometimes patients reported either episodes of diarrhoea or constipation, or 
else alternated between the two symptoms. The spastic colon group was the larger of the 
two, comprising around 80% of individuals. The second smaller group, those with 
painless diarrhoea, reported no abdominal pain, and diarrhoea was the sole clinical 
manifestation. Although classified here as a subtype of IBS, painless diarrhoea in the 
absence of organic disease would now be classified as a separate disorder, namely 
functional diarrhoea. 14 Alternatively, these patients may have been suffering from bile 
acid diarrhoea, now known to be a common cause of such symptoms among patients 
with suspected IBS, 15, 16 but remaining hitherto unrecognised at that time, having only 
been first described in 1967.17 All patients underwent a psychological evaluation, and it 
was observed that the presence of psychological factors was especially important for 
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both triggering and perpetuating gastrointestinal symptoms. A small subset of patients 
reported symptom onset following a gastrointestinal infection. 
1.1.3 The Manning Criteria 
Among all of the descriptions of IBS discussed thus far, there is a common 
theme emerging: that the disorder can be identified based on certain patterns of 
gastrointestinal symptoms, occurring in the absence of organic pathology. There is, 
however, no clear consensus as yet regarding which specific pattern of symptoms 
should be preferred, there being marked variability between clinical definitions. This 
highlights the importance of the landmark paper by Manning et al., published in the 
British Medical Journal in 1978, which was the first to propose a clear set of symptom-
based criteria for diagnosing IBS, later termed the Manning criteria. 18 Crucially, these 
criteria were examined to evaluate their ability to discriminate IBS from organic 
disease. Symptom-based diagnostic criteria, although extensively revised over the 
intervening years, remain the cornerstone of IBS diagnosis today, illustrating the vital 
importance of this work to the field. 
109 patients, referred to the outpatient clinic with abdominal pain, diarrhoea, or 
constipation, were asked to complete a questionnaire enquiring about the occurrence, 
over the preceding 12 months, of 15 symptoms thought to be characteristic of IBS. 
When these patients were followed-up, 65 ultimately received a final diagnosis, of 
whom 32 were diagnosed with IBS (49.2%), the remainder having organic pathology. 
The incidence of each of the 15 questionnaire symptoms was compared between the two 
patient groups, identifying four symptoms that were significantly more common among 
patients with IBS: looser stools at onset of pain, more frequent bowel movements at 
onset of pain, pain eased after bowel movement, and visible abdominal distension. Over 
90% of patients with IBS endorsed two or more of these symptoms, compared with only 
30% of those with organic disease. Passage of mucus per rectum and tenesmus, the 
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sensation of incomplete evacuation, were more common among patients with IBS, but 
the difference was not statistically significant. Nevertheless, when these two symptoms 
were used in combination with the other four, the ability to discriminate between IBS 
and organic disease was increased, all six symptoms being present in six patients with 
IBS (19%), but only one patient (3%) with organic disease. The authors suggested that 
the use of these criteria might enable clinicians to be more confident in making a 
diagnosis of IBS, thereby reducing the use of unnecessary investigations. 
1.1.4 The Kruis Score 
In 1984, Kruis et al. proposed a scoring system for diagnosing IBS and 
discriminating it from organic disease. 19 They collected data from 479 consecutive 
outpatient referrals, identifying 399 patients who complained of abdominal pain, 
flatulence, or altered bowel habit. These patients underwent extensive diagnostic 
testing, including laboratory testing of blood and stool, endoscopic investigation, and 
radiological examination, to determine whether they had IBS or were suffering from an 
organic condition. Following this process, 56 patients were excluded for technical 
reasons, leaving 209 with organic disease, 108 with IBS, and 26 with an overlap 
between the two. 
 Patients answered a short questionnaire about their symptoms, and the patient’s 
physician completed a checklist regarding the presence of eight features suggestive of 
organic disease, including blood abnormalities, such as anaemia or raised erythrocyte 
sedimentation rate (ESR), abnormal findings on clinical examination, and concerning 
features in the clinical history, such as blood in the stools. Logistic regression analysis 
was conducted using these data to derive a weighted score for distinguishing IBS from 
organic disease, with typical IBS symptoms reported by the patient attracting positive 
values, and clinical signs suggestive of organic pathology assigned negative values. It 
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was determined that the optimum threshold was a score of ≥44, diagnosing IBS with a 
sensitivity of 64% and a specificity of 99%.  
Following its original publication, the Kruis scoring system has been evaluated 
in three other studies. 20-22 When results from all four studies were combined, 
encompassing a total of 1,171 patients, the pooled sensitivity and specificity were 77% 
(95% confidence interval (CI), 68% - 85%) and 89% (95% CI, 76% - 97%), 
respectively. 23 Despite its reasonable performance for diagnosing IBS accurately, the 
Kruis scoring system, or similar statistical models, have never been widely adopted, 
due, in part, to technological limitations 24 and will, therefore, not be discussed further. 
However, it is worth noting that, more recently, attention has returned to statistical 
modelling approaches for diagnosing and subgrouping IBS, 25-27 and the ready 
availability of computing capabilities, including smartphones, would make such an 
approach easier to utilise nowadays than when it was first proposed. 24 
1.1.5 The Rome Criteria 
Subsequently, the focus returned to the development of symptom-based 
diagnostic criteria for IBS, with factor analysis studies demonstrating that the lower 
gastrointestinal symptoms thought to constitute IBS clustered together, 28 the aim being 
to augment the performance of the existing Manning criteria. 29 This led to the 
publication of the Rome criteria in 1990. 30 These criteria are the work of the Rome 
Foundation, a committee of gastroenterologists and allied academics in the field of 
gastrointestinal health who, based on a consensus of expert opinion, and with reference 
to current available evidence, have sought to categorise not only IBS, but all functional 
gastrointestinal disorders. The Rome criteria continue to be the accepted gold standard 
for diagnosing IBS and, as new research has emerged over the years, the Rome 
Foundation have revised the criteria three times, most recently in 2016. 14 Use of these 
criteria aims to promote making a positive diagnosis of IBS, with recourse to limited 
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clinical investigations, and to facilitate the recruitment of homogeneous populations of 
patients to research studies investigating epidemiology, underlying pathophysiological 
mechanisms, and trials of treatments. 
The original version of the criteria, Rome I, defined IBS according to more 
restrictive criteria than those used previously. 30 They mandated the presence of 
abdominal pain or discomfort, either relieved by defaecation, or else associated with a 
change in the frequency or consistency of stools. In contrast to the Manning criteria, 
which emphasised the presence of looser stools only, 18 it was recognised that a 
constipated bowel habit, with hard or less frequent stools, was equally relevant. The 
passage of mucus was no longer a primary diagnostic criterion, considered instead to be 
a supporting feature of the diagnosis that might be present in some cases, and the same 
applied to the presence of abdominal bloating or distension. Finally, symptoms needed 
to have been present, either continuously or intermittently, for at least 3 months, the first 
time a minimum duration of symptoms had been specified. Similarly, the frequency of 
some symptoms was also detailed, the irregular pattern of defaecation needing to be 
present at least 25% of the time, although formal subgrouping of IBS according to stool 
pattern would not be introduced until Rome II. In addition, the need to avoid 
unnecessary investigation was stipulated, but limited testing, mainly to exclude 
inflammatory pathology, was advised. This comprised blood tests, namely a full blood 
count (FBC) and an ESR, and a sigmoidoscopy.  
 Rome II, the first revision of the criteria, were published in 1999. 31 The key 
diagnostic features, though benefitting from some additional clarification, remained 
essentially unchanged, and although symptoms needed to have been present for at least 
3 of the previous 12 months, it was suggested that these need not have been 
consecutive. Examination of the large bowel, whether endoscopic or radiological, was 
still recommended, but should be guided by factors such as the age of the patient and 
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the nature of their symptoms. The Rome III criteria, published in 2006, retained the 
same cardinal symptoms, abdominal pain or discomfort associated with a change in 
stool frequency or form, but they also defined the minimum required frequency of 
abdominal pain or discomfort for the first time, this being at least 3 days per month over 
the last 3 months. 32 Overall, to diagnose IBS, the full criteria needed to be fulfilled for 
the last 3 months, with symptom onset at least 6 months previously. 
 The most recent iteration of the diagnostic criteria for IBS, Rome IV, were 
published in 2016, and made some important changes compared with their predecessor. 
14 Firstly, “discomfort” was removed from the definition, as this was felt to be a vague 
term that was not understandable in some languages. 33 Second, the minimum required 
frequency of abdominal pain was increased from at least 3 days per month, to at least 1 
day per week. This change reflected the findings of a normative survey showing that 
adopting a higher threshold for the frequency of abdominal pain required to meet 
criteria would lead to fewer healthy people in the general population being misclassified 
as having IBS, potentially making the Rome IV criteria more specific for IBS compared 
with Rome III. 33 Third, it was no longer necessary for abdominal pain to be relieved by 
defaecation. Instead, it should be “related to defaecation”, acknowledging that some 
patients with IBS report that their pain worsens following a bowel movement. 14 
Limited clinical investigation to exclude certain organic diseases that can mimic IBS, 
such as coeliac disease or inflammatory bowel disease, continued to be recommended. 
 The specific details of each version of the Rome criteria are summarised in 




Table 1.1. Symptom-based Diagnostic Criteria for IBS. 





1. Looser stools at onset of pain 
2. More frequent bowel movements at the onset of 
pain 
3. Pain eased after bowel movement (often) 
4. Visible abdominal distension 
5. Mucus per rectum 
6. Feeling of incomplete bowel emptying 
The more of these symptoms that are present, the more 
likely it is that a patient’s abdominal pain, altered bowel 
habit, or both, are due to IBS 
None specified 
Rome I 30 
1. Abdominal pain or discomfort, relieved by 
defaecation, or associated with a change in 
frequency or consistency of stool; and 
2. An irregular pattern of defaecation at least 25% of 
the time (three or more of): 
a. altered stool frequency 
b. altered stool form 
c. altered stool passage 
(straining/urgency/tenesmus) 
d. passage of mucus 
e. bloating or feeling of abdominal distension 
≥3 months 
Rome II 31 
Abdominal discomfort or pain that has two of three 
features: 
a. Relieved with defaecation; and/or 
b. Onset associated with a change in 
frequency of stool; and/or 
c. Onset associated with a change in form of 
stool 
≥12 weeks 
(which need not 
be consecutive) 






Recurrent abdominal pain or discomfort at least 3 days per 
month in the last 3 months associated with two or more of 
the following: 
a. Improvement with defaecation 
b. Onset associated with a change in 
frequency of stool 
c. Onset associated with a change in form of 
stool 
Symptom onset 
≥6 months prior 
to diagnosis 
Rome IV 14 
Recurrent abdominal pain, on average, at least 1 day per 
week in the last 3 months, associated with two or more of 
the following criteria: 
a. Related to defaecation 
b. Associated with a change in frequency of 
stool 
c. Associated with a change in form of stool 
Symptom onset 




1.1.6 Validation of the Rome Criteria for Diagnosing IBS 
The accuracy of the Rome criteria for diagnosing IBS has been examined in a 
number of validation studies. 23, 33-37 Accuracy of a diagnostic test is usually described 
in terms of the sensitivity, the probability of the test being positive if the disease is 
present, and specificity, the probability of the test being negative if the disease is absent. 
However, the positive and negative likelihood ratios (LR), which are derived from the 
sensitivity and specificity, provide a more useful measure of the diagnostic performance 
of a test for use in clinical practice. These summarise how many times more or less 
likely patients with the disease are to have a particular test result than patients without 
the disease. LRs above 10 or below 0.1 are generally regarded as useful for ruling in or 
ruling out a disease, respectively. 38 
A systematic review and meta-analysis from 2008 identified a single eligible 
study reporting the diagnostic accuracy of the Rome I criteria among 602 patients 
referred to a gastroenterology clinic. 23 All patients had symptoms suggestive of IBS 
and underwent investigation to exclude organic disease. The sensitivity and specificity 
of the Rome I criteria for diagnosing IBS were 71% and 85%, respectively, with a 
positive LR of 4.8. At that time, there were no validation studies evaluating the Rome II 
or Rome III criteria; however, a subsequent Canadian study, published in 2013, assessed 
the diagnostic performance of all versions of the Rome criteria published at that time, in 
1,848 consecutive adult patients with gastrointestinal symptoms who underwent 
colonoscopy and testing of coeliac serology to exclude organic disease. 34 The 
sensitivity and specificity of the Rome II criteria were 90.2% and 71.7% respectively, 
with a positive LR of 3.19 and a negative LR of 0.14. Similarly, the Rome III criteria 
had a positive LR of 3.35 and a negative LR of 0.39, whilst sensitivity and specificity 
were 68.8% and 79.5%, respectively. The modest performance of these criteria was 
confirmed by the findings of an updated systematic review from 2015, 35 and a 
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subsequent validation study, which showed very similar performance of the Rome III 
criteria with a positive and negative LR for diagnosing IBS of 3.87 and 0.37, 
respectively. 36 
It is important to note that, overall, the accuracy of the Rome III criteria for 
diagnosing IBS was very similar to the performance of previous iterations. Hence, with 
the publication of Rome IV, the aim was to make the criteria more specific for 
diagnosing IBS, as already described, and validation studies suggest that this aim has 
been achieved. One such study, performed by the Rome Foundation, that included more 
than 800 patients with a functional gastrointestinal disorder, estimated the sensitivity of 
the Rome IV criteria for diagnosing IBS to be 63%. 33 Specificity was reported to be 
97%, based on findings from a separate cohort of almost 6000 people from the general 
population. 33 These results give a positive LR of the Rome IV criteria in diagnosing 
IBS of 21; in other words, patients meeting these criteria are 21 times more likely to 
have IBS than to not have IBS. This calculation was, however, based on findings from 
two separate cohorts, rather than a single validation study. A subsequent independent 
validation study in over 500 patients, which also compared the Rome IV criteria with 
the Rome III criteria, reported more modest performance; the sensitivity and specificity 
were 82.4% and 82.9% respectively, with a positive LR of 4.82 and a negative LR of 
0.21. 37 Nevertheless, the Rome IV criteria performed better than the Rome III criteria, 
the latter having positive and negative LRs for diagnosing IBS of 2.45 and 0.22 
respectively, with a sensitivity of 85.8% and a specificity of 65.0%. 37 Overall, if 
applied to a patient population with a pre-test probability of IBS of 50%, such as might 
be the case in people with lower gastrointestinal symptoms referred to secondary care, 




1.1.7 Clinical Consequences of Moving to the Rome IV Diagnostic Criteria 
for IBS and the Stability of an IBS Diagnosis 
The changes made to the Rome IV criteria for IBS were intended to increase their 
specificity over prior iterations, which, as discussed, had shown only modest success in 
diagnosing IBS among unselected patients with lower gastrointestinal symptoms. 34, 39 
Although recent validation studies suggest this aim has been achieved, 37 because Rome 
IV is more restrictive, the prevalence of IBS among individuals in population-based 
surveys is likely to fall when using the Rome IV criteria. Studies that have examined the 
implications of the changes made between the Rome III and Rome IV criteria for 
diagnosing IBS, however, have suggested that there is limited difference. Aziz et al. 
reported that 85% of 542 patients from a tertiary referral population in Sweden with 
Rome III-defined IBS met the Rome IV criteria, but noted that symptoms were more 
severe among those with Rome IV IBS, and quality of life was impaired to a greater 
extent. 40 A second study, conducted in secondary and tertiary care in the Netherlands, 
reported almost identical findings; more than 85% of people meeting the Rome III 
criteria for IBS still met the Rome IV criteria, albeit symptoms were more severe, and 
quality of life worse, in people with Rome IV-defined IBS. 41  
It is important, however, to recognise that both of these studies have some key 
limitations. Crucially, neither study applied the Rome III and Rome IV criteria for IBS 
simultaneously, but instead approximated Rome IV by using a surrogate measure from 
their existing questionnaire data. In the first study, this comprised the reporting of 
abdominal pain on ≥2 days in the last 10 days, 40 whereas the reporting of abdominal 
pain once per week in a symptom diary was used in the second study. 41 Any 
methodology that approximates the Rome IV criteria retrospectively, rather than 
applying the full criteria contemporaneously, requires caution when interpreting the 
results because the true impact of using the Rome IV criteria relative to the Rome III 
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criteria is likely to have been misrepresented, the effect being at risk of either over- or 
underestimation. 
Another important consideration is what happens to individuals who met Rome III 
criteria for IBS, but who no longer meet criteria for IBS when Rome IV is applied 
instead, in terms of being reclassified to another functional bowel disorder. Only one 
study has examined this, with approximately one-third of patients meeting criteria for 
functional constipation, functional diarrhoea, or functional abdominal bloating or 
distension. 41 This issue is clinically important because disorders like functional 
diarrhoea and functional bloating are less well understood than IBS, with far fewer 
evidence-based treatments available. 
In contrast to the other two studies, a third tertiary care study, which applied both 
iterations of the criteria simultaneously, demonstrated less diagnostic agreement 
between Rome III and Rome IV, with only 45.6% of those with Rome III-defined IBS 
meeting the Rome IV criteria. 42 Symptom severity was once again higher among those 
with Rome IV IBS, but there were few other differences. However, this study included 
only 175 patients with Rome-defined IBS from a highly specialised tertiary care setting 
meaning that the findings may not be generalisable to patients with IBS consulting in 
other clinical settings, such as primary care.  
Overall, further studies, recruiting larger populations of patients with IBS across a 
range of clinical settings, and which apply the Rome III and Rome IV criteria for IBS 
simultaneously, are needed in order to adequately explore the effect of the changes 
made between the two iterations on the characteristics of people with IBS. As well as 
being relevant to clinical practice, this issue has implications for the conduct of research 
studies and drug trials in IBS, where the Rome criteria are commonly used to define 
study inclusion. Indeed, it seems likely that trials recruiting patients according to Rome 
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IV criteria are evaluating treatments in patients with more severe symptoms compared 
with previous trials that used Rome III, and this needs to be considered when 
interpreting study results and comparing treatments. 
1.2 Subgrouping Patients with IBS 
Once a diagnosis of IBS has been made based on the cardinal features, current 
diagnostic criteria advocate subgrouping people with IBS based on their stool pattern, 
and this is intended to help guide treatment. However, because IBS is a disorder with 
multiple biological, psychological, and social influences, the Rome Foundation have 
also recommended evaluating a broader range of factors, not limited to gastrointestinal 
symptoms, in the assessment of anyone with IBS. Currently, this approach is intended 
for use on an individual patient basis only; however, the inclusion of factors beyond 
stool pattern in the formal subgrouping of IBS might create a framework that more 
accurately represents this complex disorder. 
1.2.1 IBS Subgroups Based on Stool Form 
For the first time, the Rome II criteria recommended that patients with IBS 
should be classified into different subgroups based on their stool pattern – those with 
predominant diarrhoea and those with predominant constipation – to help direct 
treatment, and for entry into clinical trials targeting a specific stool pattern. 31 This 
classification system was refined and expanded for Rome III, the different subgroups 
now being defined according to the percentage of all bowel movements with abnormal 
stool form. 32 Patients experiencing hard or lumpy stools for ≥25% of all bowel 
movements and loose or watery stools for <25% of all bowel movements were 
classified as having IBS with constipation (IBS-C), whereas reciprocally, if ≥25% of all 
bowel movements were loose or watery and <25% were hard or lumpy, patients were 
classified as having IBS with diarrhoea (IBS-D). If both stool forms occurred for ≥25% 
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of all bowel movements, patients were classified as having IBS with mixed stool form 
(IBS-M), whereas if there was insufficient abnormality of stool consistency to meet any 
of these three stool subgroups, patients were determined to have IBS unclassified (IBS-
U).  
The Rome IV criteria used a broadly similar system of subgrouping, but with 
two important changes. 14 Firstly, subgrouping calculations were now based only on 
days with at least one abnormal bowel movement, rather than including all bowel 
movements, reflecting the fact that many patients with IBS have periods when their 
bowel movements are normal. Second, abnormal bowel habit was defined with specific 
reference to the Bristol stool form scale (BSFS), 43 whereby constipation refers to BSFS 
types 1 and 2 and diarrhoea refers to types 6 and 7 (Table 1.2). The different approaches 
to subgrouping patients with IBS are shown in Table 1.3. 
Use of this classification system is important because the current management of 
IBS is symptom-based, with treatment choice largely dictated by the patient’s 
predominant stool pattern. Indeed, most drugs used to treat IBS are designed to address 
either constipation or diarrhoea, and hence, if they were used in an incorrect subgroup, 
this might lead to a worsening of bowel symptoms. It is, therefore, important to 
understand, when assessing the clinical utility of the current approach to subgrouping 
patients with IBS, whether these stool subgroups remain stable over time. 
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Table 1.2 The Bristol Stool Form Scale. 43   
Type Description 
1 Separate hard lumps like nuts (difficult to pass) 
2 Sausage shaped but lumpy 
3 Like a sausage but with cracks on its surface 
4 Like a sausage or snake, smooth and soft 
5 Soft blobs with clear-cut edges (passed easily) 
6 Fluffy pieces with ragged edges, a mushy stool 




Table 1.3 Subgrouping Patients with IBS According to Different Iterations of the 
Rome Criteria. 
Criteria Method of Subgrouping 
Rome II 31 
 
1. Fewer than three bowel movements a week 
2. More than three bowel movements a week 
3. Hard or lumpy stools 
4. Loose (mushy) or watery stools 




One or more of 2, 4, or 6 and none of 1, 3, or 5 
 
Constipation-predominant: 
One or more of 1, 3, or 5 and none of 2, 4, or 6 
Rome III 32 
 
• IBS-C: hard or lumpy stools ≥25% and loose (mushy) or watery 
stools <25% of bowel movements 
• IBS-D: loose (mushy) or watery stools ≥25% and hard or lumpy 
stools <25% of bowel movements 
• IBS-M: hard or lumpy stools ≥25% and loose (mushy) or watery 
stools ≥25% of bowel movements 
• IBS-U: insufficient abnormality of stool to meet criteria for IBS-C, 
IBS-D, or IBS-M 
Rome IV 14 
 
• IBS-C: Bristol stool form types 1 or 2 ≥25% and Bristol stool form 
types 6 or 7 <25% of bowel movements a 
• IBS-D: Bristol stool form types 6 or 7 ≥25% and Bristol stool form 
types 1 or 2 <25% of bowel movements a 
• IBS-M: Bristol stool form types 1 or 2 ≥25% and Bristol stool form 
types 6 or 7 ≥25% of bowel movements a 
• IBS-U: insufficient abnormality of stool to meet criteria for IBS-C, 
IBS-D, or IBS-M (i.e. Bristol stool form types 1 or 2 <25% and 
Bristol stool form types 6 or 7 <25% of bowel movements a) 
 




1.2.2 Stability of Subgroups Based on Stool Form 
Overall, studies suggest that IBS subgroups defined according to predominant 
stool pattern lack stability. 44-48 One study assessed 317 female patients with Rome II 
IBS using questionnaires and stool diaries at 3-monthly intervals over 1 year. 44 At 
baseline, 36% had IBS-D, 31% IBS-M, and 34% IBS-C, and there were no differences 
between groups, aside from stool frequency. Throughout the 1-year follow-up period, 
although the proportion of individuals in each subgroup remained consistent, more than 
75% of people transitioned to another subgroup at least once. IBS-M was the least 
stable subgroup, and changes between IBS-D and IBS-C were uncommon. Two other 
studies among patients with IBS showed broadly similar findings, with most changes in 
subgroup being either from or to IBS-M, and transition from diarrhoea to constipation 
or vice versa being rare. 45, 46  
In another study of 185 people with Rome III IBS, there was considerable 
variability in stool consistency over a 3-month period – 78% experienced both 
loose/watery and hard/lumpy stools. 47 There was an average of three fluctuations 
between these two stool forms per month; however, an individual’s overall stool pattern 
was stable from month to month. A subsequent study showed that loose/watery stools 
and hard/lumpy stools generally occurred as discrete, well-defined episodes. 48  
Overall, the explanation for this fluctuation between different IBS subgroups 
remains uncertain. A number of factors are likely to be involved, including the natural 
variability of the condition, the impact of treatment, and the role of differing 
pathophysiologies between patients, but the relative importance of these is unknown. 
Furthermore, the degree of fluctuation may vary according to the diagnostic criteria 
used to define IBS. In a recent study, comparing IBS symptoms at baseline and 1-year 
follow-up, there was a change in IBS stool subgroup in up to one-in-three people, and 
this was higher when IBS was defined according to the Rome IV criteria compared with 
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Rome III. 49 Moreover, fluctuation between IBS stool subgroups did not depend solely 
on whether a new treatment was initiated, or whether the choice of treatment was 
deemed appropriate based on IBS stool subgroup at baseline. 
1.2.3 Multi-Dimensional Clinical Profile (MDCP) 
Importantly, although relied upon for classifying patients with IBS, stool pattern 
is only one element of this complex, multi-faceted disorder. As will be discussed, IBS is 
a disorder of gut-brain interaction, and mood and psychological health play an 
important role in the development and persistence of symptoms. 50-54 Moreover, mood 
disorders are much more common in people with IBS than among healthy individuals, 
55 and the reporting of extra-intestinal symptoms, also referred to as somatisation, is 
common. In addition, as will be highlighted, there are multiple risk factors for IBS and 
the pathophysiology is complex, including genetic factors, alterations in the 
microbiome, and changes in visceral sensitivity. Conceivably, therefore, alternative 
approaches, integrating factors other than stool pattern, may offer a more nuanced 
means of classifying people with IBS.  
An alternative algorithm could involve use of gastrointestinal symptoms, 
including stool pattern, in combination with psychological profiles, such as anxiety, 
depression, and extra-intestinal symptoms, as well as key pathophysiologies, for 
example visceral hypersensitivity, which may be an important contributor to symptom 
severity, independent of psychological factors such as somatisation, anxiety, or 
depression. 56 Indeed, there are those patients with IBS whose symptoms are 
predominantly gastrointestinal, and who have only minimal psychological distress and, 
conversely, those patients for whom IBS symptoms are part of a broader picture that 
includes anxiety, depression, and somatisation-type behaviours.  
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In acknowledgment of the fact that IBS is a disorder of gut-brain interaction, 
with biopsychosocial influences, the Rome Foundation developed the multi-dimensional 
clinical profile (MDCP). This is a framework that, in addition to the cardinal clinical 
symptoms needed to make a diagnosis of IBS, includes assessment of additional clinical 
features, psychological factors, and impact of the illness, in order to build a unique 
clinical profile for each patient (Table 1.4). 57 The MDCP is intended to guide a 
clinician in their treatment of an individual patient by focusing attention on a holistic 
approach, aiming to address sometimes overlooked dimensions of the illness 
experience, thereby optimising management. However, the MDCP has yet to be adopted 
into routine clinical practice, and is not incorporated into current diagnostic criteria, but 





Table 1.4 Rome Foundation Multi-Dimensional Clinical Profile for IBS. 57  
Component Explanation 
A. Categorical Diagnosis The standard diagnosis of IBS according to the Rome criteria 
B. Clinical Modifiers 
Additional symptoms or subtypes, historical information, physical 




• Post-infection IBS 
• Stool pattern – IBS-D, -C, -M, or -U 
• Urgency 
• Faecal incontinence 
• Bloating 
• Overlap with inflammatory bowel disease 
C. Impact on Daily Activities 
“Overall, how much do your symptoms currently interfere with 






D. Psychosocial Modifiers 
Psychological and psychosocial modifiers and comorbidities that 
influence the patient’s experience of illness and behaviours that 




• Existing psychiatric or psychological diagnosis, or 
quantitative measure e.g. anxiety state using hospital 
anxiety and depression scale 
• Patient reported e.g. traumatic life event, such as history 
of trauma or abuse, major work disruption, significant 
bereavement 
E. Physiological Modifiers of 
Function and Biomarkers* 




• Colonic motility and transit: manometry, radio-opaque 
marker x-ray, scintigraphy, magnetic resonance imaging 
• Colonic visceral sensitivity: rectal barostat 
• Evidence of inflammation: faecal calprotectin, colonic 
biopsies and histology 
• Other: microbiome analysis and profiling 




1.2.4 Novel Approaches to Subgrouping Patients with IBS 
If the approach advocated by the MDCP is to be translated into a formal 
classification system for IBS, being able to demonstrate that statistical models 
incorporating factors other than gastrointestinal symptoms can be used to derive new 
and distinct patient subgroups, and that those additional factors are of relevance to 
clinical management, would provide useful supporting evidence. 58 Previous studies 
examining whether the performance of the Rome criteria for diagnosing IBS can be 
augmented by the addition of other factors are inconsistent. One study found that, by 
incorporating clinical information regarding nocturnal stools, extra-intestinal symptom 
reporting, and mood disorders, as well as haemoglobin and C-reactive protein (CRP) 
measurements, the positive LR and specificity of the Rome III criteria for IBS were 
both increased. 36 However, another study found no significant improvement in the 
performance of the Rome III or Rome IV criteria for diagnosing IBS when abnormal 
levels of anxiety or depression, or high levels of extra-intestinal symptom reporting, 
were included. 37  
Both of these studies examined the utility of making changes to the symptom-
based criteria for diagnosing IBS. Adopting a similar approach, but instead modifying 
how individuals with IBS are subgrouped once a diagnosis has been made according to 
Rome criteria, might be more valuable. Four previous studies have examined this issue 
by using a combination of gastrointestinal symptoms and psychological profiles, 26, 27, 59 
and in one study, physiological parameters were also included. 60 The first of these was 
conducted in 172 patients with IBS in a tertiary care setting in Sweden, 26 and the 
second study, from the same group of investigators, included people meeting criteria for 
IBS in an internet-based survey of healthy adults in the general population in the United 
States of America (USA), Canada, and the United Kingdom (UK). 27 In both of these 
studies distinct subgroups of patients appeared to exist, and generally comprised those 
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whose symptoms were predominantly intestinal, and who had only minimal 
psychological distress, and those for whom IBS symptoms were part of a broader 
picture, which included anxiety, depression, or extra-intestinal symptoms.  
These subgroups were not, however, reproducible across different patient 
cohorts or different iterations of the Rome criteria, with variation seen in both the 
number and specific characteristics of the subgroups between studies. Moreover, as one 
study was conducted in a small number of patient in tertiary care, this may limit the 
generalisability of the findings, 26 and although participants in the population-based 
study met the Rome criteria for IBS, this does not necessarily mean that they had the 
condition. 27 A third study included 107 patients diagnosed with IBS using the now 
outdated Rome I criteria and conducted a K means cluster analysis using intestinal 
symptoms, psychological health, and rectal distension thresholds. 60 Three distinct 
groups of patients were observed, two of which had low rectal distension thresholds and 
were distinguished by low or high psychological co-morbidity. The third group had high 
rectal distension thresholds and low disease impact overall. A final study, involving 332 
adults in the community, who met the Rome criteria and had received a medical 
diagnosis of IBS, demonstrated clusters distinguished by low or high severity of 
intestinal and extra-intestinal symptoms, which were further differentiated by the extent 
of impairment in IBS-related quality of life. 59 However, the study combined patients 
meeting either the Rome II or Rome III criteria together, and did not, therefore, examine 
whether there were any differences in the subgroups dependent on how IBS was 
defined.  
In addition, all of these studies failed to validate the models they proposed. This 
means that, although each model may be a good fit for classifying the patient cohort in 
which it was derived, it may perform less well in other cohorts of people with IBS. 
Nonetheless, although the three models were unique, having each been constructed 
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using different variables, and with IBS defined according to different iterations of the 
Rome criteria, the general principle that patients can be separated into groups using their 
psychological profile as well as their gastrointestinal symptoms is a consistent finding 
in these studies.  
Further studies are required that explore novel approaches to subgrouping in 
larger cohorts of people with IBS, and that make comparisons between different 
iterations of the Rome criteria. Moreover, subgrouping models require validation, and 
longitudinal follow-up of novel subgrouping models should be undertaken in order to 
understand their natural history and prognostic value. In turn, this will help to determine 
whether using these subgroups to personalise treatment may be a useful approach to 
adopt in clinical practice. 
1.3 The Epidemiology, Natural History, and Impact of IBS 
It has already been discussed that symptom-based diagnostic criteria, such as the 
Rome criteria, aim to make a positive diagnosis of IBS without recourse to extensive 
investigation, and that the subsequent subgrouping of people according to their 
predominant stool pattern is intended to help direct treatment. Novel approaches to 
subgrouping people with IBS may lead to more personalised treatment of the condition, 
and this could improve outcomes and reduce costs. In order to place this in context and 
understand why it might be valuable, it is vital to appreciate that IBS is a common and 
costly condition, which has substantial implications for the individual patient, and for 
society as a whole.    
1.3.1 Epidemiology 
1.3.1.1 Global Prevalence of IBS 
In 2012, a systematic review and meta-analysis involving 260,960 individuals 
across 81 countries worldwide calculated a pooled global prevalence of IBS of 11%. 61 
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The prevalence varied widely, however, dependent on both the criteria used to define 
IBS and also according to country, ranging from 1.1% in one Iranian study and another 
conducted in the USA, to 45% in Pakistan. The specific reasons for this variation were 
unclear. Although there might be genuine differences in the population prevalence of 
IBS between countries, possibly mediated by ethnicity or the differential effect of risk 
factors such as diet or genetics, any differences might equally be the result of 
methodological variation between studies. For example, prevalence was higher when 
participants were allowed to self-administer the study questionnaire, compared with 
when it was administered face-to-face or over the telephone by an interviewer. 61 
Indeed, heterogeneity between studies was substantial in many of the analyses, 
confirming that differences in either the methodology, the clinical characteristics of 
participants, or a combination of these factors was probably relevant to understanding 
the variability in reported prevalence between studies. In addition, the potential 
diversity of IBS symptoms between countries and the complexities of applying 
diagnostic criteria to non-Western populations might also be relevant. A Rome 
Foundation working group re-examined the literature in 2017. 62 Again, the reported 
prevalence of IBS varied widely, from 1.1% in France and Iran to 35.5% in Mexico, and 
the extent of methodological variance between studies was substantial with measures of 
heterogeneity approaching 100%. This finding led the authors to conclude that 
calculating a pooled global prevalence was unlikely to be meaningful.  
Overall, the findings of these two studies serve to illustrate the problems 
inherent in characterising the prevalence of IBS around the world. Furthermore, in some 
countries, including the majority of African nations, the prevalence of IBS was 
unknown as there were no available data, and there was also a lack of data from many 
Eastern European, Middle Eastern, and Central American countries. 61, 62 A subsequent 
study published in 2019 used an online population-based survey to estimate the 
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prevalence of functional gastrointestinal disorders in the USA, Canada, and the UK 
using both the Rome III and Rome IV criteria. 63 The prevalence of IBS using the Rome 
IV criteria was very similar between the three countries, ranging between 4.4% and 
4.8%. Rome IV-defined IBS was only around half as prevalent as Rome III-defined 
IBS, mainly because of the increased minimum frequency of abdominal pain required 
by the Rome IV criteria. 
Due to the uncertainty surrounding pooled estimates of global prevalence, and 
the variation in prevalence between countries in separate studies, a Rome Foundation 
global survey sought to quantify the prevalence of several disorders of gut–brain 
interaction, including IBS, among 73,000 adults in 33 countries around the world using 
the Rome III and IV diagnostic criteria. 64 The worldwide prevalence of IBS was 4.1% 
using the Rome IV criteria, compared with 10.1% when the Rome III criteria were used. 
Most recently, the systematic review and meta-analysis from 2012 has been updated, 
and includes the results of this global survey. 65 This meta-analysis reported a pooled 
prevalence of IBS according to the Rome III criteria of 9.2%, based on the results of 53 
studies, with almost 400,000 participants, from 38 countries. Once again, the pooled 
prevalence of IBS defined using the Rome IV criteria was lower at 3.8%, based on 
findings from six studies, conducted in 34 countries, and comprising approximately 
82,000 individuals.  
The marked fall in the prevalence of IBS that results from the changes made 
between the Rome III and Rome IV criteria is noteworthy, and reflects the more 
restrictive nature of Rome IV. As discussed, this has important clinical implications 
because, although, and as intended, the criteria are now more specific for diagnosing 
IBS, 37 many patients’ symptoms will no longer be considered consistent with IBS. 
Instead, they will be diagnosed as having another functional bowel disorder, such as 
functional diarrhoea or unspecified functional bowel disorder, that are much less well 
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understood than IBS, and for which there is a lack of evidence-based treatments. 
Moreover, there will be an impact on treatment trials, and the interpretation of results, 
because the patient populations recruited using the Rome IV criteria will differ from 
those recruited using Rome III criteria, and may have more severe symptoms and higher 
degrees of psychological comorbidity. 
1.3.1.2 Prevalence According to Sex and Age 
In an analysis of 56 studies worldwide, the prevalence of IBS was modestly, but 
significantly, higher in women than men (odds ratio (OR) 1.67; 95% CI: 1.53–1.82). 66 
A recently updated meta-analysis reported similar findings based on 30 studies using 
the Rome III criteria (OR 1.46; 95% CI: 1.33-1.59), but found no studies reporting IBS 
prevalence according to sex using the Rome IV criteria. 65 When data were examined 
according to country, however, there were no differences between the prevalence of IBS 
in women compared with men in studies conducted in South Asian, South American, or 
African countries. 61 Indeed, in contrast to findings in Western cohorts, epidemiological 
studies in India have consistently found no difference in prevalence between the sexes. 
67 With respect to age, the prevalence of IBS decreased modestly with increasing age, 
although this trend did not reach statistical significance. 61 However, the odds of IBS 
were significantly lower in those aged ≥50 years compared with those <50 years (OR 
0.75; 95% CI: 0.62–0.92), although heterogeneity was substantial. 
1.3.1.3 Prevalence According to Ethnicity 
Although variations exist in the prevalence of IBS according to geography, data 
relating to the role of ethnicity are very limited. One US study found that IBS occurs 
less frequently in African-Americans compared with white individuals, 68 which was 
also the finding of a systematic review on this topic. 69 This review also identified three 
community surveys from Singapore and Malaysia that showed no difference in 
prevalence between individuals of Chinese, Malay, or Indian ethnicity. 70-72 
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1.3.2 Natural History 
Overall, the incidence of IBS in Western populations is estimated to be 1-2% per 
year. 73 Consequently, many people will suffer with IBS symptoms over the course of 
their lives. Moreover, IBS is a chronic condition; a survey of nearly 4,000 individuals in 
the general population demonstrated that, of those with IBS at baseline, around two-
thirds of patients reported persistent symptoms at 10-year follow-up. 73 In the same 
study, around 15% of those who did not have IBS originally developed the condition 
over the same time period. The development of symptoms in those who were previously 
asymptomatic may reflect, in part, the role of the bi-directional gut-brain axis. As 
discussed, in one study higher levels of anxiety and depression at baseline were 
significant predictors of the development of IBS after 1 year of follow-up. 52 Similarly, 
some patients who have IBS at baseline, no longer meet criteria for IBS at follow-up. 74 
However, although symptoms fluctuate, the prevalence of IBS remains fairly stable, 
because the number of people whose symptoms disappear are matched by the number 
who develop new-onset symptoms. 39 Moreover, when patients no longer meet criteria 
for IBS, this is often because, rather than having resolved, their gastrointestinal 
symptoms have instead changed, such that there can be transition between different 
functional gastrointestinal disorders. 75, 76 Indeed, a Swedish study found that there was 
considerable symptom fluctuation between those reporting IBS, dyspepsia, or minor 
symptoms not meeting criteria for a functional gastrointestinal disorder over a 7-year 
period. 77 Symptom overlap is also frequently observed, such that IBS may co-exist with 
other functional gastrointestinal disorders, 78 or with other medically unexplained 
conditions, such as chronic fatigue syndrome, 79 or fibromyalgia. 80 Finally, it is 
alarming to note that around one-third of patients with functional gastrointestinal 
disorders will undergo unnecessary abdominal surgery for their symptoms, including 
cholecystectomy and hysterectomy. 81 A multivariate analysis examining rates of 
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surgery in patients with IBS, and adjusting for multiple confounders, showed that 
having IBS was independently associated with rates of cholecystectomy three-fold 
higher, appendicectomy and hysterectomy two-fold higher, and back surgery 50% 




1.3.3 The Impact of IBS 
1.3.3.1 Quality of Life 
It has long been recognised that IBS has a substantial effect on quality of life, 83, 
84 which might be greatest in those with IBS-D, 85 for whom the fear of incontinence in 
a social situation can be especially debilitating. 86 Indeed, patients with IBS-D report 
more avoidance of places without bathrooms and reluctance to leave home, whereas 
individuals with IBS-C are more likely to report avoiding sex, difficulty concentrating, 
and feeling self-conscious. 87 The effects of IBS symptoms on work, including loss of 
earnings, socialising, and the ability to travel also have a negative effect on quality of 
life. 88 Overall, patients with IBS report feeling a loss of freedom and spontaneity, 
highlight the unpredictability of their symptoms, and can feel stigmatised by family, 
friends, and physicians, who might struggle to understand the effects on their life. 89 
Indeed, patients with severe symptoms appear more willing to accept substantial 
degrees of risk for resolution of their symptoms. For example, a questionnaire-based 
study showed they would accept a median 1% risk of sudden death from a hypothetical 
medication in return for a 99% chance of a cure. 90 In another questionnaire study, 
people with IBS were found to be willing to give up 25% of their remaining life 
expectancy, an average of 15 years, to be symptom-free. 91  
Consulting with a gastroenterologist regarding IBS symptoms has, 
unfortunately, been associated with only a small, non-statistically significant 
improvement in quality of life, which was not maintained over time in one study. 92 This 
finding might reflect the fact that many patients with IBS report dissatisfaction with 
clinical management overall, and feel that a patient-centred approach is lacking. Indeed, 
it has been suggested that long term quality of life might be affected more by 
psychological well-being than by improvement in gastrointestinal symptom severity. 93, 
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94 This understanding highlights the importance of adopting a holistic attitude to care, 
which can be sometimes overlooked in favour of a largely symptom-driven approach. 
1.3.3.2 Healthcare Costs 
Overall, direct care costs of IBS — those costs that are entirely attributable to 
resource use for healthcare delivery, including investigation and treatment of the 
condition — are substantial. Estimates range from £45.6–200 million per annum in the 
UK, 95 $2 billion per annum in China, 96 and €3–4 billion per annum in Germany. 97 An 
appraisal in 2013, based on an analysis of 35 studies, suggested direct cost estimates in 
the USA vary considerably, with figures of between $1,562 and $7,547 per patient per 
year. 98 Estimates encompassing six European countries, although more conservative, 
were nevertheless considerable at between €1,183–3,358 per capita, 99 and similar 
values were seen in an evaluation of European patients with IBS-C, 100 for whom the 
biggest cost drivers were hospitalisation and visits to the emergency department. 
However, comparing costs between countries is difficult due to variations in methods 
used to calculate them, and the year in which the analyses were conducted. Indeed, 
many of the available cost analyses require updating in order to reflect current tariffs, 
and no study has sought to map the global health economic landscape of IBS. 
1.3.3.3 Issues for Society 
Patients with IBS often find it difficult to work due to their symptoms. 
Accordingly, they might take time off, referred to as absenteeism, or instead report that, 
although at work, they struggle to perform at their best, so-called presenteeism. Studies 
relating to absenteeism in IBS are conflicting. It has been suggested that although 
people with IBS are more likely to take time off work, the total amount of time is no 
different to people without IBS. 101 However, one survey of 40,000 individuals across a 
number of European countries demonstrated that those with IBS took almost twice as 
many days off per year compared with those without IBS. 102 Overall, studies in Europe 
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and Canada suggest that anywhere between 5–50% of people with IBS require some 
time off work due to symptoms. 86, 95 A questionnaire study in 2018 of 525 patients with 
IBS reported that 24% of employed patients reported absenteeism. 103 Presenteeism is 
more difficult to quantify due its subjective nature, but was reported by 86% of patients 
with IBS in the same questionnaire study, for whom higher degrees of work impairment 
were linked to severity of symptoms and gastrointestinal-specific symptom anxiety. 103 
Estimates of presenteeism are somewhat lower in other studies, ranging between 2–
32%. 95  
Indirect costs of absenteeism and presenteeism, in terms of loss of work 
productivity, are considerable and similar to those for other chronic conditions, such as 
asthma or migraine. 104 In an analysis of data from 13 European countries, an estimated 
mean per-capita indirect cost for IBS was €2,314 per year, 99 higher than in China (~ 
€670). 96 Although an updated analysis is needed, a study in 2003 found that 
absenteeism cost employers in the USA an average of $901 each year per employee 
with IBS, compared with $528 per employee without IBS. 105 Additional costs to 
society might be incurred if patients who are unable to work due to their IBS symptoms 
claim sickness or disability benefits. In a longitudinal population-based study in 
Denmark, the expected number of weeks on sickness benefits was 61% higher among 
those with IBS symptoms, which remained statistically significant following adjustment 
for age, sex, time in education, comorbidity, and mental vulnerability. 106 There was 
also a trend towards an increased number of weeks on disability benefits among those 
with IBS symptoms, compared with people without IBS symptoms, but this difference 
was not statistically significant following adjusted analysis. 106 
Finally, the effect on families of those with IBS is relatively unknown. In one 
study, the partners of 152 patients with IBS were under significantly more strain, and 
bore a greater perceived burden, compared with the partners of 39 healthy controls, and 
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this effect increased in correlation with the severity of a patient’s IBS. 107 It is 
conceivable that these effects have implications for the health and economic 
contribution of partners, which are absent from previous assessments of the cost of IBS 
to society, but this situation requires further research. 
1.4 Pathophysiology of, and Risk Factors for, IBS 
The pathophysiology of IBS is complex and incompletely understood (Figure 1-1). 
As discussed, IBS is defined according to a pattern of symptoms, but it is likely that the 
underlying pathophysiology varies between patients, such that the same, or similar, 
symptoms may have a variety of different causes. Indeed, differences in underlying 
pathophysiology or risk factors for IBS might be hitherto underappreciated factors in 
the differentiation of IBS subgroups. These are alluded to by the MDCP, but 
conventional subgrouping uses only stool pattern, and attempts to generate new 
subgrouping models have, thus far, augmented this approach using only psychological 
factors. Conceivably, however, any quantifiable risk factor could be incorporated into a 
subgrouping model, contingent on methodological feasibility, and so a more detailed 













































1.4.1 The Gut-Brain Axis and Psychological Comorbidity 
Psychological comorbidity, including stress, anxiety, or depression is frequently 
associated with IBS and might exacerbate symptoms. Indeed, this is highlighted within 
the MDCP framework. One meta-analysis demonstrated that the prevalence of both 
anxiety disorders and depressive disorders among patients with IBS was 23%, with 
anxiety and depressive symptoms being even more common, with a prevalence of 39% 
and 29%, respectively. 55 Psychological comorbidity contributes to the aetiology of IBS 
as part of an integrated biopsychosocial model. It is important to consider that 
psychological symptoms might have developed as a consequence of the severity and 
effect of IBS on an individual, or might instead have been present prior to the onset of 
gastrointestinal symptoms. 108  
Within this construct, the gut-brain axis, the interaction between the central 
nervous system (CNS) and the enteric nervous system, is important in the 
pathophysiology of IBS and functions in a bi-directional manner. 51 The CNS can alter 
gut physiology, such as motility or visceral sensitivity, which in turn mediates IBS 
symptomatology, such as transit and stool pattern, or the experience of pain. Similarly, 
changes in the gut can feed back to the brain, resulting in effects on psychological well-
being and health. The microbiome might also be important in this mechanism. 109 
Indeed, higher levels of anxiety and depression at baseline in people without IBS were 
significant predictors for the development of IBS after 1 year of follow-up. 52 When 
these findings were examined over the longer term, with follow-up at 12 years, the same 
association was seen for anxiety, but not for depression. 51 Both these studies also found 
that, among patients with IBS with no psychological comorbidity at baseline, there was 
a significant increase in the reporting of anxiety and depression at follow-up. 51, 52  
In addition to the presence of mood disorders, people with IBS often complain of 
extra-intestinal symptoms, such as fatigue, insomnia, headache, palpitations, dizziness, 
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or breathlessness, and this is particularly the case among those with IBS-M. 110 The 
association between IBS and extra-intestinal symptom reporting, often referred to as 
somatisation, could relate to CNS sensitisation, a neurophysiological mechanism that 
would explain the occurrence of both painful and non-painful symptoms. 111 Studies 
suggest that individuals with high levels of somatisation have more severe IBS 
symptoms, 112, 113 which might, in part, be due to an association between increased 
somatisation and visceral hypersensitivity, 114 and these individuals are more likely to 
consult with a doctor regarding their IBS. 113 In addition, the relationship between 
general anxiety, which, as already discussed, is common in IBS, and IBS symptom 
severity might be mediated by somatisation, 112 or instead by gastrointestinal symptom-
specific anxiety. 115, 116 Fear and worry related to gastrointestinal symptoms in IBS has 
been postulated as a key driver of symptom severity and quality of life impairment, 117, 
118 although findings of a recent study cast doubt on whether gastrointestinal symptom-
specific anxiety plays such a central role. 119 Nevertheless, the study concluded that 
awareness of both gastrointestinal and extra-intestinal symptoms is strongly associated 
with reporting of more severe symptoms in IBS overall. 119 
1.4.2 Psychological Stressors 
It is widely acknowledged that a history of abuse, whether psychological, 
physical, or sexual, and other forms of psychological trauma, are strongly associated 
with IBS, 120 and that this may especially be the case among patients with symptoms 
that are refractory to medical management. 121 In a study of 206 consecutive female 
patients who were referred to secondary care with gastrointestinal symptoms, 44% 
reported a history of sexual or physical abuse, of whom one-third had never disclosed 
this information before. 122 A history of physical and sexual abuse was more likely 
among people with functional gastrointestinal disorders than those with organic disease 
(OR 11.4; 95% CI: 2.22-58.5, and OR 2.08; 95% CI: 1.03-4.21, respectively), and those 
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reporting abuse had significantly more extra-intestinal symptoms (p<0.001). Among 
patients referred to the gastroenterology outpatient department, those with a history of 
abuse were significantly more likely to report IBS-type symptoms compared with those 
with no history abuse (OR 1.7; 95% CI: 1.2-2.5). 123 The prevalence of sexual abuse 
among people with IBS was 31.6% in one study of 196 outpatients, significantly higher 
than the prevalence among patients with organic disease (14%, p = 0.0005), and healthy 
controls (7.6%, p<0.0001). 124 Similarly, the prevalence of general trauma, physical 
punishment, and emotional abuse, in early life, before the age of 18, are all significantly 
higher among IBS patients than healthy individuals, 125 and associated with increased 
symptom severity. 126 Nevertheless, the association between IBS and abuse, whether 
occurring in childhood or adult life, might be explained in part by controlling for other 
psychosocial factors, for example having a diagnosis of depression, in logistic 
regression analyses. 127, 128  
1.4.3 Genetic Susceptibility 
Many patients with IBS report having relatives who share their diagnosis, or who 
report similar symptoms, and indeed studies have observed familial aggregation of IBS, 
suggesting an underlying genetic component. 129, 130 Nonetheless, such findings are 
confounded by the fact that, within families, individuals will often have shared 
childhood experiences or environmental exposures in common, which might equally 
explain clustering of IBS symptomatology. Moreover, findings from twin studies are 
conflicting. Some studies demonstrate increased concordance of an IBS diagnosis in 
monozygotic twins compared with dizygotic twins, 131, 132 and others show no notable 
difference. 133 In one study having a mother with IBS was equally as important as 
having a monozygotic twin with IBS. 131 Consequently, any genetic influence in IBS is 
likely to be polygenic, whereby common variants in a large number of genes and their 
interaction with environmental factors have a role in determining the clinical 
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manifestations of IBS. As a result, efforts have focused on trying to identify possible 
genetic markers in IBS and how these might correlate with certain patient subgroups. 
 Owing to the role that serotonin (5-hydroxytrypyamine (5-HT)) has in the gut-
brain axis, as both a brain neurotransmitter related to mood and as an enteric 
neurotransmitter important in mediating gastrointestinal motility and physiology, the 
genetics of serotonergic pathways are amongst the most widely studied, specifically 
genetic variations in the serotonin reuptake transporter (SERT). 134 It has been 
suggested that a genetic polymorphism in the promotor region of the SLC6A4 gene 
encoding SERT might be associated with IBS. In a meta-analysis of 27 studies with 
7,039 participants, the risk of IBS was significantly associated with the SERT insertion 
or deletion polymorphism in both Asian (dominant model: P=0.001; recessive model: 
P=0.0003; allele model: P=0.001) and white individuals (dominant model: P=0.04; 
additive model: P<0.0001), but only for those with IBS-C when patients were stratified 
by stool pattern (recessive model: P=0.04). 135 Other studies have identified rare 
pathogenic variants in genes encoding sucrase–isomaltase 136 or SCN5A, 137 a voltage 
gated sodium channel, suggesting that IBS symptoms in a small proportion of patients 
might relate to disaccharide intolerance or ion channelopathies. Indeed, a genome-wide 
association study (GWAS) meta-analysis of five European cohorts supports the 
hypothesis of ion-channel involvement in IBS pathophysiology. 138  
 Another GWAS study comparing UK biobank data from 9,576 people with IBS 
and 336,449 healthy controls looked for significant genome-wide findings and 
investigated associations further in a multicentre population of tertiary care patients 
from Europe and the USA and a small Swedish population cohort. 139 This study 
identified variants at a locus on chromosome 9 that were associated with risk of IBS in 
women only, and additionally associated with constipation, which might support a 
rationale for investigating the role of sex hormones in the pathophysiology of IBS. In 
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addition, familial dysautonomia has been linked to mutations of a gene residing at this 
locus. 140 This is a rare condition affecting the autonomic and sensory nervous systems, 
which leads to a variety of symptoms including labile blood pressure, altered pain 
sensation, speech difficulties, episodic vomiting and abnormal gastrointestinal motility. 
Consequently, this finding might support the role of autonomic dysfunction in IBS 
pathophysiology; however, these associations are tentative and require further 
examination.  
Studies in Japanese individuals have identified associations between IBS 
symptoms and single nucleotide polymorphisms in genes encoding the corticotropin-
releasing hormone (CRH) receptor 1 and 2. 141, 142 CRH is key to the body’s stress 
response and studies have shown that administration of exogenous CRH can induce an 
increase in colonic motility, and that motility can be reduced using CRH-receptor 
antagonists. These findings, together with the fact that altered gastrointestinal motility is 
a component of IBS pathophysiology, have led some to conclude that the CRH pathway 
plays a part in IBS. 141, 142 
 Although our understanding of the role that genetics might play in the aetiology 
of IBS is expanding, many unanswered questions remain, particularly whether these 
gene mutation associations actually contribute to pathophysiological mechanisms. 
Consequently, current knowledge does not support a role for genetic testing in clinical 
practice, because how these findings should be interpreted and acted upon is unclear at 
the present time. 
1.4.4 Dietary Factors 
Patients with IBS frequently report that symptoms are associated with eating 
certain foods. 143, 144 Consequently, many patients will exclude these from their diet with 
the aim of improving symptoms. 145 However, should they report a positive response, 
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this is more likely to reflect the fact that, to some degree at least, symptoms of IBS are 
expected to be meal-related, as per diagnostic criteria, rather than reflecting a true food 
allergy, mediated via an immune response. 
Patients may seek to identify perceived food intolerances using bloods tests, 
although there is currently insufficient evidence to support this approach. In one 
randomised controlled trial (RCT), 150 patients were randomised to either a 12-week 
diet excluding foods to which they showed cross-reactivity on immunoglobulin (Ig) G 
antibody testing, or to a sham diet, where they excluded the same number of foods to 
which they had tested positive, but not the specific foods to which they reacted. 146 A 
greater proportion of patients following the true exclusion diet reported symptom 
improvement, but this was not statistically significant. In another study, leucocyte 
activation testing of peripheral blood samples was conducted to identify possible food 
intolerance, and patients were randomised to a true versus sham elimination diet. 147 
Participants following a true elimination diet had a significantly greater improvement in 
symptom scores, compared with those allocated to a sham diet. However, there was no 
significant difference in the proportion of patients reporting adequate relief of IBS 
symptoms, nor in quality of life measures. More recently, one study suggested that 
people with IBS may have atypical food allergies, which are not mediated via classical 
IgE pathways, although this requires corroboration. 148 Although individual dietary 
components might be a factor in the pathogenesis of IBS, the interaction of diet with the 
gut microbiome and the composition of microorganisms living in the gut might also be 
important. 149 
1.4.5 The Gut Microbiome 
Interest has been growing into the role that the gut microbiome, with a particular 
focus on bacteria, might play in health and gastrointestinal disease. It has previously 
been shown that the faecal microbiota of people with IBS differs significantly from that 
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of healthy individuals, 150 and might influence colonic transit, contributing to altered 
bowel habits. 151 The existence of a microbiome ‘signature’ specific to IBS has been 
proposed, with reduced microbial diversity and the presence of methanogenic or 
Clostridiales species associated with more severe symptoms. 152 Indeed, Clostridiales 
species might adversely affect gastrointestinal physiological activity via their possible 
role in serotonin synthesis, although this speculative link requires further investigation. 
153 However, in contrast to these findings, a recent study found no such microbial 
signature when comparing the faecal microbiome of people with IBS with healthy 
individuals. 154 Inflammatory pathways, changes in intestinal permeability, and the gut 
metabolome, which includes products of bacterial metabolism of intestinal contents, 
have also been suggested to play a part in a microbiome-related construct of 
gastrointestinal disease. 155 In addition, dietary changes, such as long-term restriction of 
fermentable oligo-, di-, and mono-saccharides, and polyols (FODMAP), can lead to 
alterations in the microbiome. 156 Overall, understanding of this field is in its infancy 
and examining the faecal microbiome remains a tool for researchers, not clinicians. 
Current knowledge is not sufficiently well-developed to enable reliable interpretation of 
an individual’s faecal microbiome, understand how this might relate to the 
pathophysiology of IBS, and use this information to target treatment appropriately. 157 
1.4.6 Post-Infection IBS 
Infective gastroenteritis is frequently identified as a risk factor for developing 
IBS, referred to as post-infection IBS (PI-IBS), 158 with such patients generally 
experiencing looser and more frequent stools rather than constipation. 159 Early studies 
determined that a quarter of individuals with infective gastroenteritis reported 
persistence of altered bowel habits 6 months after their infective episode, with one in 14 
people developing IBS. 160 A range of bacterial pathogens have been implicated in PI-
IBS, including Campylobacter jejuni, Escherichia coli, and Salmonella enterica serovar 
47 
 
Typhimurium, 161 as well as Clostridioides difficile 162 and Vibrio cholerae. 163 
Symptoms can persist for many years following the initial infection, 164 sometimes for 
more than a decade in some studies, 165 and the development of IBS in this context 
appears to be independent of other risk factors, such as age and sex. 166 Associations 
have also been demonstrated between viral infections such as norovirus, 167, 168 and 
protozoal infections such as Giardia lamblia. 169, 170 However, there are far fewer 
available studies than for bacterial pathogens, 171 and symptoms following viral 
infection might be relatively transient with a similar prevalence of IBS among exposed 
and non-exposed individuals by 6 months. 158, 168  
 A systematic review and meta-analysis of 45 cohort studies involving 21,421 
individuals with infective enteritis who were followed for between 3 months and 10 
years to identify the development of IBS, reported a pooled prevalence of IBS at 12 
months following infection of 10%, rising to 15% beyond 12 months. 172 The risk of 
IBS in those with enteritis was four-fold higher than in individuals without, and this risk 
was significantly associated with female sex (OR 2.2; 95% CI: 1.6–3.1), psychological 
comorbidity, such as anxiety (OR 2.0; 95% CI: 1.3–2.9) or somatisation (OR 4.1; 95% 
CI: 2.7–6.0), and antibiotic use (OR 1.7; 95% CI: 1.2–2.4). Individuals with protozoal 
enteritis were found to be at highest risk of IBS, with around 40% developing the 
condition compared with 13% of those with a bacterial aetiology. 172 Although an 
increased risk was seen across different geographic regions, the majority of studies were 
in European and North American populations. One study of PI-IBS from Bangladesh in 
345 patients with acute gastroenteritis demonstrated that, although patients with a 
history of acute gastroenteritis had a significantly higher prevalence of IBS than age-
matched and sex-matched healthy controls, approximately one in 10 of those fulfilling 
criteria for PI-IBS actually had post-infection malabsorption or sprue following 
investigation. 173 A study in East Indian patients hospitalised with acute gastroenteritis 
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found that a quarter developed IBS within 6 months of the infection, and this finding 
was associated with younger age and increased duration of the gastroenteritis. 174 
Another prospective cohort study of individuals with shigellosis, following an outbreak 
in a Korean hospital, observed a significantly increased risk of developing IBS up to 3 
years after the infection (OR 3.93; 95% CI: 1.20–12.86), but by 10 years the prevalence 
of IBS was similar between the Shigella cohort and healthy controls (23.3% versus 
19.7%; P=0.703). 175 Overall, the prognosis for PI-IBS and non-PI-IBS appears to be 
the same, with symptoms persisting beyond 12 months in ~75% of cases and few 
differences in clinical features between the stool subgroups. 159 
1.4.7 Low-Grade Gut Mucosal Inflammation and Immune Activation 
The role of low-grade mucosal inflammation in the pathogenesis of IBS was first 
proposed in the early 1960s. In an analysis of surgically resected colon specimens from 
patients with IBS, Hiatt and Katz observed increased numbers of mast cells in the 
muscularis externa of the bowel wall, a finding similar to the increase seen in colonic 
resection specimens from people with ulcerative colitis. 176 It has been suggested that, 
rather than being separate conditions, IBS and inflammatory bowel disease may be part 
of spectrum, albeit the precise nature of the inflammatory process differs between the 
two diseases. 177 Among those with IBS, it is the increase in mucosal mast cell density 
throughout the gastrointestinal tract, but particularly in the colon, that has been the most 
consistent histological finding. 178 Indeed, a previous systematic review identified 16 
studies examining the presence of low-grade inflammation in full-thickness intestinal or 
endoscopic mucosal biopsies obtained from patients with IBS and healthy controls. 179 
The numbers of mast cells, and to a lesser extent T lymphocytes and B lymphocytes, 
were all increased among people with IBS, but no study showed a significant difference 
in numbers of neutrophils or eosinophils between the two groups. Although duodenal 
eosinophilia has been proposed as an important pathophysiological mechanism in 
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functional dyspepsia, on the whole, evidence does not support a comparable role of 
eosinophils in IBS. 180 Of note, however, a recent study has discovered evidence of 
atypical food allergies in some patients with IBS, mediated via eosinophil activation, 
and further investigation of these findings is required. 148  
The increase in mucosal mast cells in IBS may be due to exogenous triggers. For 
example, enteric infection can result in immune sensitisation to microbial antigens, 
leading to mast cell activation and degranulation. 181 Food antigens and chronic stress 
could have similar sensitising effects. 182 The release of histamine and tryptase alters 
visceral sensitivity and adversely affects normal gastrointestinal motor function, 181 
resulting in persistent gastrointestinal symptoms even after an enteric infection has 
resolved. This mechanism offers a potential explanation for why some people develop 
PI-IBS, although this has not been proven. A subsequent systematic review from 2019 
again noted increased colonic mast cells among people with IBS, but also suggested that 
alterations in lymphocyte populations, particularly gut-homing T lymphocytes, might 
indicate that loss of mucosal homeostasis is an important driver of symptoms in IBS. 183 
This increase in T lymphocytes and the accompanying cytokine response, in addition to 
the potential role of mast cells, is evidence that increased immune activation might be 
relevant to the pathophysiology of IBS. A detailed systematic review of immune 
markers in people with IBS demonstrated a consistent reduction in interleukin (IL)-10 
in the peripheral circulation and increased levels of IL-6, IL-8, and tissue necrosis factor 
alpha (TNF-α). 184 IL-10 was similarly reduced in intestinal mucosal samples across a 
number of studies. IL-10 is an anti-inflammatory cytokine, 185 which is responsible for 
regulating TNF-α-converting enzyme. 186 Consequently, a reduction in IL-10 leads to 
elevated levels of TNF-α, a cytokine involved in systemic inflammation and responsible 
for the regulation of immune cells. 187 In inflammatory bowel disease, TNF-α is thought 
to be an important driver of mucosal inflammation, and is a target for biologic drugs, 
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such as infliximab, which have proven efficacy for treating the disease. 188 These 
findings hint at a role for cytokine-driven inflammation in IBS; however, there are some 
inconsistencies in the available evidence. Although increased levels of circulating TNF-
α were found in people with IBS compared with healthy controls in one meta-analysis, 
there was no difference in circulating levels of IL-10. 189 
Overall, identifying the presence of low-grade mucosal inflammation and 
immune activation would probably require patients to undergo routine colonoscopy and 
biopsies, and this approach would not be cost-effective. In addition, it would be 
unpleasant for the patient, and the emphasis is on making a diagnosis of IBS without 
recourse to invasive investigations. 190 Moreover, there is currently no evidence that 
identifying mucosal inflammation in IBS can change patient management or alter 
clinical outcomes. Similarly, serological analysis of cytokines in IBS, although offering 
a less invasive approach, has no evidence of benefit, and has not been validated for use 
in everyday clinical practice.  
1.4.8 Intestinal Permeability 
The physical integrity of the mucosal barrier in the gut is maintained by tight 
junctions, also called intracellular adhesion complexes, which are proteins, composed of 
intra-membrane proteins, occludins, and claudins. 191 Tight junctions encircle the 
epithelial cells of the luminal epithelium and attach them to one another. 191 In simple 
terms, they are important for regulating paracellular permeability to ions, water, and 
molecules, and prevent microbes and unwanted antigens from crossing into the systemic 
circulation. 191 This physical barrier is further enhanced via the production of mucus by 
goblet cells, and by a biochemical barrier comprising digestive secretions, antimicrobial 
peptides, and other mucosal cell products, such as cytokines, as well as by an 
immunological barrier, organised within the lymphoid follicles, comprising B cells, T 
cells, dendritic cells, and neutrophils. 192 The normal intestinal barrier can be challenged 
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by a variety of factors, such as dietary constituents, enteric infections and associated 
toxins, and the presence of chronic inflammation. This can result in an increase in 
intestinal permeability, which, in turn, leads to an increase in antigen presentation to the 
mucosal immune system. 193  
Increased intestinal permeability may have a role in the pathogenesis of IBS, 
most likely via an integrated pathway in which it both contributes to, and is partly 
driven by, low-grade mucosal inflammation. 194 Moreover, by invoking an immune 
response, increased permeability may adversely affect afferent nerves, leading to 
visceral hypersensitivity and pain. 194 Although the details of these mechanisms require 
further investigation, several studies have been able to demonstrate the presence of 
increased intestinal permeability in some people with IBS, albeit there are 
inconsistencies in the findings. One of the earliest studies demonstrated a significant 
increase in gut permeability among patients with PI-IBS following Campylobacter 
enteritis, 195 and a subsequent study noted subtle increases in intestinal permeability 
among those with IBS irrespective of whether they had a history of prior enteric 
infection. 196 In a third study, small intestinal permeability was significantly increased 
among people with IBS-D compared with healthy controls, 197 and those without a 
history of gastroenteritis had more severe defects. Finally, a study assessing paracellular 
permeability in colonic biopsies found it was significantly higher in patients with IBS, 
regardless of stool subgroup, compared with healthy controls. 198  
Other studies have examined possible causes of increased permeability in IBS. 
One study used confocal endoscopic microscopy to image the terminal ileum during 
diagnostic colonoscopy in order to quantify the epithelial gap density of people with 
IBS compared with healthy controls. 199 IBS patients had significantly more epithelial 
gaps in the mucosa of their small intestine, suggesting that abnormal epithelial cell 
extrusion may be the cause of altered intestinal permeability. Exposure to certain food 
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antigens can also increase epithelial gaps. 200 Cell extrusion is a mechanism of 
homeostatic regulation normally intended to remove cells in response to stressors, such 
as cellular overcrowding in tissues. 201 However, a number of enteric pathogens, such as 
Salmonella, can hijack this process and use it to invade host gut epithelium, 202 which 
may be particularly relevant to the pathogenesis of PI-IBS. In addition, colonic biopsies 
from people with IBS exhibit increased translocation of commensal and pathogenic 
bacteria compared with controls, and this may be driven by mast cells. 203 Another study 
examined the expression of tight junction proteins in colonic mucosal biopsies. 204 
Expression of tight junction proteins was significantly lower in people with IBS 
compared with healthy controls; however, subgroup analysis according to stool pattern 
showed this finding was restricted to those with IBS-D, and there was no difference 
between patients with either IBS-C or IBS-M and healthy individuals. Overall, although 
increased intestinal permeability is present in some individuals with IBS, its precise role 
in the pathophysiology of the disorder requires clarification, and whether it might offer 
new targets for treatment is uncertain. 
1.4.9 Gastrointestinal Transit and Motility 
Changes in gastrointestinal transit and motility have long been postulated as 
contributing to symptoms in IBS. Various techniques for measuring colonic transit are 
available, including colonic scintigraphy and wireless motility capsule, although most 
are unavailable outside of specialist centres. 205 The standard means of assessing colonic 
transit is the radio-opaque marker test, which is relatively simple, and widely available. 
A capsule containing 20 radio-opaque markers is swallowed by the patient, and a plain 
abdominal radiograph is taken 5 days later. 206 Retention of five or more markers is 
indicative of slow transit, but care must be taken not to over-interpret the result, as it has 
been shown that the number of retained markers does not correlate with symptom 
severity or quality of life among people with constipation. 207 Moreover, stool 
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consistency, defined using the BSFS, has been demonstrated to correlate well with 
transit time, 43 so using investigations to measure this routinely in clinical practice is 
probably unnecessary. 
Studies have sought to better understand the relationship between transit time 
and symptoms in IBS. One study in 21 female patients with IBS, which assessed 
changes in colonic transit, stool frequency, and stool consistency between baseline and 
12-week follow-up, confirmed the correlation between transit time and altered bowel 
habit. 208 In another study of 359 patients with IBS, colonic transit time was abnormal in 
72 participants (20%), of whom around three-quarters had accelerated transit and one-
quarter had delayed transit. 209 A significant association was seen between these 
abnormalities in colonic transit time and abnormal stool pattern, subgrouped as per the 
Rome III criteria for IBS, but they were of very limited relevance to other GI symptoms 
in IBS, including abdominal pain and bloating. Conversely, a study of patients with 
IBS-C found that they experienced more abdominal bloating, and had prolonged colonic 
and orocaecal transit times, compared with healthy controls. 210 Moreover, IBS-C 
patients with delayed gastrointestinal transit had a greater degree of abdominal 
distension compared with IBS-C patients with normal transit. 210 However, a recent 
study, which examined a wide range of neurophysiological parameters and their 
association with gastrointestinal symptoms in IBS, found no significant correlation 
between colonic transit time and bloating, although this study included patients with 
IBS-M and IBS-D in the analysis, as well as those with IBS-C. 211  
In addition to abnormal transit, other changes in gastrointestinal motility may 
also be relevant to IBS pathophysiology. A recent study of neurophysiological 
parameters in IBS used a transnasal catheter to assess small bowel motility, finding no 
significant correlation with gastrointestinal symptoms. 211 However, previous studies 
have observed a number of abnormalities in small bowel motor activity among patients 
54 
 
with IBS, although none appears to be specific to the condition. 212 These include 
increased frequency and duration of discrete cluster contractions, 213 increased 
retrograde jejunal contractions, 214 and an exaggerated motor response to meal 
ingestion. 215 Exaggerated colonic motility in response to eating has also been observed 
in people with IBS, 216 and those with IBS-D tend to have increased colonic motility in 
terms of numbers of high amplitude propagating contractions, whilst the opposite is true 
of IBS-C. 217 Finally, some patients with IBS have delayed gastric emptying, especially 
those with IBS-C, 218 or where there is symptom overlap with functional dyspepsia. 219 
Nevertheless, overall, the extent to which any of these physiological changes are 
responsible for causing symptoms in IBS remains uncertain. 
5-HT might play an important role, and has long been recognised to affect 
intestinal motility in humans. 220 It may contribute to symptoms in IBS via its effects on 
gut transit and intestinal fluid secretion. 221 Studies have shown elevated postprandial 
plasma 5-HT levels in patients with IBS-D, 222 and reduced postprandial levels in 
patients with IBS-C. 223, 224 These findings may reflect reduced 5-HT reuptake in IBS-D 
and impaired release in IBS-C, 225 and studies have also suggested 5-HT metabolism is 
relevant, with higher turnover of mucosal 5-HT in patients with IBS-D. 226 In patients 
with constipation, the frequency of defaecation has been shown to be inversely related 
to plasma 5-HT levels. 224 The role of 5-HT in IBS is further supported by the findings 
of drug trials which demonstrate that antagonists of the 5-HT3 receptor are effective 
treatments for IBS-D. 227, 228 Similarly, agonists of the 5-HT4 receptor are effective for 
treating constipation. 205      
1.4.10 Visceral Sensitivity 
Abnormal visceral sensitivity has been demonstrated in patients with IBS. 229, 230 
Visceral perception is quantified by pain and discomfort thresholds, or sensory ratings 
in response to rectal or colonic distension, usually administered by a barostat, which is a 
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computerised distension device. 231 Visceral hypersensitivity, or reduced pain thresholds 
to rectal distension, has been demonstrated in up to 60% of patient with IBS, 232 but to a 
greater extent in those with IBS-D than IBS-C, with an approximate prevalence of 60% 
and 40%, respectively.   
Studies examining the relationship between visceral sensitivity and gastrointestinal 
symptoms are unclear and inconsistent. Although some studies have shown an 
association between visceral hypersensitivity and IBS symptom severity, and the 
severity of abdominal pain and bloating, 56, 233-235 others have not. 224, 236 This has led to 
the suggestion that visceral hypersensitivity may simply reflect cognitive and emotional 
factors, an increased tendency to report symptoms, or both, 237 but again not all studies 
support this. 224 Indeed, a recent study reported a gradual increase in gastrointestinal 
symptom severity with increasing visceral sensitivity, which was consistent across 
several large patient cohorts from Sweden, Belgium, and the USA, even after 
adjustment for the tendency to report symptoms or psychological comorbidity. 56 
The association between abnormal visceral sensitivity and bowel habit is even less 
clear, likely in part because stool consistency and stool form, and to a much lesser 
extent frequency, are generally considered to be related to gastrointestinal transit time, 
as discussed. 43 However, one study reported a weak, but significant, inverse correlation 
between rectal pain thresholds and the severity of diarrhoea in patients with IBS, 235 and 
another study in a small number of patients with IBS-C reported a tendency for stool 
frequency, but not stool form, to correlate inversely with rectal sensory threshold. 224 
Patients with IBS-C who have lost their natural call to stool (non-urge) are also more 
likely to be rectally hyposensitive than IBS-C patients who experience a constant 
sensation of incomplete evacuation. 238 All these studies suggest that, in terms of bowel 
habit, rectal sensation may be equally as important as transit time, by altering patient 
perception of rectal faecal contents and the frequency of defaecation in individuals with 
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functional bowel disorders. The potential importance of intact rectal sensation for 
normal bowel function is also supported by the observation that patients with functional 
evacuation disorders or pelvic floor dyssynergia often exhibit rectal hyposensitivity. 239 
Overall, although visceral sensitivity is likely to be an important pathophysiological 
mechanism in IBS, both with respect to abdominal pain and altered stool pattern, it is 
not routinely measured as part of the clinical assessment of a patient, but, instead, 
remains a focus for research in IBS. 
1.5 The Treatment of IBS 
In general, treatment is targeted at addressing a patient’s most troublesome 
symptoms, be that abdominal pain, diarrhoea, constipation, or bloating. Although, as 
discussed already, several factors have been implicated in the pathogenesis of IBS, 
including the gut-brain axis, alterations in the microbiome, genetic factors, and visceral 
hypersensitivity, there is currently no role for using these to guide therapy in routine 
clinical practice. Moreover, it is likely that, even among patients with the same 
symptoms, the underlying pathophysiology responsible for them will vary. 
Consequently, although treatments may be designed to address theoretical 
pathophysiological abnormalities, there is no way to assess response through objective 
measurement of these and, instead, the clinician must rely on patient-reported symptom 
response to determine treatment success.  
Subgrouping patients with IBS is designed to help facilitate targeted treatment, and 
one of the principle benefits of developing new methods of subgrouping patients that go 
beyond gastrointestinal symptoms in isolation, would be the opportunity to help 
personalise the management of patients. In particular, although the current practice of 
using stool pattern to subgroup people with IBS might help to identify those who may 
benefit from antidiarrhoeal medications or laxatives, it does not, for example, assist in 
prioritising who is most likely to need, or benefit from, psychological therapies. A 
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greater emphasis on personalised treatment could, therefore, help to reduce the costs to 
the individual, to healthcare, and society which, as discussed, are considerable. It is 
therefore important to review what treatments are currently available for IBS, and the 
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1.5.1 The Importance of Good Communication 
Before embarking on the prescription of any treatment, it is vital to recognise the 
role that good communication plays in management. An online survey of people with 
IBS revealed that many had a negative view of their relationship with healthcare 
professionals, with concerns about not being heard and a lack of empathy. 240 Indeed, 
patients report a sense of frustration and isolation, stating that consultation with medical 
experts rarely clarified their understanding of IBS or improved their management. 241 
This might in part reflect unrealistic expectations of patients, many of whom 
demonstrate a willingness to try any treatment in their desperation for a cure, only to be 
left disappointed when symptoms are not relieved completely. 242 However, it also 
reflects a mismatch between patients’ ideal expectations of a consultation, and the 
reality of their experiences. In one survey of over 1000 patients, more than 90% wanted 
their doctor to give comprehensive information about IBS and provide sources for 
additional information, to listen well and answer questions, and to provide information 
about medication. 243 Unfortunately, in recalling their prior experiences of healthcare, 
only 40% felt that their doctor provided information, 64% felt they had been listened to, 
and 47% felt supported.  
Equally, many patients have significant misconceptions regarding the nature of 
IBS and the prognosis. In one questionnaire study of over 250 patients with IBS, less 
than one-third knew abdominal pain was a key symptom, 40% thought colonoscopy 
could diagnose IBS, 30% believed IBS increased the risk of developing inflammatory 
bowel disease, and one in seven believed that IBS could lead to cancer. 244 There are 
also issues with doctors’ perceptions of IBS; the majority of general practitioners (GPs) 
in one study believed it was primarily a psychological disorder, 245 or in another survey 
a response to stress. 246 Moreover, a qualitative study revealed that many doctors hold 
two contrasting views of IBS, the first being a publicly expressed “medical” definition, 
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and the second being a private view, incorporating their own experiences of managing 
patients and absorbed prejudices. 247  
It is therefore clear that there is a mismatch between views of doctors and 
patients regarding IBS, which may limit the usefulness of the patient-clinician 
interaction. A recent systematic review identified five practices that help foster a more 
positive, meaningful, and engaged consultation. 248 First, doctors should prepare with 
intention, taking a moment to focus before greeting a patient. Second, they should listen 
intently and completely. Third, they should explore what the patient cares about, and 
agree on what matters most, setting priorities in partnership. Fourth, they should seek to 
connect with the patient’s story, considering life experiences that influence their health, 
as well as acknowledging positive action and success. Finally, doctors should explore 
the patient’s emotions, taking note of any emotional cues.  
Adopting this holistic approach has the potential to improve outcomes for 
patients with IBS, 249 ensuring that their ideas and concerns are elicited. It is also vital to 
provide a clear explanation about the nature of IBS as a functional gastrointestinal 
disorder and what this means, including why investigations have been normal, and that 
this is expected. Patient expectations should also be managed appropriately with 
discussion focusing on the prognosis of IBS, explaining that around two-thirds of 
patients experience chronic symptoms, 73 with treatment targeted at improving 
symptoms, rather than complete symptom relief. Finally, doctors should outline 
treatment options, including the role of second-line treatment if initial management 




1.5.2 General Dietary and Lifestyle Advice 
A discussion of simple dietary and lifestyle advice should be part of the care of 
all patients with IBS. The concept of self-help is important in empowering patients to 
take control of managing their condition. 
1.5.2.1 Diet 
Empirical dietary management represents an important first-line treatment 
strategy. The National Institute for Health and Care Excellence (NICE) endorse a food 
fact sheet produced by the British Dietetic Association, providing patients with clear 
and concise dietary advice. 250 This gives general recommendations, emphasising the 
importance of eating regular meals, limiting alcohol and caffeine intake, maintaining 
adequate hydration, and reducing processed food consumption. There is also advice 
relating to specific symptoms. For example, patients with flatulence and bloating are 
recommended to limit intake of gas-producing food like beans and pulses, and are 
informed of the potentially beneficial effects of eating linseeds. However, the latter is 
based primarily on anecdotal observations. A 4-week RCT in 40 patients failed to show 
a benefit for either whole or ground linseeds over normal diet in terms of improvement 
in IBS symptom severity, or individual symptoms, including bloating. 251 Patients with 
diarrhoea are cautioned to avoid sugar-free sweets, mints, gum, and soft drinks that 
contain sorbitol, mannitol, or xylitol. Advice is also given regarding dietary fibre, which 
is discussed in greater detail below, with an increased intake recommended for those 
with constipation, but a reduction in patients with diarrhoea. 
1.5.2.2 Fibre 
The role of dietary fibre in treating IBS was first examined over 40 years ago. 
Bran is an example of insoluble fibre, which undergoes little physical change as it 
passes through the gut, bulking stools and increasing stool water content, with the 
potential to accelerate gastrointestinal transit times. 252 However, fibre may also be 
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soluble in water, such as ispaghula, forming a gel that interacts with gut bacteria, 
resulting in production of metabolites, including short-chain fatty acids and secondary 
bile acids. 253 These metabolites may, in turn, stimulate gastrointestinal transit, possibly 
through effects on enteric nerves and smooth muscle, or play a role in immune-mediated 
anti-inflammatory pathways. 254  
 A systematic review and meta-analysis published in 2014 examined effect of 
dietary fibre supplementation on IBS symptoms. 255 Overall, there was a significant 
benefit of fibre on global symptoms (relative risk (RR) of symptoms persisting = 0.86; 
95% CI 0.80-0.94) in 14 RCTs, containing 906 patients. However, subgroup analysis 
demonstrated that benefit was confined to RCTs of ispaghula (RR = 0.83; 95% CI 0.73-
0.94), with no evidence for bran (RR = 0.90; 95% CI 0.79-1.03). Fibre can exacerbate 
pain, bloating, and flatulence, and, although the meta-analysis found there were 
insufficient data to enable analysis of adverse events according to fibre type, these side-
effects are generally considered to be a greater issue for insoluble fibres. 256  
Due to its ability to improve stool viscosity and frequency, fibre is perhaps 
deployed most logically for treating IBS-C, although the evidence for this is 
inconclusive, and there remains a need for larger and more rigorously conducted trials. 
Overall, soluble fibre is simple to use, inexpensive, and safe; however, patients should 
be reminded to increase their intake slowly to avoid exacerbating symptoms. Bran 
should not be recommended. 
1.5.2.3 Probiotics 
As discussed, some investigators have demonstrated that the faecal microbiome 
of patients with IBS differs significantly from that of healthy volunteers, 150 and this 
might, in part, be responsible for causing symptoms, either directly, or via effects on 
gastrointestinal transit. 152, 257 This has led to interest in whether probiotics, which are 
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live or attenuated microorganisms that may have beneficial effects in humans, can be 
used to alter the microbiome, and thereby improve symptoms.  
 The results of a systematic review and meta-analysis of 53 RCTs of probiotics, 
involving 5545 patients, showed that combination probiotics, evaluated in 21 RCTs, had 
a significant effect (RR = 0.79; 95% CI 0.68-0.91). 258 A total of 33 RCTs reported 
effect of probiotics on either global IBS symptoms and abdominal pain. Once again, 
combination probiotics showed a significant benefit over placebo in this analysis; 
however, for single-organism probiotics containing either Lactobacillus or 
Bifidobacterium alone, no benefit was observed. With respect to effect on bloating, 
combination probiotics showed a non-significant trend towards a reduction in bloating 
scores, but there was no evidence of benefit with Lactobacillus, Bifidobacterium, or 
Saccharomyces. 
 On balance, these results suggest some probiotics may be beneficial in IBS; 
however, which combination, strain, or species should be preferred in any individual 
patient remains unclear. The longer-term efficacy of probiotics is unknown, and the 
mechanism by which they may work, and their effect on the microbiome, requires 
clarification. The quality of evidence is also low as the majority of trials are small, and 
many are at an unclear risk of bias. Moreover, there is substantial heterogeneity between 
studies of probiotics with respect to bacterial strains and species, and caution is 
therefore needed when interpreting the results of these meta-analyses. Overall, it is 
reasonable to advise patients wishing to try probiotics to take a combination product for 





It is widely accepted that physical exercise plays an important role in 
maintaining good physical and mental health, 259-261 and that benefit is derived from 
even small increases in physical activity. 261 With respect to gastrointestinal symptoms, 
exercise can accelerate gastrointestinal transit, 262 improve intestinal gas clearance in 
patients with bloating, 263 and might increase gut microbial diversity, with the potential 
to positively impact symptoms via the gut-brain axis. 264 It is therefore reasonable to 
assume that exercise will benefit patients with IBS. 
 One RCT, comparing 12 weeks of an exercise intervention with usual care, 
invited 305 patients with IBS to participate, of whom only 56 (18%) agreed. 265 The 
exercise group reported significant improvements in constipation, compared with 
patients assigned to usual care, but there were no significant improvements in other IBS 
symptoms, or quality of life. In a second trial, 102 patients with IBS were randomised to 
a physical exercise programme or usual care for 12 weeks, 75 of whom completed the 
trial. 266 There was a significant difference in improvement in IBS symptom severity 
scores with exercise. These positive effects persisted in 39 patients followed up for a 
median of 5.2 years. 267 
 A systematic review from 2018 summarised findings from 14 RCTs of exercise 
therapy in IBS, involving a total of 683 patients, 268 and included the two 
aforementioned RCTs. 265, 266 Other interventions studied were diverse, including 
aerobic exercise, yoga, Tai Ji, and mountaineering. The authors concluded that exercise 
appeared to be an effective treatment, but highlighted that studies were at high risk of 
bias. Moreover, heterogeneity of study design prevented formal meta-analysis. 
Nevertheless, patients with IBS should be encouraged to increase physical activity, 
where feasible, as there is the potential for symptom improvement. 
1.5.2.5 Leisure Time and Relaxation 
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NICE guidelines for the treatment of IBS advise encouraging patients to make 
the most of their leisure time, and to create opportunities for relaxation. 269 The impact 
of this advice on symptoms and quality of life is uncertain; however, it has been 
demonstrated that everyday stress and IBS symptoms are related, 270 and patients with 
IBS report greater stress than controls. 271 Although the relationship between stress and 
gastrointestinal symptoms may be reciprocal, rather than causal, there remains a clear 
logic for promoting relaxation among patients with IBS, which may benefit some 
individuals. The role of formal psychological therapy is discussed in more detail below. 
1.5.3 Specialised Dietary Advice 
If first-line dietary advice is ineffective, patients should be referred for 
assessment by a specialist dietitian. It is important to recognise that, although exclusion 
diets are commonplace in IBS management, the mechanisms by which they might work 
remain unclear. Dietetic assessment is key to ensuring that any diet is followed 
correctly, and that nutritional requirements are not compromised. 
1.5.3.1 Low FODMAP Diet 
One of the most widely utilised diets in IBS is a low FODMAP diet. 272 A 
systematic review and meta-analysis published in 2018 identified seven RCTs 
comparing a low FODMAP diet with various dietary controls, including habitual diet or 
a high FODMAP diet, involving 397 participants. 273 Meta-analysis demonstrated a 
benefit in patients adopting a low FODMAP diet, compared with control (RR = 0.69; 
95% CI 0.54-0.88). However, quality of evidence was very low. No trials were at low 
risk of bias, due primarily to the difficulties of blinding in dietary intervention studies, 
sample sizes were small, and heterogeneity was significant, driven by the variation in 
the control interventions used in trials. This means the efficacy of a low FODMAP diet 
may have been overestimated. Furthermore, trials only examined the initial exclusion 
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phase of the diet, and did not evaluate effects of the managed re-introduction of 
FODMAP-containing foods according to tolerance, which is recommended longer-term. 
Overall, the exclusion of foods high in FODMAPs may reduce IBS symptoms, and can 
be recommended to patients, although there is a need for higher quality evidence to 
guide management.  
1.5.3.2 Gluten-Free Diet 
As already discussed, all patients with IBS symptoms should be tested for 
coeliac disease; however, patients testing negative may still report that they experience 
symptoms related to eating food containing gluten. This situation is described as non-
coeliac gluten sensitivity, the pathogenesis of which is poorly understood, and for which 
there is no specific diagnostic test. 274 Management therefore relies upon a period of 
gluten exclusion, and assessment of symptomatic response.  
 A systematic review and meta-analysis from 2018 identified two RCTs of a 
gluten-free diet (GFD) in IBS, involving 111 patients. 273 In each trial, participants had 
already noted a symptomatic response to gluten exclusion, and were randomised to 
either continue a GFD, or consume a diet contaminated with gluten. Individually, both 
trials reported statistically significant results in favour of a GFD, showing that a greater 
proportion of those randomised to receive a gluten-contaminated diet reported IBS 
symptom flares. 275, 276 However, when study results were pooled, there was no 
significant difference (RR 0.42; 95% CI 0.11-1.55). 273 It is important to recognise that 
the gluten-challenge design of the trial might increase the likelihood of some patients 
reporting symptoms, due to their anticipation of the potential for negative consequences. 
 Overall, if a patient with IBS has already adopted a GFD and experienced an 
improvement in their symptoms, it might be reasonable for them to continue this 
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approach, following dietetic assessment. However, current evidence does not support 




1.5.4 First-Line Drug Treatments 
If dietary and lifestyle advice are inadequate for improving symptoms, then a 
number of first-line drug treatments, targeting individual symptoms, are available. 
1.5.4.1 Antispasmodics and Peppermint Oil 
Conventional analgesic drugs, such as paracetamol, non-steroidal anti-
inflammatory drugs, and opiates are unlikely to relieve pain in IBS, and some have the 
potential to exacerbate gastrointestinal symptoms. Instead, antispasmodic drugs, 
including peppermint oil, should be used to ameliorate pain and bloating, based on the 
theory that dysmotility and gut spasm might be the underlying cause of these symptoms, 
and that antispasmodics relax gut smooth muscle. 
A meta-analysis from 2008 identified 22 studies comparing 12 different 
antispasmodics with placebo in 1778 patients. 277 Fewer patients assigned to 
antispasmodics had persistent symptoms after treatment compared with those taking 
placebo (RR = 0.68; 95% CI 0.57-0.81), although heterogeneity between studies was 
significant. The analysis included a wide range of drugs, including some, such as 
otilonium, cimetropium, and pinaverium that are unavailable in many countries. 
However, hyoscine is widely available, and pooled results from three RCTs in over 400 
patients showed that it was an efficacious treatment (RR = 0.63; 95% CI 0.51-0.78). 
Conversely, neither mebeverine nor alverine were more efficacious than placebo, 
although, in both cases, data came from a single small trial. Overall, total adverse events 
were significantly more common with antispasmodics, particularly dry mouth, blurred 
vision, and dizziness. Another meta-analysis conducted as part of the American College 
of Gastroenterology guidelines in 2018, 278 and pooling data from seven RCTs, 
demonstrated a statistically significant result in favour of peppermint oil compared with 
placebo (RR = 0.54; 95% CI 0.39-0.76). However, there was significant heterogeneity 
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between study results, and the overall quality of evidence was low. Total adverse events 
were no more common with peppermint oil compared with placebo.  
Overall, currently available evidence, although modest, supports the role of 
antispasmodics, particularly hyoscine, and peppermint oil in treating IBS, and NICE 
recommends that physicians should consider prescribing them. 269 The two can be used 
in combination, if desired. However, these drugs may appear less effective from the 
perspective of secondary care physicians since many patients referred with IBS are 
likely to have failed to respond to these treatments in primary care.  
1.5.4.2 Antidiarrhoeals 
As discussed, patients with IBS-D can be particularly debilitated by loose stools, 
with urgency and incontinence, 279 restricting and disrupting daily life. 86 Consequently, 
many patients use loperamide to control their diarrhoeal symptoms. Although widely 
used, evidence for its efficacy is lacking. There have been only two small trials in IBS, 
both conducted over 30 years ago, and involving only 42 patients with either IBS-D, 280 
or IBS-M. 281 A pooled analysis of data from these trials demonstrated no statistically 
significant effect of loperamide, compared with placebo on global IBS symptoms, 278 
although in the RCTs themselves there were improvements in stool frequency and 
consistency. Despite the fact that patients frequently report inadequate symptom relief 
with the drug, 282 and due in part to a lack of efficacious alternatives, it is likely some 
patients will continue to use loperamide. Indeed, NICE guidance advocates loperamide 
as the first-choice drug for diarrhoea in IBS, 269 but physicians should be aware that 
patients may be dissatisfied with this strategy. 
1.5.4.3 Laxatives 
NICE guidelines recommend laxatives should be considered for treating IBS-C, 
with patients advised on how to adjust the dose according to clinical response. 269 
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Lactulose should be avoided as it may cause bloating, but otherwise, which laxatives 
should be preferred is unclear. Both osmotic and stimulant laxatives are efficacious in 
chronic constipation. 283 However, there is little evidence in IBS-C, beyond the findings 
of two trials of polyethylene glycol (PEG), an osmotic laxative. In the first of these 
studies, 42 patients with IBS-C were randomised to either PEG or placebo for 30 days. 
284 There was relief of symptoms and an increase in bowel movements in both the 
treatment and the placebo arms of the trial; however, there was no significant difference 
between the two. Conversely, in another study, which recruited 139 patients with IBS-
C, there was a significant increase in spontaneous bowel movements with PEG, 
compared with placebo, after 4 weeks. 285 There was also a trend towards improvements 
in bloating with PEG, but no evidence of benefit in terms of effect on abdominal pain. 
Unfortunately, the long-term efficacy of laxatives in IBS, which is important given the 
chronicity of symptoms, remains unclear. Overall, these limited data suggest that PEG 
might be efficacious in terms of improving bowel frequency in IBS-C, at least in the 
short-term, but the impact on global symptoms appears minimal. Nevertheless, use of 
laxatives, which are widely available and relatively inexpensive, is a reasonable first-
line approach, with escalation to second-line drugs reserved for patients who report an 
unsatisfactory clinical response.  
1.5.5 Second-Line Drug Treatments 
Patients may report inadequate relief of symptoms with first-line treatments, and 
for patients who are referred to see a gastroenterologist, it is perhaps more likely that 
this will be the case. In this situation, second-line treatment with central 
neuromodulators, such as TCAs or selective serotonin reuptake inhibitors (SSRIs), can 
be utilised. Again, this approach is endorsed by NICE guidelines. 269 Their use is 
underpinned by the central role of the gut-brain axis in IBS pathophysiology, which has 
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already been discussed. Central neuromodulators might act on pathways between gut 
and brain to improve IBS symptoms. 
A systematic review and meta-analysis from 2019 identified 18 RCTS 
comparing TCAs or SSRIs with placebo in IBS, recruiting a total of 1127 patients, with 
a significant benefit in favour of central neuromodulators (RR = 0.66; 95% CI 0.57-
0.76). 286 However, there was significant heterogeneity between studies, although only 
among trials of SSRIs. A subgroup analysis showed an overall benefit in favour of 
TCAs for abdominal pain, compared with placebo (RR = 0.59; 95% CI 0.42-0.83). The 
effect of these drugs on bowel habit is unclear. Most studies did not recruit participants 
on the basis of stool pattern, nor did they evaluate specific stool consistency endpoints. 
Given that constipation is a frequently reported side effect of TCAs, these drugs may 
have a positive impact in IBS-D, but only one trial examined this. 287 Equally, using 
TCAs to treat abdominal pain in patients with IBS-C may exacerbate constipation. In 
terms of safety, eight RCTS provided data for total adverse events, with a significantly 
higher incidence with central neuromodulators (RR of any adverse event = 1.56; 95% 
CI 1.23-1.98).  
Overall, the available data supports the use of central neuromodulators for 
treating IBS, when first-line treatments are ineffective. TCAs should be preferred, and 
the dose increased depending on symptomatic response, although dose titration beyond 
50mg may lead to higher rates of adverse events. If symptoms do not improve, SSRIs 
are a reasonable alternative. Although there is no evidence from RCTs to support the 
use of serotonin norepinephrine reuptake inhibitors (SNRIs), they are beneficial in other 
chronic painful disorders, 288 and there are reports of efficacy in some patients with IBS, 
particularly those with psychological comorbidity. 289 Therefore, SNRIs can be 
considered for the treatment of abdominal pain in some patients with IBS for whom 
other central neuromodulators have proven ineffective. 
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1.5.6 Second-Line Drug Treatments Targeting Abnormalities of Stool 
Pattern 
As already discussed, antidiarrhoeals and laxatives can be used in the treatment 
of abnormal stool pattern; however, where these prove ineffective, second-line drugs 
targeting abnormalities in stool pattern are available. 
1.5.6.1 Drugs for Constipation 
A number of novel secretagogues have been developed over the last 10 years, 
although not all are widely available. These share a common general mechanism of 
action, although the precise pharmacological effects differ between drugs. Broadly, they 
activate ion channels in epithelial cells of the gut mucosa, increasing electrolyte and 
fluid content of the intestinal lumen, thereby softening stools and increasing 
gastrointestinal transit. 
 One of the first of these drugs to be developed and licensed was lubiprostone, a 
prostaglandin E1 derivative. It activates chloride type-2 channels on the apical surface of 
intestinal enterocytes. The efficacy of lubiprostone 8mcg twice daily in IBS-C was 
evaluated in two placebo-controlled trials, in a total of 1,171 patients. 290 In both trials, a 
significantly greater proportion of patients randomised to lubiprostone reported 
moderate or significant relief of IBS symptoms; however, nausea was a common 
adverse event, affecting 8% of participants.  
 Linaclotide and plecanatide stimulate the guanylate cyclase-C receptor. In two 
RCTs conducted in North America, linaclotide 290mcg once daily was superior to 
placebo for IBS-C, at 12 weeks in one trial, and 26 weeks in the second. 291, 292 The 
primary endpoint used was a composite of improvement in both abdominal pain and 
stool frequency, as recommended by the Food and Drug Administration (FDA) for IBS 
treatment trials. Plecanatide, at doses of 3mg or 6mg once daily, was superior to placebo 
in two RCTs, recruiting 2,189 patients with IBS-C, 293 and using the same endpoint, 
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although there was no difference in efficacy between the two doses. Perhaps 
unsurprisingly, the main adverse event reported for both drugs was diarrhoea.  
 Finally, tenapanor, which inhibits the gastrointestinal sodium-hydrogen 
exchanger-3, is licensed for the treatment of IBS-C in the USA. A phase III placebo-
controlled trial of 12 weeks of tenapanor 50mg twice daily, in 629 patients, assessed 
response using the FDA composite endpoint. 294 The drug was significantly more 
efficacious than placebo. The main adverse event was diarrhoea; 6.5% of those taking 
tenapanor discontinued the drug as a result, compared with 0.7% of those taking 
placebo.  
Overall, these findings support the use of secretagogues in IBS-C. They may be 
best placed for patients who report inadequate relief following optimal or maximum 
tolerated doses of laxatives from different classes. 269 
1.5.6.2 Drugs for Diarrhoea 
A number of second-line drugs with a diverse range of mechanisms of action are 
available for treating IBS-D. One of these is the minimally absorbed antibiotic 
rifaximin. The rationale for its use is the observation that patients with IBS can exhibit 
changes in their faecal microbiota, 152 and because some studies have shown an overlap 
between small intestinal bacterial overgrowth and IBS, although evidence for this is 
largely of low quality. 295 In two RCTs, each recruiting almost 600 patients, rifaximin 
500mg three times daily for 14 days was superior to placebo. 296 Efficacy was defined 
as adequate relief of IBS symptoms for 2 of the first 4 weeks after completion of 
treatment. However, the difference in response rates between treatment and placebo 
arms was modest, at around 8%. The main adverse event was headache, affecting 6% of 
patients. Due to the modest effect, and concerns over potential for adverse events with 
repeated courses of rifaximin, FDA approval was not forthcoming. A “re-treatment” 
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trial was therefore conducted. In this study, 2579 patients with IBS-D received a 2-week 
course of open-label rifaximin. The 636 patients who responded and then relapsed were 
re-randomised to up to two further 2-week courses of rifaximin, 10 weeks apart, or 
placebo. 297 After the first course, 33% of those taking rifaximin responded compared 
with 25% of those taking placebo, with similar response rates following the second 
course. In each case, these differences reached statistical significance, but again the 
therapeutic gain was modest.  
Drugs that activate µ-opioid receptors in the intestine, such as loperamide, retard 
gut motility and can treat diarrhoea, whereas those acting on δ-opioid receptors can 
improve pain. Eluxadoline, a mixed µ- and δ-opioid receptor drug, has been evaluated 
in two RCTs in IBS-D, recruiting over 2400 patients. 298 The primary endpoint was a 
composite of improvement in abdominal pain and stool consistency at 12 weeks. Both 
trials demonstrated that eluxadoline at doses of 75mg twice daily and 100mg twice daily 
were significantly more efficacious than placebo; however, differences in response rates 
were modest. In a subsequent study, 346 adults with IBS-D who reported inadequate 
symptom relief with loperamide were randomised to receive eluxadoline 100mg twice 
daily or placebo for 12 weeks. 299 Once again, a significantly greater proportion of 
patients taking eluxadoline achieved the composite endpoint, compared with those 
taking placebo. A particular concern with eluxadoline is the risk of pancreatitis, 
especially in patients with prior cholecystectomy.  
 5-HT3 receptor antagonists, such as alosetron and ramosetron, retard gut 
motility. A previous meta-analysis of eight RCTs of alosetron for the treatment of IBS-
D, involving 4987 patients, demonstrated a benefit of alosetron (RR = 0.79; 95% CI 
0.69-0.90) when compared with placebo. 300 Although licensed for use in women with 
IBS-D in the USA, the drug was withdrawn due to subsequent safety concerns relating 
to ischaemic colitis and severe constipation. It has been reintroduced for the treatment 
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of severe IBS-D in women in the USA, and observational data from around 2000 
patients suggest it is safe and efficacious in this patient group, 301 but it is not available 
elsewhere. There are no such safety concerns with ramosetron, and data from five 
Japanese RCTs demonstrate consistently that it is significantly more efficacious than 
placebo for treating IBS-D. 302 Ramosetron is only available in Japan and some other 
Asian countries. However, data from a small crossover trial of ondansetron, 228 and a 
recent trial of bimodal release ondansetron, 303 suggest this 5-HT3 receptor antagonist 
may also be beneficial in IBS-D.  
Unfortunately, the availability of second-line drug options for IBS-D is limited. 
Rifaximin is licensed in North America for IBS, but is not universally available, and 
eluxadoline has been withdrawn in many countries. It would appear that 5-HT3 receptor 
antagonists are efficacious and, where alosetron or ramosetron are unavailable, 
ondansetron may be a reasonable alternative. Other options include bile acid 
sequestrants, such as colesevelam, given the overlap between IBS and bile acid 
diarrhoea, although there are no RCTs of these agents in IBS-D. 304 
1.5.7 Psychological Therapies 
The efficacy of a number of psychological therapies in IBS has been 
investigated. Among the most widely utilised is cognitive behavioural therapy (CBT). 
Early trials of CBT suggested it was efficacious in IBS, 305, 306 although individual trial 
results are conflicting, with some RCTs finding no benefit compared with standard IBS 
care. 307 One problem with any trial of psychological therapy is the inability to blind 
participants to treatment, meaning studies are rarely at low risk of bias. Furthermore, 
sample sizes are often small, reflecting the intensive nature of psychological 
interventions, which often require a skilled practitioner working face-to-face with a 
motivated patient over several weeks. These practical constraints may limit availability 
in clinical practice. More recently, larger studies have examined the role of minimal-
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contact CBT, 308 which participants can self-administer at home, or CBT delivered via 
the telephone or internet. 309 These approaches require therapist input, but at a reduced 
frequency, meaning they can be made more widely available. Results of such trials 
suggest these approaches are efficacious at improving IBS symptoms. 308, 309 The 
beneficial effects of CBT delivered over the telephone or via the internet persisted up to 
24 months after completion of treatment in one study. 310  
 Gut-directed hypnotherapy has also been used in IBS, and, again, small studies 
indicate it is likely to be efficacious, 311, 312 although it has been suggested that delivery 
outside specialist centres is less beneficial. 313 Similar to CBT, treatment with 
hypnotherapy requires a skilled practitioner, but it has been delivered remotely in one 
uncontrolled study. 314 Group hypnotherapy may also improve patient access to 
treatment. In a multicentre RCT comparing individual and group hypnotherapy with 
educational support as a control, hypnotherapy was significantly more efficacious than 
education for adequate relief of symptoms at 3 months and, in a per-protocol analysis, 
group hypnotherapy was non-inferior to individual hypnotherapy. 315   
 Overall, several psychological therapies are efficacious in IBS, although it 
remains difficult to know which should be preferred, and patient access may be limited. 
CBT-based treatment and gut-directed hypnotherapy have the largest evidence base, and 
CBT has demonstrated longer-term efficacy. NICE recommends psychological 
therapies for patients who remain symptomatic following medical treatment, but only 
after 12 months has elapsed. 269 There is an argument for earlier deployment of such 
therapies, especially among patients with evidence of psychological comorbidity at 
baseline as, given our understanding of the role of the gut-brain axis, this could alter the 
clinical course of IBS, preventing symptoms from becoming refractory and improving 
outcomes. This should be a focus for future treatment trials.  
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1.5.8 Personalised Treatment in IBS 
This summary of the current treatment paradigm for IBS has highlighted that a 
broad range of options are available. Most are intended to address a single 
gastrointestinal symptom, such as abdominal pain, and, indeed, current guidelines for 
the management of IBS recommend targeting treatment towards the patient’s 
predominant symptom(s). In addition, subgrouping people with IBS according to their 
stool pattern can help direct treatment with respect to diarrhoea and constipation. 
Nevertheless, there are a number of problems with this situation. 
Firstly, most patients experience a cluster of different gastrointestinal symptoms 
simultaneously and may have an alternating bowel habit. Therefore, understanding how 
best to deploy combinations of different treatments is important, but difficult. Second, 
most gastrointestinal symptoms have a range of different treatments options available. 
Although this choice is helpful, knowing which drug should be preferred is challenging. 
As has been shown, conventional meta-analysis is a useful tool for understanding the 
efficacy of individual treatments by pooling all available trial data together. It does not, 
however, facilitate comparison of different drugs, and there are few head-to-head drug 
trials in IBS, with most drugs having been compared with placebo only. Fortunately, 
network meta-analysis is a statistical technique that can help to resolve this uncertainty, 
enabling estimation of the relative efficacy of treatments. This can assist physicians and 
patients to make better informed treatment choices. Finally, IBS is a complex condition, 
a disorder of gut-brain interaction, with a complicated underlying pathophysiology that 
is likely to differ between patients, even in the presence of identical gastrointestinal 
symptoms. Extra-intestinal symptoms and psychological comorbidity are important, but 
the current management paradigm does not emphasise these, and psychological 
therapies are often the last step in current treatment algorithms. 
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Consequently, more integrated approaches to management that seek to direct 
treatment according to a mixture of factors, rather than focussing on a single 
gastrointestinal symptom in isolation, may offer a means of personalising the care of 
people with IBS, which might improve outcomes. To some extent, this could be 
achieved on a case-by-case basis by the individual physician, particularly one with an 
interest in the management of IBS, who strives to apply the recommendations of the 
MDCP in their daily clinical practice. However, new approaches to the subgrouping of 
all patients with IBS might provide a more widely applicable framework, and one that 
could be easily utilised, even by those gastroenterologists without a subspecialist 
interest in functional gastrointestinal disorders. Not only might this promote a more 
personalised attitude to treatment overall, but it could also help to ensure that the 
approach was standardised between patients, with the aim of providing high-quality and 
high-value care to all those suffering from IBS.
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The overarching aims of this thesis are to investigate new approaches to 
subgrouping people with IBS which look beyond gastrointestinal symptoms in isolation, 
and incorporate additional factors, such as measures of psychological health, and to 
assess the stability of these new subgroups in order to understand whether they could be 
used to personalise treatment or predict clinical outcomes. This will be achieved by 
firstly examining the current practice of subgrouping people with IBS according to 
predominant stool pattern, and using this to direct treatment, through investigation of 
the relative efficacy of drugs developed specifically to target either IBS-C, or IBS-D 
and IBS-M. Second, a cohort of individuals with IBS will be characterised at baseline, 
examining whether demographic and clinical differences exist between people 
dependent on whether the Rome IV or Rome III criteria are used to define IBS. Finally, 
mathematical modelling will be used to derive new subgroups in the cohort, including 
making a comparison between the Rome III and Rome IV criteria, and longitudinal 
follow-up will be undertaken. The following pieces of work have been conducted: 
2.1 Assessing the Relative Efficacy of Secretagogues in Patients with 
Irritable Bowel Syndrome with Constipation 
As discussed, the Rome criteria advocate subgrouping patients with IBS according 
to their predominant stool form, be that constipation, diarrhoea, or a mixture of both 
stool types. The aim of this classification is to help direct treatment. First-line treatment 
for IBS-C includes dietary changes, such as increasing fibre intake, and use of laxatives; 
however, a number of second-line drugs, called secretagogues, have also been 
developed. These drugs, including linaclotide, plecanatide, lubiprostone, and tenapanor, 
treat constipation by increasing electrolyte and fluid flux into the intestinal lumen, and 
increasing gut motility. Each secretagogue has been evaluated individually in rigorous 
RCTs which demonstrate that they are effective for the treatment of IBS-C in 
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comparison to placebo; however, their relative efficacy remains uncertain because no 
head-to-head trials have been conducted.  
Consequently, the aim of this study, described in Chapter 3, was to conduct a 
network meta-analysis to appraise the relative efficacy and safety of secretagogues for 
the treatment of IBS-C. Network meta-analysis is a statistical technique that facilitates 
indirect treatment comparisons between active therapies in different trials, where these 
therapies share a common comparator, such as a placebo. It also enables the ranking of 
treatments to inform clinical decision making. 
Although it makes clinical sense to identify and treat individual symptoms, such as 
constipation, with a suitable drug, it is plausible that treatment response is mediated, at 
least in part, by additional factors, such as fundamental pathophysiological 
abnormalities or psychological health, that are not routinely assessed. Similarly, the 
underlying cause of a particular symptom might also vary between patients. 
Consequently, by considering treatment outcomes across a number of drugs designed 
specifically to target stool form abnormalities, this network meta-analysis also allows 
some assessment of the extent to which subgrouping patients with IBS using stool 
pattern alone, as per Rome criteria for IBS-C, is useful for determining choice of 
treatment, and whether all drugs have similar efficacy. 
2.2 Assessing the Relative Efficacy of Pharmacological Therapies in Patients 
with Irritable Bowel Syndrome with Diarrhoea or Mixed Stool Pattern 
The treatment of people with IBS-D or IBS-M is broadly similar to the approach 
taken with respect to people with IBS-C; should individuals report an inadequate 
response to first-line therapies, such as anti-diarrhoeal medications, a range of second-
line drugs are available. These drugs, which include alosetron, ramosetron, eluxadoline, 
and rifaximin, have contrasting mechanisms of action. Alosetron and ramosetron may 
retard gut motility and alter rectal compliance via serotonergic pathways, eluxadoline is 
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a peripherally-acting mixed opioid receptor agonist and antagonist that reduces visceral 
sensitivity and slows gut transit, and rifaximin is a minimally absorbed antibiotic that 
may exert its therapeutic effects via changes to the gut microbiome. Again, each of 
these drugs has been shown to be effective for the treatment of IBS-D and IBS-M in 
placebo-controlled trials, but their relative efficacy is unknown because, similar to 
secretagogues in IBS-C, head-to-head trials are lacking.  
Thus, the aim of Chapter 4, was to conduct a network meta-analysis of second-line 
pharmacological therapies for IBS-D and IBS-M to evaluate their relative efficacy and 
safety, and to facilitate ranking of treatments. This study, therefore, complements the 
work conducted in Chapter 3 analysing treatment trials in IBS-C. It also offers a further 
opportunity to appraise the merits of directing treatment according to predominant stool 
pattern in isolation, in this case IBS-D or IBS-M, using drugs specifically intended for 
this purpose, among patients who were subgrouped in this way using the Rome criteria. 
2.3 Describing the Epidemiological, Clinical, and Psychological 
Characteristics of Individuals with Self-reported Irritable Bowel 
Syndrome and Exploring Differences Based on the Rome IV Versus 
Rome III Criteria 
As discussed, IBS is diagnosed according to symptom-based criteria, called the 
Rome criteria. These criteria define the cardinal symptoms of IBS as abdominal pain, 
related to defaecation, associated with a change in the frequency and/or form of stools. 
The most recent iteration, Rome IV, was published in 2016 and made several key 
changes to their predecessor, Rome III, in an attempt to make the criteria more specific 
for diagnosing IBS. Changes included removing the term “discomfort” from the 
definition, whilst also increasing the minimum frequency of abdominal pain required to 
meet criteria from at least three times per month to at least once per week. Together, 
these changes serve to make the Rome IV criteria more restrictive. This has potentially 
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important implications for clinical practice and recruitment to research studies, as many 
previous drug trials, such as several of those detailed in Chapters 2 and 3, recruited 
patients using the Rome III criteria, which may select patients with less severe 
symptoms, compared with trials applying the stricter Rome IV criteria. Although 
previous studies suggest that most people meeting Rome III criteria for IBS still meet 
Rome IV criteria, these studies had important methodological flaws including, most 
notably, use of a retrospective surrogate set of criteria to approximate Rome IV, rather 
than applying the full Rome III and Rome IV criteria simultaneously.  
Consequently, the aim of the study reported in Chapter 5 was to recruit a large 
cohort of people with IBS, and examine whether demographic and clinical differences 
exist between participants dependent on whether the Rome IV or Rome III criteria are 
used to define IBS, by applying both sets of criteria simultaneously. The study also 
examined what happened to individuals who met Rome III criteria for IBS, but no 
longer met criteria according to Rome IV, in terms of their reclassification to one of the 
other four functional bowel disorders. Having comprehensively evaluated the baseline 
characteristics of this cohort, these data were subsequently used to fulfil the aim of 
exploring novel approaches to subgrouping patients with IBS as outlined below.  
2.4 Using Latent Class Analysis to Identify Distinct and Reproducible 
Subgroups of People with Irritable Bowel Syndrome Based on 
Gastrointestinal Symptoms and Psychological Profiles 
In addition to the pattern of gastrointestinal symptoms that define IBS, it is 
recognised that other factors, such as psychological health and the reporting of extra-
intestinal symptoms, called somatisation, are also relevant to IBS symptomatology. 
Consequently, the current practice of subgrouping people with IBS according to their 
predominant stool pattern does not accurately reflect the complex, multifactorial nature 
of this disorder. In turn, this means that, although this classification system might help 
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clinicians to select treatments for diarrhoea or constipation, as described in Chapters 3 
and 4, it does not help to identify individuals who may benefit from other treatments, 
such as psychological therapies, or combinations of different approaches. Although the 
Rome IV criteria have placed greater emphasis on elements of the illness experience 
other than gastrointestinal symptoms, such as considering the impact of IBS on daily 
life, or the role of psychological stressors, this approach is only designed to be used on a 
case-by-case basis. If, instead, patients with IBS could be classified, not only by clinical 
symptoms, but also by psychological profiles, this may lead to more a tailored approach 
to treatment, with the potential to improve outcomes and reduce costs. The few studies 
that have examined this issue have suggested that such an approach is feasible. 
Nevertheless, these studies have limitations, including a failure to validate the 
subgrouping models they derived, and one study used a small cohort of patients 
recruited in a subspecialty setting. There are, therefore, issues regarding the 
generalisability of these findings, including inconsistencies in the number, and 
characteristics, of subgroups between studies, as well as within studies, dependent on 
which iteration of the Rome criteria was used to define IBS. 
Consequently, having explored the broader contrasts between Rome III and Rome 
IV-defined IBS in Chapter 5, in terms of both gastrointestinal symptoms and 
psychological health, the aim of this study, detailed in Chapter 6, was to derive new 
subgroups of people with IBS by using a combination of these factors. Moreover, the 
study aimed to investigate whether these were reproducible, irrespective of diagnostic 
criteria used to define IBS, and examined whether there are differences between the 
subgroups with respect to demographic characteristics. The subgroups were derived 
using latent class analysis, a method of cluster-based mathematical modelling, and the 
study also aimed to validate the statistical model, thereby assessing whether it could 
legitimately be applied to other cohorts of people with IBS. This is an important 
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requirement of any new classification system if it is to be incorporated into clinical 
practice.  
2.5 Examining the Natural History and Prognostic Value of a Novel 
Classification System for Irritable Bowel Syndrome  
Previous longitudinal studies have demonstrated that the stool subgroups used to 
classify people with IBS are unstable over time. Patients often move between 
subgroups, and this fluctuation is not entirely explained by the treatment that patients 
receive. An alternative approach to subgrouping people with IBS, such as is described 
in Chapter 6, may prove better suited to promoting a more personalised approach to 
treatment, since it includes assessment of psychological health in addition to 
gastrointestinal symptoms. However, in order to appraise the feasibility of this concept, 
a longitudinal follow-up study is required, and this was the aim of the work described in 
Chapter 7. By applying the baseline model to follow-up data collected after 12-months 
in the same cohort of people, it was possible to assess the stability of these novel 
subgroups over time. In addition, the reasons for any changes in subgroup membership 
could be examined, including the role of treatment, and the prognostic value of the 




CHAPTER 3  
Assessing the Relative Efficacy of Secretagogues in Patients with 




It has already been discussed that patients with IBS are subgrouped according to 
the predominant stool pattern they experience, into those who report diarrhoea ≥25% of 
the time (IBS-D), constipation ≥25% of the time (IBS-C), or experience mixed stool 
pattern IBS and report both diarrhoea and constipation ≥25% of the time (IBS-M). 14 
This classification system according to predominant stool pattern is important, because 
it is used to guide treatment and, increasingly, novel pharmacological therapies are 
directed towards either IBS-C or IBS-D. Traditionally, first-line treatment for IBS-C has 
included soluble fibre, such as ispaghula. 278 A previous systematic review and meta-
analysis identified seven RCTs of ispaghula, 255 and although this was superior to 
placebo in terms of global symptom improvement, only one of these trials was at low 
risk of bias, 316 and none restricted their recruitment to patients with IBS-C. Laxatives, 
such as PEG, are often used for the treatment of IBS-C, 269  but there have been only 
two RCTs conducted, 284, 285 and although both trials reported a significant improvement 
in number of stools, there was no effect on abdominal pain scores. 
In the last 10 years, several novel secretagogues have been developed for the 
treatment of IBS-C. Lubiprostone is a prostaglandin E1 derivative, which activates the 
intestinal chloride channel type-2 on the apical surface of small intestinal enterocytes. 
Activation leads to chloride and water efflux into the luminal cavity. Linaclotide and 
plecanatide are peptides that stimulate the guanylate cyclase-C receptor, leading to 
electrolyte and fluid transport into the intestinal lumen. Tenapanor is a small-molecule 
inhibitor of the gastrointestinal sodium-hydrogen exchanger-3, which results in 
increased intraluminal sodium and water excretion. Although there is evidence from 
high-quality RCTs that all of these therapies are effective for the treatment of IBS-C, 
their relative efficacy is unknown. This is because there have been no head-to-head 
trials of these drugs. It is unlikely that any such trials will ever be performed, as they 
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would be expensive to conduct, because they would need huge numbers of patients in 
order to demonstrate superiority of one drug over another.  
Network meta-analysis can circumvent this problem to some extent, allowing 
indirect treatment comparisons between active therapies in placebo-controlled trials, and 
enabling the ranking of treatments in order to inform clinical decisions. 317 
Unfortunately, individual RCTs do not always use an identical design, recruit 
homogeneous groups of patients, or assess efficacy using the same endpoints. However, 
in the case of IBS-C, the FDA have made recommendations for the design of treatment 
trials, and endorsed standardised endpoints that should be used to judge the efficacy of 
novel therapies. It has, therefore, been possible to conduct a network meta-analysis of 
RCTs of very similar design, using identical treatment duration and, in many instances, 
identical efficacy endpoints, in order to examine the relative efficacy and safety of 
secretagogues tested in IBS-C. 
Another important consideration is that, even though it is logical to treat 
constipation with an appropriate drug as part of the management of people with IBS-C, 
it is plausible that treatment response is mediated, at least in part, by additional factors 
that do not form part of a routine clinical assessment. It has already been highlighted 
that these factors, such as fundamental pathophysiological abnormalities or 
psychological health, are potentially important with respect to IBS symptomatology. 
Moreover, the cause of constipation, and the relative role of these different contributory 
factors, might also vary between patients. Consequently, by considering treatment 
outcomes across a number of drugs designed specifically to target stool pattern 
abnormalities, this network meta-analysis also allows some assessment of the extent to 
which subgrouping patients with IBS using stool pattern alone, as per Rome criteria for 





3.2.1 Search Strategy and Study Selection 
A search of the medical literature was conducted using MEDLINE (1947 to June 
2018), EMBASE, EMBASE Classic (1947 to June 2018), and the Cochrane central 
register of controlled trials. In addition, clinicaltrials.gov was searched for unpublished 
trials, or supplementary data for potentially eligible studies. RCTs examining the effect 
of secretagogues (lubiprostone, linaclotide, plecanatide, and tenapanor) in adult patients 
(>16 years) with IBS-C were eligible for inclusion (Table 3-1).The first period of cross-




Table 3-1. Eligibility Criteria. 
Randomised controlled trials. 
Adults (participants aged >16 years). 
Diagnosis of IBS with constipation based on either a clinician’s opinion, or meeting 
specific diagnostic criteria*, supplemented by negative investigations where trials 
deemed this necessary. 
Compared lubiprostone, linaclotide, plecanatide, or tenapanor with each other, or with 
placebo. 
Minimum treatment duration of 12 weeks. 
Follow-up duration of 12 weeks. 
Dichotomous assessment of response to therapy in terms of effect on global IBS 
symptoms following therapy†.  
 
*Manning, Kruis score, Rome I, II, III, or IV. 
†Preferably patient-reported, and according to the FDA-recommended endpoint for IBS 




A diagnosis of IBS-C was based on either a clinician’s opinion, or meeting 
specific diagnostic criteria, for example the Rome criteria. Studies recruiting patients 
with chronic idiopathic constipation (CIC), or mixed populations of patients with IBS-C 
or CIC, where data were not reported separately for IBS-C, were ineligible. Only RCTs 
that examined the efficacy of currently licensed doses of lubiprostone, linaclotide, and 
plecanatide or, in the case of tenapanor, the dose taken forward to phase III trials, and 
which compared them with each other, or with placebo, were considered eligible. A 
minimum treatment duration of 12 weeks was required, in line with FDA 
recommendations for the design of treatment trials for the functional gastrointestinal 
disorders. All endpoints were extracted at 12 weeks, even for RCTs that provided 
efficacy data at other time points. This was done in order to provide as much 
homogeneity as possible between individual trial results, and to avoid overestimating 
the efficacy of one drug relative to another, as the placebo effect tends to wane with 
time. 318 Studies had to report a dichotomous assessment of response to therapy. First 
and senior authors of studies were contacted to provide additional information on trials, 
where required.  
The literature search was conducted independently by two investigators. Studies 
on IBS were identified with the terms: irritable bowel syndrome and functional 
disease(s), colon (both as medical subject headings (MeSH) and free text terms), and 
IBS, spastic colon, irritable colon, or functional adj5 bowel (as free text terms). These 
were then combined using the set operator AND with studies identified with the 
following terms: lubiprostone (both as a MeSH and free text term), and Amitiza, 
linaclotide, Constella, Linzess, plecanatide, Trulance, and tenapanor (as free text 
terms).  
There were no language restrictions, and abstracts identified by the initial search 
were evaluated independently by two investigators for eligibility. All potentially 
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relevant papers were obtained and evaluated in detail. Foreign language papers were 
translated, where required. Articles were assessed independently by two investigators, 
using pre-designed eligibility forms, according to the pre-defined eligibility criteria. 
Disagreements between investigators were resolved by discussion.  
3.2.2 Outcome Assessment 
The efficacy of all drugs, compared with each other or with placebo, in IBS-C 
was assessed in terms of failure to respond to therapy, with the endpoints of interest 
used to define response reported below. Secondary outcomes included adverse events 
occurring as a result of therapy (overall numbers, as well as individual adverse events, 
including diarrhoea, headache, abdominal pain, abdominal distension, or nausea). 
3.2.3 Data Extraction 
All data were extracted independently by two investigators on to a Microsoft 
Excel spreadsheet (XP professional edition; Microsoft Corp, Redmond, WA, USA) as 
dichotomous outcomes (response or no response to therapy). Some of the included 
eligible RCTs used different primary endpoints. However, the majority of trials of 
linaclotide, plecanatide, and tenapanor adhered to the FDA-recommended endpoint for 
patients with IBS-C, and reported treatment efficacy according to the proportion of 
patients experiencing a ≥30% improvement in abdominal pain accompanied by an 
increase of ≥1 complete spontaneous bowel movement (CSBM) per week from baseline 
for ≥50% of weeks. The RCTs of lubiprostone also applied these criteria retrospectively 
to a subset of patients in the two phase III studies.  
 In addition, due to the multitude of endpoints reported within the individual 
trials, it was also possible to assess the efficacy of therapies according to other 
dichotomous endpoints to define response to treatment, including: a) the primary 
endpoint used in each individual RCT; b) a ≥30% improvement in abdominal pain for 
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≥50% of weeks (abdominal pain responder); c) an increase of ≥1 CSBMs per week from 
baseline for ≥50% of weeks (CSBM responder); and d) a ≥30% improvement in 
bloating for ≥50% of weeks (bloating responder). 
For all included studies the following data were also extracted for each trial, 
where available: country of origin, number of centres, criteria used to define IBS-C, 
proportion of female patients, and dose and duration of therapy. Data were extracted as 
intention-to-treat analyses, with drop-outs assumed to be treatment failures (i.e. no 
response to therapy), wherever trial reporting allowed. If this was not clear from the 
original article, an analysis was performed on all patients with reported evaluable data. 
3.2.4 Quality Assessment and Risk of Bias 
Two investigators performed this independently at the study level. 
Disagreements were resolved by discussion. The Cochrane handbook was used to assess 
risk of bias, 319 by recording the method used to generate the randomisation schedule 
and conceal treatment allocation, whether blinding was implemented for participants, 
personnel, and outcomes assessment, whether there was evidence of incomplete 
outcomes data, and whether there was evidence of selective reporting of outcomes. 
3.2.5 Data Synthesis and Statistical Analysis 
A network meta-analysis was performed using the frequentist model, with the 
statistical package “netmeta” (version 0.9-0, https://cran.r-
project.org/web/packages/netmeta/index.html) 320 in R (version 3.4.2), 321 and reported 
according to the preferred reporting items for systematic reviews and meta-analyses 
(PRISMA) extension statement for network meta-analyses, 322 in order to explore 
indirect treatment comparisons of the efficacy and safety of each medication. Network 
meta-analysis results usually give a more precise estimate, compared with results from 
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standard, pairwise analyses, 323, 324 and can also rank treatments to inform clinical 
decisions. 317 
The symmetry and geometry of the evidence was examined by producing a 
network plot with node and connection size corresponding to the number of study 
subjects and number of studies respectively. A comparison adjusted funnel plot was 
produced to explore publication bias or other small study effects, for all available 
comparisons versus placebo, using Stata version 14 (Stata Corp., College Station, TX, 
USA). This is a scatterplot of effect size versus precision, measured via the inverse of 
the standard error. Symmetry around the effect estimate line indicates the absence of 
publication bias, or small study effects. 325 A pooled RR with 95% CIs was calculated to 
summarise the effect of each comparison tested, using a random effects model as a 
conservative estimate. There were no direct comparisons between the active treatment 
groups, so it was not possible to perform consistency modelling to check the correlation 
between direct and indirect evidence. 326   
Global statistical heterogeneity across all comparisons was assessed using the I2 
measure from the “netmeta” statistical package. The I2 measure ranges between 0% and 
100%, and is typically considered low, moderate, and high for values of 25% to 49%, 
50% to 74%, and ≥75% respectively. 327 The treatments were ranked according to their 
P-score. The P-score is a value between 0 and 1, with a higher score indicating a greater 
probability of the treatment being ranked as best. 328  However, the magnitude of the P-
score should be considered, as well as the treatment rank. The mean value of the P-score 
is always 0.5, so if treatments cluster around this value they are likely to be of similar 
efficacy. In the main analysis, data for the FDA-recommended endpoint to define 
treatment response in IBS-C was pooled, for all included RCTs that reported these data.  
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In addition, analyses were performed to assess the overall safety of each 
medication, including overall numbers of adverse events, as well as occurrence of 
diarrhoea, headache, abdominal pain, abdominal distension, or nausea.  
3.2.6 Principles of Network Meta-Analysis 
In simple terms, where two treatments, A and B, share a common comparator, for 
example a placebo, C, but have not themselves been directly compared in a trial, 
network meta-analysis enables the treatment effect between A and B to be estimated 
indirectly (Figure 3-1). This is because the magnitude and direction of the effect 
between treatment A and B and the shared comparator, placebo C, are all known from 
existing trial data. These data are referred to as direct evidence. If treatment D is now 
included, which has been compared with both treatment A and placebo C (Figure 3-2), 
the connections of the network become more complex and, by considering all the direct 
and indirect treatment estimates together, the relative efficacy of all included treatments 
can be estimated. Furthermore, as discussed, statistics can be used to rank treatments 

















Treatment A and treatment B have both been compared with treatment C directly in 
trials. This data can be used to calculate the treatment estimate between treatments A 
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= indirect evidence 
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Treatment D has now been added to the network. Treatment A and treatment D have 
been compared directly, but an indirect estimate is also available between them via their 
comparisons with treatment C. Overall, this diagram illustrates how treatments in the 
network can be compared with one another, either directly, indirectly, or using both 








= direct evidence 




The search strategy generated 1163 citations, 75 of which appeared to be relevant 
to the systematic review and were retrieved for further assessment (Figure 3-3). Of 
these, 62 were excluded for various reasons, leaving a total of 13 eligible articles, 
reporting on 15 trials that contained a total of 8462 patients. There were three RCTs, 
reported in two articles, 290, 329 of lubiprostone in IBS-C, six trials of linaclotide (four of 
which used linaclotide 290mcg once-daily (o.d.), the licensed dose in the USA, 291, 292, 
330, 331 and two a dose of 250mcg or 500mcg o.d., the licensed doses in Japan), 332, 333 
three RCTs of plecanatide, reported in two articles, 293, 334 and three RCTs of tenapanor. 
335-337 A further article was also included because it provided supplementary data, 
reporting efficacy according to FDA-recommended endpoints for lubiprostone in the 
two phase III RCTs. 338 However, it should be pointed out that this article did not report 
data for all patients included in these two trials. This was because some of the recruited 
patients would not have met the updated FDA-recommended CSBM and abdominal 
pain thresholds for inclusion in an IBS-C treatment trial, and they were, therefore, 
excluded from the analysis.
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Excluded (n = 62) because: 
• Dual publication = 51 
• No study results posted on 
clinicaltrials.gov = 4 
• No dichotomous data extractable 
= 3 
• Outcome of interest not reported 
= 2 
• Mixed population of patients 
with functional bowel disorders, 
no data for IBS patients 
available = 1 
• Pooled analysis of eligible and 
included trials = 1 
Studies identified in literature 
search (n = 1163) 
Studies retrieved for evaluation 
(n = 75) 
Eligible articles (n = 13) 
reporting: 
• 3 trials of lubiprostone 
• 6 trials of linaclotide 
• 3 trials of plecanatide 
• 3 trials of tenapanor 
Excluded (title and abstract revealed 
not appropriate) (n = 1088) 
101 
 
Agreement between investigators for trial eligibility for the 75 articles retrieved 
was excellent (Kappa statistic = 0.96). Detailed characteristics of individual RCTs are 
provided in Table 3-2. Risk of bias for all included trials is reported in Table 3-3. 
Twelve trials were at low risk of bias. 291, 292, 329-333 290, 293, 335 No trials making head-to-
head comparisons of one drug versus another were identified, meaning that direct 
evidence was only available in comparison with placebo. Active medications could, 






Table 3-2. Characteristics of Randomised Controlled Trials of Secretagogues Versus Placebo in IBS-C. 
Study Country and 




Primary Endpoint Used to Define Symptom 




Number of Patients Assigned to 
Active Drug, Dosage, Schedule, 
and Duration of Therapy 
Johanson 2008 329 USA, 19 sites Rome II criteria Treatment effectiveness rated as at least ‘moderately 
effective’ for all 4 weeks of the month, or ‘quite a bit 
effective’ for 2 or more of the 4 weeks of the month 
100 (90.0) 52 patients received lubiprostone 
8mcg b.i.d.* for 12 weeks 
Drossman 2009a 290  
and Chang 2016a 338 
USA, multiple sites Rome II criteria Moderate or significant relief of IBS symptoms for all 
4 weeks of the month, or significant relief for 2 or 
more of the 4 weeks of the month for 2 out of 3 months 
590 (90.0) 396 patients received lubiprostone 
8mcg b.i.d. for 12 weeks 
Drossman 2009b 290 
and Chang 2016b 338 
USA, multiple sites Rome II criteria Moderate or significant relief of IBS symptoms for all 
4 weeks of the month, or significant relief for 2 or 
more of the 4 weeks of the month for 2 out of 3 months 
581 (90.0) 387 patients received lubiprostone 
8mcg b.i.d. for 12 weeks 
Johnston 2010 330 USA and Canada, 92 
sites 
Rome II criteria ≥3 CSBMs† per week and an increase of 1 CSBM per 
week from baseline for ≥9 of 12 weeks 
170 (92.4) 85 patients received linaclotide 






Chey 2012 292 USA, 102 sites Rome II criteria ≥30% improvement in abdominal pain score and an 
increase of ≥1 CSBM from baseline for 6 of 12 weeks 
805 (89.6) 402 patients received linaclotide 
290mcg o.d. for 26 weeks 
Rao 2012 291 USA and Canada, 
118 sites 
Rome II criteria ≥30% improvement in abdominal pain score and an 
increase of ≥1 CSBM from baseline for 6 of 12 weeks 
803 (90.5) 406 patients received linaclotide 
290mcg o.d. for 12 weeks 
Fukudo 2018 332 Japan, 66 sites Rome III criteria Global assessment of relief of IBS symptoms 331 (90.5) 112  and 107 patients received 
linaclotide 250mcg or 500mcg o.d. 
respectively for 12 weeks 
Yang 2018 331 China, USA, 
Canada, Australia, 
and New Zealand 
Rome III criteria Considerable or complete relief of IBS symptoms for 6 
of 12 weeks 
839 (82.0) 406 patients received linaclotide 
290mcg o.d. for 12 weeks 
NCT02316899 
(unpublished) 333 
Japan, 61 sites Rome III criteria Global assessment of relief of IBS symptoms 500 (87.8) 249 patients received linaclotide 
500mcg o.d. for 12 weeks 
Miner 2014 334 USA, 99 sites Rome III criteria ≥30% improvement in abdominal pain score and an 
increase of ≥1 CSBM from baseline for 6 of 12 weeks 
171 
(unclear) 
86 patients received plecanatide 






Brenner 2018a 293 North America, 130 
sites 
Rome III criteria ≥30% improvement in abdominal pain score and an 
increase of ≥1 CSBM from baseline for 6 of 12 weeks 
1054 (76.4) 351 and 349 patients received 
plecanatide 3mg or 6mg o.d. 
respectively for 12 weeks 
Brenner 2018b 293 North America, 140 
sites 
Rome III criteria ≥30% improvement in abdominal pain score and an 
increase of ≥1 CSBM from baseline for 6 of 12 weeks 
1135 (71.8) 377 and 379 patients received 
plecanatide 3mg or 6mg o.d. 
respectively for 12 weeks 
Chey 2017 335 USA, 79 sites Rome III criteria ≥30% improvement in abdominal pain score and an 
increase of ≥1 CSBM from baseline for 6 of 12 weeks 
178 (86.8) 89 patients received tenapanor 




USA, 111 sites Rome III criteria ≥30% improvement in abdominal pain score and an 
increase of ≥1 CSBM from baseline for 6 of 12 weeks 
610 (81.4) 309 patients received tenapanor 




USA, 117 sites Rome III criteria ≥30% improvement in abdominal pain score and an 
increase of ≥1 CSBM from baseline for 6 of 12 weeks 
593 
(unclear) 
293 patients received tenapanor 
50mg b.i.d. for 26 weeks 
* b.i.d.; twice-daily  






Table 3-3. Risk of Bias of Randomised Controlled Trials of Secretagogues Versus Placebo in IBS-C. 
Study, drugs, and doses Method of Generation of 
Randomisation Schedule 
Stated? 
Method of Concealment of 
Treatment Allocation 
Stated? 
Blinding? No Evidence of 
Incomplete Outcomes 
Data? 
No Evidence of 




Johanson 2008 329, 
lubiprostone 8mcg b.i.d. 
Yes Yes Double Yes Yes Yes 
Drossman 2009a 290 and Chang 
2016a 338, lubiprostone 8mcg 
b.i.d. 
Yes Yes Double Yes Yes Yes 
Drossman 2009b 290 and 
Chang 2016b 338, lubiprostone 
8mcg b.i.d. 
Yes Yes Double Yes Yes Yes 
Johnston 2010 330, linaclotide 
290mcg o.d. 
Yes Yes Double Yes Yes Yes 
Chey 2012 292, linaclotide 
290mcg o.d. 






Rao 2012 291, linaclotide 
290mcg o.d. 
Yes Yes Double Yes Yes Yes 
Fukudo 2018 332, linaclotide 
250cmg or 500mcg 
Yes Yes Double Yes Yes Yes 
Yang 2018 331, linaclotide 
290mcg o.d. 
Yes Yes Double Yes Yes Yes 
NCT02316899 (unpublished) 
333, linaclotide 500mcg o.d. 
Yes Yes Double Yes Yes Yes 
Miner 2014 334, plecanatide 
3mg o.d. 
No No Double Yes Yes No 
Brenner 2018a 293, plecanatide 
3mg or 6mg o.d. 
Yes Yes Double Yes Yes Yes 
Brenner 2018b 293, plecanatide 
3mg or 6mg o.d. 
Yes Yes Double Yes Yes Yes 
Chey 2017 335, tenapanor 
50mcg b.i.d. 







336, tenapanor 50mcg b.i.d. 
No No Double Yes Yes No 
NCT02686138 (unpublished) 
337, tenapanor 50mcg b.i.d. 
No No Double Yes Yes No 
 





3.3.1.1 Failure to Achieve the FDA-recommended Endpoint to Define Treatment 
Response 
Eleven RCTs, reported in nine separate articles, 291-293, 331, 334-338  provided 
dichotomous data for failure to achieve the FDA-recommended endpoint to define relief 
of global symptoms in IBS-C. One of these was a post hoc analysis of the two phase III 
RCTs of lubiprostone, which reported efficacy according to FDA-recommended 
endpoints. 338 These trials included a total of 6641 patients, 3747 of whom were 
randomised to active treatment, and 2894 to placebo. The network plot is provided in 
Figure 3-4. When data were pooled there was borderline moderate global statistical 
heterogeneity (I2 = 29.4%). The comparison adjusted funnel plot for publication bias, or 
other small study effects, showed no asymmetry around the zero line (Figure 3-5). All 
treatments were significantly more effective than placebo, but linaclotide 290mcg o.d. 
was ranked as the most effective (P-score 0.91), in three RCTs (RR 0.81; 95% CI 0.76 
to 0.86) (Figure 3-6). This means that the probability of linaclotide being the most 
effective when all treatments, including placebo, were compared with each other was 
91%. Indirect comparison of active treatments revealed no significant differences 
between individual drugs and dosages (Table 3-4).
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Figure 3-4. Network Plot for Failure to Achieve the FDA-recommended Endpoint 















Placebo A 11 2,894 
Lubiprostone 8mcg b.i.d. B 2 289 
Linaclotide 290mcg o.d. C 3 1,225 
Plecanatide 3mg o.d. D 3 814 
Plecanatide 6mg o.d. E 2 728 





Figure 3-5. Funnel Plot for Failure to Achieve the FDA-recommended Endpoint to 
Define Treatment Response. 
 
Note: The horizontal axis represents the difference between the comparison-specific and 




Figure 3-6. Forest Plot of the Indirect Evidence for Failure to Achieve the FDA-
recommended Endpoint to Define Treatment Response. 
 
 
Note: The P-score is the probability of each treatment being ranked as best in the 








Table 3-4. League Table of Results for Failure to Achieve the FDA-recommended Endpoint to Define Treatment Response. 
Linaclotide  
290mcg o.d. 
     
0.96 (0.87; 1.06) 
Tenapanor  
50mg b.i.d. 
    
0.94 (0.83; 1.06) 0.98 (0.86; 1.11) 
Lubiprostone  
8mcg b.i.d. 
   








0.81 (0.76; 0.86) 0.85 (0.79; 0.92) 0.87 (0.78; 0.96) 0.87 (0.81; 0.94) 0.88 (0.82; 0.94) Placebo 
 
Relative risk with 95% confidence intervals in parentheses. Comparisons, column versus row, should be read from left to right, and are ordered relative 
to their overall efficacy. The treatment in the top left position is ranked as best after the network meta-analysis of indirect effects. Boxes shaded green 
denote a statistically significant difference. 
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3.3.1.2 Failure to Achieve the Primary Endpoint Used to Define Treatment 
Response in Each Trial 
When dichotomous data were pooled for failure to achieve relief of global 
symptoms of IBS-C, according to the primary endpoint used in each of the 15 eligible 
trials, 290-293, 329-337 there were 4846 patients randomised to active treatment and 3616 to 
placebo. There was no global statistical heterogeneity (I2 = 1.8%). The comparison 
adjusted funnel plot for publication bias, or other small study effects, showed some 
asymmetry around the zero line (Figure 3-7). All treatments were significantly more 
effective than placebo, with the exception of linaclotide 250mcg o.d., although the latter 
analysis was based on only 112 patients receiving this dose in one RCT, the summary 
RR was similar to the other drugs, and the CIs were wide. Overall, again linaclotide 
290mcg o.d. was ranked as the most effective (P-score 0.88), in four RCTs (RR 0.80; 
95% CI 0.77 to 0.84) (Figure 3-8). On indirect comparison of active treatments, 
significant differences were seen with linaclotide 290mcg o.d. compared with 
plecanatide 3mg o.d., plecanatide 6mg o.d., and lubiprostone 8mcg twice-daily (b.i.d.), 




Figure 3-7. Funnel Plot for Failure to Achieve the Primary Endpoint Used to 
Define Treatment Response in Each Trial. 
 
Note: The horizontal axis represents the difference between the comparison-specific and 




Figure 3-8. Forest Plot of the Indirect Evidence for Failure to Achieve the Primary 
Endpoint Used to Define Treatment Response in Each Trial. 
 
Note: The P-score is the probability of each treatment being ranked as best in the 






Table 3-5. League Table of Results for Failure to Achieve the Primary Endpoint Used to Define Treatment Response in Each Trial. 
Linaclotide 290mcg 
o.d. 
        
1.00 (0.90; 1.11) 
Linaclotide 500mcg 
o.d. 
       
0.95 (0.80; 1.13) 0.95 (0.78; 1.15) 
Linaclotide 250mcg 
o.d. 
      
0.94 (0.87; 1.02) 0.94 (0.84; 1.05) 0.99 (0.83; 1.19) 
Tenapanor  
50mg b.i.d. 
     
0.92 (0.86; 0.99) 0.92 (0.83; 1.02) 0.97 (0.81; 1.16) 0.98 (0.90; 1.06) 
Plecanatide  
6mg o.d. 
    




0.88 (0.82; 0.94) 0.88 (0.79; 0.97) 0.93 (0.78; 1.10) 0.93 (0.86; 1.01) 0.96 (0.89; 1.03) 0.96 (0.90; 1.03) 
Lubiprostone  
8mcg b.i.d. 
0.80 (0.77;0.84) 0.80 (0.73; 0.88) 0.85 (0.71; 1.00) 0.85 (0.80; 0.91) 0.87 (0.83; 0.92) 0.88 (0.84; 0.93) 0.91 (0.87; 0.96) Placebo 
 
Relative risk with 95% confidence intervals in parentheses. Comparisons, column versus row, should be read from left to right, and are ordered relative 
to their overall efficacy. The treatment in the top left position is ranked as best after the network meta-analysis of indirect effects. Boxes shaded green 
denote a statistically significant difference. 
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3.3.1.3 Failure to Achieve an Abdominal Pain Response 
There were 12 trials recruiting 7302 patients, reported in 10 separate articles, 291-
293, 331-333, 335-338 that reported dichotomous data for failure to achieve an abdominal pain 
response. Again, one of these papers reported a post hoc analysis of the two phase III 
RCTs of lubiprostone. 338 There were 4129 patients assigned to active therapy, and 3173 
allocated to placebo. When data were pooled there was no global statistical 
heterogeneity (I2 = 0%). The comparison adjusted funnel plot for publication bias, or 
other small study effects, showed no asymmetry around the zero line (Figure 3-9). All 
treatments were significantly more effective than placebo, with the exception of 
linaclotide 250mcg o.d. Again, linaclotide 290mcg o.d. was ranked as the most effective 
treatment (P-score 0.88), in three RCTs (RR 0.79; 95% CI 0.73 to 0.85) (Figure 3-10). 
Indirect comparison of active treatments revealed no significant differences between 




Figure 3-9. Funnel Plot for Failure to Achieve an Abdominal Pain Response. 
 
Note: The horizontal axis represents the difference between the comparison-specific and 





Figure 3-10. Forest Plot of the Indirect Evidence for Failure to Achieve an 
Abdominal Pain Response. 
 
Note: The P-score is the probability of each treatment being ranked as best in the 







Table 3-6. League Table of Results for Failure to Achieve an Abdominal Pain Response. 
Linaclotide 290mcg 
o.d. 
       
0.96 (0.85; 1.08) Tenapanor 50mg b.i.d.       
0.94 (0.85; 1.06) 0.98 (0.87; 1.11) Linaclotide 500mcg o.d.      
0.94 (0.85; 1.04) 0.98 (0.87; 1.10) 1.00 (0.89; 1.11) Plecanatide 6mg o.d.     




0.91 (0.77; 1.07) 0.95 (0.79; 1.13) 0.96 (0.81; 1.14) 0.97 (0.82; 1.14) 0.98 (0.80; 1.18) Linaclotide 250mcg o.d. 
0.91 (0.82; 1.00) 0.94 (0.84; 1.06) 0.96 (0.86; 1.07) 0.96 (0.87; 1.07) 0.97 (0.84; 1.12) 1.00 (0.85; 1.18) Plecanatide 3mg o.d.  
0.79 (0.73; 0.85) 0.82 (0.75; 0.90) 0.83 (0.77; 0.91) 0.84 (0.78; 0.90) 0.85 (0.75; 0.96) 0.87 (0.75; 1.01) 0.87 (0.81;0.93) Placebo 
 
Relative risk with 95% confidence intervals in parentheses. Comparisons, column versus row, should be read from left to right, and are ordered relative 
to their overall efficacy. The treatment in the top left position is ranked as best after the network meta-analysis of indirect effects. Boxes shaded green 
denote a statistically significant difference.
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3.3.1.4 Failure to Achieve a CSBM Response 
Failure to achieve a CSBM response was reported by 10 RCTs, which included 
6850 patients, and were published as nine separate articles. 291-293, 331-333, 335-337 In total, 
3840 patients were randomised to active therapy, and 3010 to placebo, and there was a 
high level of global statistical heterogeneity when data were pooled (I2 = 82.0%). The 
comparison adjusted funnel plot for publication bias, or other small study effects, 
showed no asymmetry around the zero line (Figure 3-11). Only linaclotide 290mcg o.d., 
linaclotide 500mcg o.d., and tenapanor 50mg b.i.d. were significantly more effective 
than placebo, with linaclotide 290mcg o.d. ranked first (P-score 0.76), in three RCTs 
(RR 0.76; 95% CI 0.65 to 0.88) (Figure 3-12). Again, indirect comparison of active 





Figure 3-11. Funnel Plot for Failure to Achieve a CSBM Response. 
 
Note: The horizontal axis represents the difference between the comparison-specific and 









Note: The P-score is the probability of each treatment being ranked as best in the 







Table 3-7. League Table of Results for Failure to Achieve a CSBM Response. 
Linaclotide 290mcg o.d.       
0.98 (0.76; 1.27) Linaclotide 500mcg o.d.      
0.94 (0.74; 1.18) 0.96 (0.73; 1.25) Tenapanor 50mg b.i.d.     
0.90 (0.64; 1.27) 0.92 (0.63; 1.33) 0.96 (0.68; 1.37) Linaclotide 250mcg o.d.    
0.90 (0.66; 1.21) 0.91 (0.65; 1.27) 0.95 (0.70; 1.31) 0.99 (0.66; 1.49) Plecanatide 6mg o.d.   
0.88 (0.65; 1.19) 0.90 (0.64; 1.25) 0.94 (0.69; 1.28) 0.98 (0.65; 1.46) 0.98 (0.68; 1.42) Plecanatide 3mg o.d. 
0.76 (0.65; 0.88) 0.77 (0.63; 0.95) 0.81 (0.68; 0.96) 0.84 (0.62; 1.14) 0.85 (0.65; 1.10) 0.86 (0.66; 1.12) Placebo 
 
Relative risk with 95% confidence intervals in parentheses. Comparisons, column versus row, should be read from left to right, and are ordered relative 
to their overall efficacy. The treatment in the top left position is ranked as best after the network meta-analysis of indirect effects. Boxes shaded green 
denote a statistically significant difference. 
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3.3.1.5 Failure to Achieve a Bloating Response 
Only five RCTs reported dichotomous data for failure to achieve a bloating 
response, and these were reported in four separate articles, 291, 292, 335, 338 and included 
2257 patients. Again, one of these papers reported a post hoc analysis of both of the two 
phase III RCTs of lubiprostone. 338 There were 1200 patients assigned to active therapy, 
and 1057 to placebo. When data were pooled there was low global statistical 
heterogeneity (I2 = 25.5%). There were too few studies to assess for publication bias, or 
other small study effects. Tenapanor 50mg b.i.d., linaclotide 290mcg o.d., and 
lubiprostone 8mcg b.i.d. were all more effective than placebo, with tenapanor ranked as 
the most effective treatment (P-score 0.79), in one RCT (RR 0.74; 95% CI 0.55 to 1.00) 
(Figure 3-13). However, the 95% CIs were wide and touched 1, and the P-score and RR 
were very similar to that for linaclotide 290mcg o.d. in two trials (P-score 0.76, RR = 
0.78; 95% CI 0.71 to 0.85). Given this was a secondary endpoint, with few trials 
reporting data, it is likely the network was underpowered to detect any differences. 
Indirect comparison of active treatments revealed no significant differences between 




Figure 3-13. Forest Plot of the Indirect Evidence for Failure to Achieve a Bloating 
Response. 
 
Note: The P-score is the probability of each treatment being ranked as best in the 






Table 3-8. League Table of Results for Failure to Achieve a Bloating Response. 
Tenapanor 50mg b.i.d.    
0.96 (0.70; 1.31) Linaclotide 290mcg o.d.   
0.87 (0.63; 1.21) 0.91 (0.78; 1.06) Lubiprostone 8mcg b.i.d.  
0.74 (0.55; 1.00) 0.78 (0.71; 0.85) 0.85 (0.75; 0.96) Placebo 
 
Relative risk with 95% confidence intervals in parentheses. Comparisons, column versus row, should be read from left to right, and are ordered relative 
to their overall efficacy. The treatment in the top left position is ranked as best after the network meta-analysis of indirect effects. Boxes shaded green 





3.3.2.1 Overall Adverse Events 
Twelve trials, recruiting 7088 patients and reported in 10 articles, provided 
overall adverse events. 290-293, 329-333, 335 There was no global statistical heterogeneity (I2 
= 0%). The comparison adjusted funnel plot for publication bias, or other small study 
effects, showed no asymmetry around the zero line (Figure 3-14). When comparing 
pooled overall adverse events, linaclotide 290mcg o.d. (four RCTs, RR = 1.12; 95% CI 
1.04 to 1.21), linaclotide 500mcg o.d. (two RCTs, RR = 1.24; 95% CI 1.01 to 1.53), and 
plecanatide 3mg o.d. (two RCTs, RR = 1.28; 95% CI 1.05 to 1.56) were associated with 
a significant increase in overall adverse events, compared with placebo (Figure 3-15). 
When ranked using a P-score, plecanatide 6mg o.d. was the best, and plecanatide 3mg 
o.d. the worst, in terms of overall adverse events (P-scores 0.69 and 0.23 respectively). 
As rates of individual adverse events were not reported separately in the plecanatide 
trials, other than the number of patients experiencing diarrhoea, which were almost 
identical with both doses of plecanatide, reasons for the higher rate of overall adverse 
events with the 3mg o.d. dose are uncertain. There may have been greater heterogeneity 
between trials of plecanatide 3mg o.d; however, importantly, on indirect comparison 
there were no significant differences between plecanatide 3mg o.d. and plecanatide 6mg 





Figure 3-14. Funnel Plot for Overall Adverse Events. 
 
Note: The horizontal axis represents the difference between the comparison-specific and 





Figure 3-15. Forest Plot of the Indirect Evidence for Overall Adverse Events. 
 
 
Note: The P-score is the probability of each treatment being ranked as best in the 






Table 3-9. League Table of Results for Overall Adverse Events. 
Placebo         
1.07 (0.86; 1.32) Plecanatide 6mg o.d.        
1.12 (1.04; 1.21) 1.05 (0.84; 1.32) 
Linaclotide 290mcg 
o.d. 
      
1.13 (0.81; 1.57) 1.06 (0.72; 1.57) 1.01 (0.72; 1.41) 
Linaclotide 250mcg 
o.d. 
     
1.20 (0.87; 1.64) 1.12 (0.77; 1.64) 1.07 (0.77; 1.48) 1.06 (0.67; 1.67) Tenapanor 50mg b.i.d.     




1.24 (1.01; 1.53) 1.17 (0.87; 1.57) 1.11 (0.89; 1.38) 1.10 (0.74; 1.62) 1.04 (0.71; 1.52) 1.03 (0.77; 1.39) 
Linaclotide 500mcg 
o.d. 
1.28 (1.05;1.56) 1.20 (0.90; 1.61) 1.14 (0.92; 1.41) 1.13 (0.77; 1.66) 1.07 (0.74; 1.56) 1.07 (0.80; 1.42) 1.03 (0.77; 1.38) Plecanatide 3mg o.d. 
 
Relative risk with 95% confidence intervals in parentheses. Comparisons, column versus row, should be read from left to right, and are ordered relative 
to their overall efficacy. The treatment in the top left position is ranked as best after the network meta-analysis of indirect effects. Boxes shaded green 
denote a statistically significant difference. 
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3.3.2.2 Adverse Events Leading to Dropout 
Adverse events leading to dropout were provided by 12 trials, reported in 10 
papers. 290-293, 329-333, 335 Linaclotide 290mcg o.d. (four RCTs, RR = 2.72; 95% CI 1.62 to 
4.57), plecanatide 6mg o.d. (two RCTs, RR = 5.37; 95% CI 1.42 to 20.4), and 
plecanatide 3mg o.d. (two RCTs, RR = 6.04; 95% CI 1.61 to 22.7) were all associated 
with significantly higher trial dropout rates due to adverse events, compared with 
placebo. When ranked using a P-score, lubiprostone 8mcg b.i.d. was the least likely to 
cause adverse events leading to dropout, and plecanatide 3mg o.d. the most likely(P-
scores 0.81 and 0.11 respectively). On indirect comparison of active treatments, 
significant differences were seen with lubiprostone 8mcg b.i.d. compared with 
linaclotide 290mcg o.d., plecanatide 6mg o.d., and plecanatide 3mg o.d., as well as 
between linaclotide 250mcg o.d. and plecanatide 3mg o.d. 
3.3.2.3 Individual Adverse Events 
In terms of individual adverse events, rates of diarrhoea were provided by 14 of 
the eligible trials, reported in 12 articles. 290-293, 329-333, 335-337 All drugs, with the 
exception of lubiprostone 8mcg b.i.d., were associated with an increased risk of 
diarrhoea and, when ranked using a P-score, lubiprostone 8mcg b.i.d. was the least 
likely to cause diarrhoea, and linaclotide 500mcg o.d. the most likely (P-scores 0.87 and 
0.20 respectively).  Indirect comparison of active treatments revealed that both placebo 
and lubiprostone 8mcg b.i.d. were significantly less likely to cause diarrhoea than all 
other individual drugs, and dosages, but there were no other differences between the 
remaining individual drugs and dosages. There were no significant differences between 
any of the active therapies and placebo, in terms of incidence of abdominal pain, 
abdominal distension, or headache. Six RCTs, reported in five articles, 290, 329, 330, 335, 336 
provided information concerning nausea. Only lubiprostone 8mcg b.i.d. was associated 
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with a significantly increased incidence of nausea, and this was the worst ranked 
treatment in this analysis (P-score 0.18). 
3.4 Discussion 
This systematic review and network meta-analysis has demonstrated that all 
secretagogues tested in IBS-C were more effective than placebo for global symptoms. 
Although all drugs performed similarly, linaclotide 290mcg o.d. was ranked first in 
terms of efficacy for global symptoms. This was irrespective of the outcome measure 
used, whether it be the FDA-recommended endpoint to define relief of global symptoms 
in IBS-C, or the primary endpoint used to define global symptom improvement in each 
trial. For the latter endpoint the probability of linaclotide being superior to another 
competing treatment, or placebo, was 88% but this does not exceed 90% to 95%, which 
may be desirable according to the literature. 328 However, for the former endpoint the 
probability was 91%. Linaclotide 290mcg o.d. was also ranked first in terms of the 
effect on both abdominal pain response and CSBM response. Tenapanor 50mg b.i.d. 
was ranked first in terms of effect on bloating response, although confidence intervals 
were wide and the P-score was very similar to that for linaclotide 290mcg o.d. In the 
analysis that used the primary endpoint to define global symptom improvement in each 
trial, linaclotide 290mcg o.d. was superior to plecanatide 3mg and 6mg o.d., as well as 
lubiprostone 8mcg b.i.d.  In terms of safety, plecanatide 6mg o.d. was the drug least 
likely to cause adverse events, and lubiprostone 8mcg b.i.d. was significantly less likely 
than all other individual drugs and dosages to cause diarrhoea, but was more likely to 
cause nausea. 
 A contemporaneous and exhaustive literature search was performed, which 
included searching the “grey” literature and clinicaltrials.gov, allowing analysis of data 
from 15 RCTs of pharmacological therapies for IBS-C, recruiting 8462 patients. The 
literature search, eligibility assessment, and data extraction were all undertaken 
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independently by two reviewers. An intention-to-treat analysis was used, wherever trial 
reporting allowed, and pooled data with a random effects model, to provide a more 
conservative estimate of the efficacy and safety of individual drugs. Finally, one 
Japanese article was translated, 333 attempts were made to contact authors of individual 
studies, and clinicaltrials.gov was accessed in order to obtain extra information, where 
required. 
 Limitations include the fact that none of the trials were head-to-head studies of 
one drug versus another, which means that these analyses were based on indirect 
comparisons, and are not protected by randomisation. This could lead to confounding 
due to underlying differences between individual RCTs. 339 However, as the design of 
the included trials was very similar, and the endpoints used and duration of follow-up 
identical, this issue should have been minimised. In addition, three of the RCTS were at 
unclear risk of bias, 334, 336, 337 and original authors did not respond to all queries 
concerning individual studies. This may mean the efficacy of some pharmacological 
therapies in IBS-C has been overestimated. 340 Data was extracted from all RCTs based 
on a comparatively short treatment duration of 12 weeks, and therefore the relative 
efficacy and safety of these drugs in the longer term are unknown. This is a potentially 
important clinical point, as patients often complain that they become tolerant to the 
effects of non-prescription laxatives over time, but this would not be uncovered by a 
trial lasting only 12 weeks. The vast majority of trials were conducted in North 
America, meaning that involved individuals may not be generalisable to patients with 
IBS-C in other countries. There were moderate levels of global statistical heterogeneity 
in the analysis using the FDA-recommended endpoint to define treatment response, and 
high levels of heterogeneity in the analysis for CSBM response. The comparison 
adjusted funnel plot for the analysis based on the primary endpoint to define global 
symptom improvement in each trial showed some asymmetry, suggestive of publication 
135 
 
bias or other small study effects, although three of the trials that were identified had not 
been published as either full papers or conference abstracts, 333, 336, 337 and were only 
identified during a search of clinicaltrials.gov. Finally, there were limited safety data for 
tenapanor.  
 All of the secretagogues examined in this network meta-analysis have proved 
their efficacy in placebo-controlled trials in IBS-C. However, when considering the 
results of this study, it is important to point out some of the limitations of the original 
trials themselves. Firstly, as has already been alluded to, complete safety data for the 
two phase III RCTs of tenapanor were not available at the time this network meta-
analysis was conducted. 336, 337 Secondly, all three trials of lubiprostone, and the earlier 
trials of linaclotide, used the less stringent Rome II criteria for IBS. Thirdly, definitions 
of each of the adverse events were not standardised between individual trials, as these 
were not the primary endpoints of interest. This has led to some debate about the 
relative safety of some of the drugs, in terms of their likelihood of causing diarrhoea. A 
recent meta-analysis reported that, based on meta-regression, there were no differences 
in the rates of diarrhoea between linaclotide and plecanatide in treatment trials in IBS-C 
and CIC, 341 an observation supported by the findings of this network meta-analysis. 
However, it is important to point out that there were subtle differences in the way that 
diarrhoea was recorded in these RCTs, 342 which mean that the data may not be 
comparable, even in a network meta-analysis. Fourthly, for the FDA-recommended 
endpoint to define treatment response in IBS-C, as well as abdominal pain and bloating 
response, the analyses for lubiprostone were based on a post hoc analysis of the two 
phase III trials. As a result, data from almost two-thirds of the recruited patients were 
unavailable, as they would not have met the updated FDA-recommended CSBM and 
abdominal pain thresholds for inclusion in an IBS-C treatment trial. This may have led 
to an overestimation of the efficacy of lubiprostone in these analyses, although 
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excluding these RCTs from the analyses would not have led to any change in the 
relative efficacy of the other three drugs. Finally, given that by the time the trials of 
plecanatide and tenapanor were conducted both linaclotide and lubiprostone were FDA-
approved for the treatment of IBS-C, it may be that patients in these more recent RCTs 
had already failed treatment with one, or both, of these drugs. This would imply that a 
more treatment-resistant group of patients were being studied in the trials of plecanatide 
and tenapanor but, as the RCTs did not report the proportion of patients who had 
previously received treatment with either linaclotide or lubiprostone, this is speculation. 
Although this may partly explain why linaclotide 290mcg o.d. was ranked first in 
almost all efficacy analyses in the network meta-analysis, lubiprostone was FDA-
approved for the treatment of IBS-C in 2008, whereas linaclotide was approved in 2012, 
so participants in the linaclotide trials may have failed therapy with lubiprostone prior to 
study entry. 
 The cost of all of these drugs relative to other treatments for IBS-C is also a 
consideration, but there have been no RCTs conducted against a less expensive, but 
potentially effective, comparator such as ispaghula or PEG. A recent cost-effectiveness 
analysis for the use of linaclotide in Scotland reported an incremental cost-effectiveness 
ratio of £7370 per quality-adjusted life year (QALY), versus an antidepressant, in 
patients with IBS-C who had already failed an antispasmodic and/or a laxative. 343 The 
authors reported that the likelihood that linaclotide was cost-effective at a willingness to 
pay of £20,000 per QALY was 73%. The choice of amitriptyline as the comparator in 
this analysis seems odd, given that although tricyclic antidepressants have the most 
evidence for their efficacy in IBS, 286 one of their side effects is constipation. Cost-
effectiveness data for the other three drugs studied in this meta-analysis are lacking. 
 Performing a network meta-analysis of secretagogues for IBS-C could be 
criticised due to the absence of trials making direct comparisons. As a result, all of the 
137 
 
conclusions in this study were derived from data based on indirect treatment 
comparisons. However, it is unlikely that pharmaceutical companies would ever 
conduct head-to-head RCTs of these agents, and even if such a study were to be 
conducted, it is likely that it would be designed as a non-inferiority trial. 344 A network 
meta-analysis circumvents this problem, allowing a credible ranking system of the 
likely efficacy and tolerability of all of the secretagogues tested in IBS-C to be 
developed, even in the absence of trials making direct comparisons. The results of this 
study are therefore still likely to be important for both patients and policy makers, in 
order to help inform treatment decisions for patients with IBS-C.  
 Nevertheless, it is interesting to note that the performance of all of the drugs 
examined in this network meta-analysis was modest overall. This is despite all of these 
drugs having very precise modes of action, aimed specifically at targeting symptoms in 
IBS-C, which suggests that factors other than gastrointestinal symptoms may have a 
role in mediating treatment response. All studies were rigorous in recruiting 
homogeneous populations of patients with IBS-C using the Rome criteria, and they 
conducted a detailed assessment of baseline characteristics, in terms of gastrointestinal 
symptoms and demographic data. However, as discussed, IBS is a complex disorder of 
gut-brain interaction, and psychological comorbidity and altered CNS processing have 
been shown to be key drivers of symptom development in some patients. 51, 52 Similarly, 
poor psychological health, in terms of anxiety and somatisation, and the reporting of 
extra-intestinal symptoms, has been associated with increased symptom severity in IBS. 
112-114, 117 Consequently, an individual’s psychological health may play a role in 
governing how well they will respond to a peripherally acting drug, such as a 
secretagogue. Other pathophysiological mechanisms, such as altered visceral sensitivity 
or changes in the gut microbiome, may also be relevant. Unfortunately, no trial in the 
network conducted any form of psychological evaluation at baseline, thereby precluding 
138 
 
an assessment of whether, and to what extent, symptom-response is influenced by 
factors such as mood or extra-intestinal symptom reporting. Understanding this has 
implications for how treatment is directed in IBS, and, if shown to be important, could 
encourage a more integrated clinical assessment of people with IBS, such as 
recommended by the Rome Foundation MDCP, 57 and facilitate a more personalised 
approach to management overall.  
 In summary, although all drugs performed similarly and were superior to 
placebo in most analyses, this network meta-analysis ranked linaclotide 290mcg o.d. 
first in terms of efficacy profile overall, and across several different endpoints. No 
difference was observed between individual treatments when the FDA-recommended 
endpoint was used to define relief of global symptoms in IBS-C, although linaclotide 
290mcg o.d. was still ranked first. However, when treatments were ranked according to 
the primary endpoint used to define treatment response in each trial, linaclotide 290mcg 
o.d. appeared superior to plecanatide 3mg and 6mg o.d., as well as lubiprostone 8mcg 
b.i.d. In terms of safety, plecanatide 6mg o.d. was the drug least likely to cause adverse 
events, and lubiprostone 8mcg b.i.d. was significantly less likely than any of the other 
drugs to cause diarrhoea. In the absence of head-to-head trials, this information should 
help clinicians to make decisions as to which drug to use, based on efficacy, safety, and 
most troublesome symptom, when first-line therapies for IBS-C fail. However, the 
modest performance of these drugs, despite their precise modes of action, raises 
questions about whether factors other than gastrointestinal symptoms at baseline, such 
as psychological health, might be important in determining treatment response in any 
individual patient. Understanding the relative efficacy of drugs and the merits of 
directing therapy according to predominant stool pattern are issues that are not only 
relevant to IBS-C, but are equally applicable to treatments for IBS-D and IBS-M. This 
will be the focus of the study reported in the next chapter. 
139 
 
CHAPTER 4  
Assessing the Relative Efficacy of Pharmacological Therapies in 





As discussed, IBS has a substantial impact on quality of life for patients with 
active symptoms, 83 which is more pronounced for patients with IBS-D or IBS-M, 85 
who account for over 50% of people with IBS. 61 These patients often report a fear of 
incontinence due to loose stools and urgency, 279 and can therefore find working and 
socialising extremely challenging. 86 Although up to one-third of these patients use 
loperamide, 282 a µ-opioid agonist, as an antidiarrhoeal agent, there is little evidence for 
its efficacy in IBS, 278 and many patients report inadequate relief of symptoms, other 
than diarrhoea, with the drug. 282 In addition, although other well-established treatments 
for IBS, such as antispasmodics or tricyclic antidepressants, may improve abdominal 
pain, 277, 286 many are not licensed for treatment of IBS.  
 Consequently, over the last 20 years, a number of other pharmacological 
therapies have been licensed for the treatment of IBS-D and IBS-M. Although they have 
different mechanisms of action, in clinical practice all these drugs tend to be utilised 
when first-line treatments have failed. Alosetron and ramosetron are both antagonists of 
the 5-HT3 receptor, an action that may serve to slow gastrointestinal transit, alter rectal 
compliance, 345, 346 and reduce visceral sensitivity. 347 Rifaximin is a minimally absorbed 
broad-spectrum antibiotic that has been tested in IBS-D and IBS-M, on the basis that 
alterations in gastrointestinal microbiota may, in part, be responsible for symptoms. 348 
Finally, eluxadoline is a peripherally acting mixed µ-and κ-opioid receptor agonist, and 
δ-opioid receptor antagonist, with minimal oral bioavailability, which reduces visceral 
hypersensitivity and slows gastrointestinal transit. 349  
 High-quality placebo-controlled RCTs have confirmed that all of these licensed 
drugs are effective treatments for IBS-D and/or IBS-M, 278, 298, 300, 350-352 but, as is the 
case for secretagogues for the treatment of IBS-C, there have been no head-to-head 
trials conducted to evaluate relative efficacy. As it is unlikely that any such trials will be 
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performed, the aim of this study was to conduct a network meta-analysis to allow 
comparisons to be made between all of these drugs, as well as to enable ranking of 
treatments, in order to inform clinical decisions.  
The validity of such network meta-analyses can be undermined if there are 
differences in the design and endpoints used in individual RCTs. However, in this case, 
the efficacy of all these drugs has been assessed according to endpoints recommended 
currently for pharmacological therapies in IBS by the FDA. In addition, as many trials 
reported the efficacy of each of these drugs, in terms of their effect on individual 
symptoms, such as abdominal pain or stool consistency, relative efficacy for each drug 
according to each of these endpoints can also be assessed. This study, therefore, 
complements the work conducted in Chapter 3 analysing treatment trials of 
secretagogues in IBS-C. It also offers a further opportunity to appraise the merits of 
directing treatment according to predominant stool form in isolation, in this case IBS-D 
or IBS-M, using drugs specifically intended for this purpose, among patients who were 





4.2.1 Search Strategy and Study Selection 
MEDLINE (1947 to November 2018), EMBASE, EMBASE Classic (1947 to 
November 2018), and the Cochrane central register of controlled trials were searched to 
identify potential studies. In addition, clinicaltrials.gov was searched for unpublished 
trials, or supplementary data for potentially eligible studies. In order to identify studies 
published only in abstract form, conference proceedings (Digestive Diseases Week, 
American College of Gastroenterology, United European Gastroenterology Week, and 
the Asian Pacific Digestive Week) between 2001 and 2018 were hand-searched. Finally, 
a recursive search was performed, using the bibliographies of all obtained articles.  
Eligible RCTs examined the effect of licensed pharmacological therapies 
(alosetron, eluxadoline, ramosetron, or rifaximin) in adult patients (>18 years) with 
IBS-D or IBS-M (Table 4-1). The first period of cross-over RCTs were eligible for 
inclusion if they provided efficacy data prior to cross-over. The definitions of IBS of 
interest included either a clinician’s opinion, or meeting specific diagnostic criteria, for 
example the Rome criteria. Only RCTs that examined the efficacy of standard doses of 
the drugs of interest, and which compared them with each other, or with placebo, were 
considered eligible.   
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Table 4-1. Eligibility Criteria. 
Randomised controlled trials  
Adults (participants aged >18 years)  
Diagnosis of IBS-D or IBS-M based on either a clinician’s opinion, or meeting 
specific diagnostic criteria*, supplemented by negative investigations where trials 
deemed this necessary. 
Compared alosetron, eluxadoline, ramosetron, or rifaximin with each other, or with 
placebo. 
Minimum follow-up duration of 12 weeks. 
Dichotomous assessment of response to therapy at 12 weeks†.  
 
*Manning, Kruis score, Rome I, II, III, or IV. 
†Preferably patient-reported, and according to the FDA-recommended endpoint for 
treatment trials in IBS, but if this was not available then as assessed by a physician or 
questionnaire data.  
144 
 
A minimum follow-up duration of 12 weeks was required, in line with FDA 
recommendations for the design of treatment trials for functional gastrointestinal 
disorders. All endpoints were extracted at 12 weeks, even for RCTs providing efficacy 
data at other time points. This was done to ensure as much homogeneity as possible 
between individual trial results, and to avoid overestimating the efficacy of one drug 
relative to another, as the placebo effect tends to wane with time. 318 Studies had to 
report a dichotomous assessment of response to therapy. First and senior authors of 
studies were contacted to provide additional information on individual trials, where 
required.  
Two investigators conducted the literature search, independently from each 
other. Studies on IBS were identified with the terms: irritable bowel syndrome and 
functional disease(s), colon (both as MeSH and free text terms), and IBS, spastic colon, 
irritable colon, or functional adj5 bowel (as free text terms). These were then combined 
using the set operator AND with studies identified with the following terms: alosetron, 
Lotronex, eluxadoline, Viberzi, Truberzi, ramosetron, Irribow, rifaximin, and Xifaxan 
(all as free text terms).  
There were no language restrictions. Two investigators evaluated all abstracts 
identified by the search for eligibility, again independently from each other. All 
potentially relevant papers were obtained and evaluated in more detail, using pre-
designed forms, in order to assess eligibility independently, according to the pre-defined 
criteria. Foreign language papers were translated, where required. Disagreements 
between investigators were resolved by discussion.   
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4.2.2 Outcome Assessment 
The efficacy of all drugs, compared with each other or with placebo, in IBS-D 
and IBS-M was assessed in terms of failure to respond to therapy, with the endpoints of 
interest used to define response reported below. Secondary outcomes included adverse 
events occurring as a result of therapy (overall numbers of adverse events, as well as 
adverse events leading to study withdrawal, and individual adverse events, including 
constipation, headache, abdominal pain, or nausea). 
4.2.3 Data Extraction 
Two investigators extracted all data independently onto a Microsoft Excel 
spreadsheet (XP professional edition; Microsoft Corp, Redmond, WA, USA) as 
dichotomous outcomes (response or no response to therapy). The included eligible 
RCTs often used different primary endpoints. However, some of the trials adhered to 
FDA-recommended endpoints, and either reported treatment efficacy according to a 
composite of improvement in both abdominal pain and stool consistency, or it was 
possible to obtain these data from the original investigators. Three of the RCTs of 
alosetron also applied these criteria retrospectively to a subset of patients in the phase 
III studies. In addition, because individual trials reported efficacy according to several 
other secondary endpoints, it was possible to assess the efficacy of therapies according 
to other dichotomous endpoints to define response to treatment. These included: a) 
relief of global IBS symptoms (global IBS symptom responder); b) relief of abdominal 
pain (abdominal pain responder); and c) improvement in stool consistency (stool 
consistency responder). 
 For all included studies, the following data were also extracted for each trial, 
where available: country of origin, number of centres, criteria used to define IBS, stool 
subgroup of IBS, proportion of female patients, and dose and duration of therapy. Data 
were extracted as intention-to-treat analyses, with dropouts assumed to be treatment 
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failures (i.e. no response to therapy), using the total number of patients randomised to 
each treatment arm as the denominator, wherever trial reporting allowed. If this was not 
clear from the original article, an analysis was performed on all patients with reported 
evaluable data. 
4.2.4 Quality Assessment and Risk of Bias 
This was performed at the study level, by two investigators independently, using 
the Cochrane risk of bias tool. 319 Disagreements were resolved by discussion. The 
method used to generate the randomisation schedule and conceal treatment allocation 
was recorded, as well as whether blinding was implemented for participants, personnel, 
and outcomes assessment, whether there was evidence of incomplete outcomes data, 
and whether there was evidence of selective reporting of outcomes. 
4.2.5 Data Synthesis and Statistical Analysis 
A network meta-analysis was performed using the frequentist model, with the 
statistical package “netmeta” (version 0.9-0, https://cran.r-
project.org/web/packages/netmeta/index.html) 320 in R (version 3.4.2). 321 This was 
reported according to the PRISMA extension statement for network meta-analyses, 322 
in order to explore indirect treatment comparisons of the efficacy and safety of each 
medication. Network meta-analysis results usually give a more precise estimate, 
compared with results from standard, pairwise analyses, 323, 324 and can also rank 
treatments to inform clinical decisions. 317 This methodology is described in detail in 
Chapter 3, but the salient points are reiterated briefly below. 
The symmetry and geometry of the evidence was examined by producing a 
network plot, and comparison adjusted funnel plots were used to explore publication 
bias or other small study effects, for all available comparisons versus placebo, using 
Stata version 14 (Stata Corp., College Station, TX, USA). A pooled RR with 95% CIs 
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was calculated to summarise the effect of each comparison tested, using a random 
effects model as a conservative estimate. The RR of failure to achieve each of the 
endpoints of interest was calculated, where if the RR is less than 1 and the 95% CI does 
not cross 1, there is a significant benefit of the drug over placebo. As there were no 
direct comparisons between the active treatment groups, it was not possible to perform 
consistency modelling to check the correlation between direct and indirect evidence. 326  
Global statistical heterogeneity across all comparisons was assessed using the I2 
measure from the “netmeta” statistical package. Treatments were ranked according to 
their P-score. The primary analysis pooled data for the FDA-recommended composite 
endpoint to define treatment response, for all included RCTs that reported these data. 
Analyses were also performed to assess the safety of each medication, including overall 
numbers of adverse events, and number of adverse events leading to study withdrawal, 
as well as individual adverse events.  
4.3 Results 
The search strategy generated 1849 citations, 58 of which appeared to be relevant 
and were retrieved for further assessment (Figure 4-1). Of these, 40 were excluded for 
various reasons, leaving 18 eligible articles reporting on 18 separate trials, which 
contained a total of 9844 patients. 227, 298, 299, 350-364 There were seven RCTs of alosetron 
(1951 patients alosetron, 1583 placebo), 227, 351, 353-357 five trials of ramosetron (1015 
patients ramosetron, 913 placebo), 352, 358-361 two RCTs of rifaximin (625 patients 
rifaximin, 635 placebo), reported in one article, 350 and four RCTs of eluxadoline (1967 
patients eluxadoline, 1155 placebo), reported in three articles. 298, 299, 362 A further two 
articles were also included because together they provided supplementary data, 363, 364 
reporting efficacy according to FDA-recommended endpoints for alosetron in three 
phase III RCTs. 227, 351, 357 These two articles restricted their analyses to female patients 
who met criteria for severe IBS-D. In addition, the rifaximin trials did not report raw 
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data for many of the analyses of interest in the original article, 350 but these data were 
obtained from the pharmaceutical company.  
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Figure 4-1. Flow Diagram of Assessment of Studies Identified in the Systematic 
Review. 
  
Excluded (n = 40) because: 
• Dual publication = 26 
• Follow-up duration less than 12 
weeks = 9 
• Mixed population of patients with 
IBS, no data for non-constipated 
IBS patients available = 2 
• Pooled analysis of adverse events 
data = 1 
• Retreatment trial following open 
label treatment with active drug = 1 
• Review article = 1 
Studies identified in literature 
search 
(n = 1879) 
Studies retrieved for evaluation  
(n = 58) 
Eligible articles (n = 18) reporting: 
• 7 trials of alosetron 
• 5 trials of ramosetron 
• 2 trials of rifaximin 
• 4 trials of eluxadoline 
Excluded (title and abstract revealed not 
appropriate) (n = 1821) 
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Agreement between investigators for trial eligibility was excellent (Kappa 
statistic = 0.80). Detailed characteristics of individual RCTs are provided in Table 4-2. 
Risk of bias for all included trials is reported in Table 4-3. Ten trials, reported in eight 
articles, were at low risk of bias. 298, 350-352, 357, 360-362 No trials made head-to-head 
comparisons of one drug versus another, meaning that direct evidence was only 
available in comparison with placebo. As a result, active medications could only be 






Table 4-2 Characteristics of Randomised Controlled Trials of Pharmacological Therapies Versus Placebo in IBS-D or IBS-M. 
Study Country and 
Number of Centres 
Diagnostic Criteria Used 
for IBS and Stool 
Subgroups of IBS 
Recruited 
Primary Endpoint Used to Define Symptom 





Number of Patients Assigned to 
Active Drug, Dosage, Schedule, 
and Duration of Therapy 
Camilleri 1999 
353 
Multinational, 68 sites Rome I criteria, 100% IBS-
D or IBS-M 
Adequate relief of pain and discomfort for ≥6 of 
the 12 weeks of therapy 
152 (44.1) 72 patients received alosetron 1mg 
b.i.d.* for 12 weeks 
Camilleri 2000 
351 
USA, 119 sites Rome I criteria, 70.8% IBS-
D, 27.8% IBS-M 
Adequate relief of IBS pain and discomfort for 
≥2 weeks per month for each of 3 months 
647 (100) 324 patients received alosetron 
1mg b.i.d. for 12 weeks 
Camilleri 2001 
227 
USA, 104 sites Rome I criteria, 71.2% IBS-
D, 27.0% IBS-M 
Adequate relief of IBS pain and discomfort for 
≥2 weeks per month for each of 3 months 
626 (100) 309 patients received alosetron 
1mg b.i.d. for 12 weeks 
Lembo 2001 
356 
USA, 180 sites Rome II criteria, 97.8% IBS-
D, 2.2% IBS-M 
Substantial or moderate improvement in global 
IBS symptoms over the last 4 weeks of therapy 
801 (100) 532 patients received alosetron 
1mg b.i.d. for 12 weeks 
Chey 2004 354 Multinational, 138 
sites 
Rome I criteria, 100% IBS-
D† 
Weekly adequate relief of IBS pain and 
discomfort at week 48 of treatment± 
569 (100) 279 patients received alosetron 






Chang 2005 355 USA and Canada, 186 
sites 
Rome I criteria, 100% IBS-
D 
Adequate relief of IBS pain and discomfort for 
weeks 5 to 12 of treatment 
386 (0) 127 patients received alosetron 
0.5mg b.i.d. and 131 received 
alosetron 1mg b.i.d. for 12 weeks 
Krause 2007 
357 
USA, number of sites 
not reported 
Rome II criteria, 100% IBS-
D 
Moderate or substantial improvement in global 
IBS symptoms over the last 4 weeks of therapy 
353 (100) 177 patients received alosetron 
1mg b.i.d. for 12 weeks 
Matsueda 
2008a 359 
Japan, number of sites 
not reported 
Rome II criteria, 100% IBS-
D 
Complete or considerable relief of global IBS 
symptoms for ≥2 of the last 4 weeks of therapy 
212 (27.3) 103 patients received ramosetron 
5mcg o.d.§ for 12 weeks 
Matsueda 
2008b 358 
Japan, number of sites 
not reported 
Rome II criteria, 100% IBS-
D 
Complete or considerable relief of global IBS 
symptoms for ≥2 of the last 4 weeks of therapy 
539 (17.9) 270 patients received ramosetron 
5mcg o.d. for 12 weeks 
Fukudo 2014 
360 
Japan, 52 sites Rome III criteria, 100% IBS-
D 
A weekly mean BSFS¶ score of ≥3 to ≤5 and a 
decrease of ≥1 point 
in mean BSFS score from baseline for ≥2 of the 
first 4 weeks of therapy± 
296 (0) 147 patients received ramosetron 
5mcg o.d. for 12 weeks 
Fukudo 2016 
352 
Japan, 70 sites Rome III criteria, 100% IBS-
D 
Complete or considerable relief of global IBS 
symptoms for ≥2 of the last 4 weeks of therapy 
576 (100) 292 patients received ramosetron 








Japan, 61 sites Rome III criteria, 100% IBS-
D 
Complete or considerable relief of global IBS 
symptoms for ≥2 of the last 4 weeks of therapy 
305 (100) 104 and 99 patients received 
ramosetron 2.5mcg or 5mcg o.d. 
respectively for 12 weeks 
Pimentel 
2011a  
(Target 1) 350 
USA and Canada, 179 
sites 
Rome II criteria, 100% IBS-
D or IBS-M 
Adequate relief of global IBS symptoms for ≥2 of 
the first 4 weeks after therapy± 
623 (73.4) 309 patients received rifaximin 
550mg t.i.d.‡ for 2 weeks 
Pimentel 
2011b  
(Target 2) 350 
USA and Canada, 179 
sites 
Rome II criteria, 100% IBS-
D or IBS-M 
Adequate relief of global IBS symptoms for ≥2 of 
the first 4 weeks after therapy± 
637 (71.2) 316 patients received rifaximin 
550mg t.i.d. for 2 weeks 
Dove 2013 362 USA, 263 sites Rome III criteria, 100% IBS-
D 
≥30% reduction in worst abdominal pain score 
and at least 2 points, and a daily BSFS score of 3 
or 4 on ≥66% of daily diary entries at week 4± 
348 (69.3) 176 patients received eluxadoline 
100mg b.i.d. for 12 weeks 
Lembo 2016a  
(IBS-3001) 298 
USA, Canada and UK, 
295 sites 
Rome III criteria, 100% IBS-
D 
≥30% reduction in worst abdominal pain score on 
≥50% of days and, on the same days, a daily 
BSFS score of <5 at week 12 
1282 (65.4) 429 and 426 patients received 
eluxadoline 75mg or 100mg b.i.d. 






Lembo 2016b  
(IBS-3002) 298 
USA, Canada and UK, 
261 sites 
Rome III criteria, 100% IBS-
D 
≥30% reduction in worst abdominal pain score on 
≥50% of days and, on the same days, a daily 
BSFS score of <5 at week 12 
1146 (67.0) 381 and 383 patients received 
eluxadoline 75mg or 100mg b.i.d. 
respectively for 26 weeks 
Brenner 2018 
(RELIEF) 299 
USA and Canada, 
number of sites not 
reported 
Rome III criteria, 100% IBS-
D 
≥40% reduction in worst abdominal pain score on 
≥50% of days and a daily BSFS score of <5 at 
week 12 
346 (69.9) 172 patients received eluxadoline 
100mg b.i.d. for 12 weeks 
* b.i.d.; twice-daily  
†Also recruited patients with IBS-M, but data were only extractable for those with IBS-D at 12 weeks 
±Efficacy data were extracted at 12 weeks for the purpose of this analysis 
§o.d.; once-daily  
¶BSFS; Bristol stool form scale 






Table 4-3. Risk of Bias of Randomised Controlled Trials of Pharmacological Therapies Versus Placebo in IBS-D or IBS-M. 




Stated Method of 
Concealment of 
Treatment Allocation 
Blinding No Evidence of 
Incomplete Outcomes 
Data 
No Evidence of 
Selective Reporting of 
Outcomes 
Low Risk of Bias 
Camilleri 1999 353, alosetron 
1mg b.i.d. 
No No Double No Yes No 
Camilleri 2000 351, alosetron 
1mg b.i.d. 
Yes Yes Double Yes Yes Yes 
Camilleri 2001 227, alosetron 
1mg b.i.d. 
Yes No Double Yes Yes No 
Lembo 2001 356, alosetron 
1mg b.i.d. 
No No Double No Yes No 
Chey 2004 354, alosetron 1mg 
b.i.d. 






Chang 2005 355, alosetron 
0.5mg or 1mg b.i.d. 
Yes No Double Yes Yes No 
Krause 2007 357, alosetron 
1mg b.i.d. 
Yes Yes Double Yes Yes Yes 
Matsueda 2008a 359, 
ramosetron 5mcg o.d. 
No Yes Double Yes Yes No 
Matsueda 2008b 
NCT00189696 358, 
ramosetron 5mcg o.d. 
No No Double Yes Yes No 
Fukudo 2014 NCT01225237 
360, ramosetron 5mcg o.d. 
Yes Yes Double Yes Yes Yes 
Fukudo 2016 NCT01870895 
352, ramosetron 2.5mcg o.d. 
Yes Yes Double Yes Yes Yes 
Fukudo 2017 NCT01274000 
361, ramosetron 2.5mcg or 
5mcg o.d. 






Pimentel 2011a  
(Target 1) NCT00731679 350, 
rifaximin 550mg t.i.d. 
Yes Yes Double Yes Yes Yes 
Pimentel 2011b  
(Target 2) NCT00724126 350, 
rifaximin 550mg t.i.d. 
Yes Yes Double Yes Yes Yes 
Dove 2013 NCT01130272 362, 
eluxadoline 100mg b.i.d. 
Yes Yes Double Yes Yes Yes 
Lembo 2016a  
(IBS-3001) NCT01553591 298, 
eluxadoline 75mg or 100mg 
b.i.d. 
Yes Yes Double Yes Yes Yes 
Lembo 2016b  
(IBS-3002) NCT01553747 298, 
eluxadoline 75mg or 100mg 
b.i.d. 






Brenner 2018 (RELIEF) 
NCT02959983 299, eluxadoline 
100mg b.i.d. 
No No Double Yes Yes No 
 




4.3.1.1 Failure to Achieve the FDA-recommended Endpoint to Define Treatment 
Response 
Ten RCTs, reported in seven separate articles, provided dichotomous data for 
failure to achieve the FDA-recommended composite endpoint, based on an 
improvement in abdominal pain and stool consistency. 298, 299, 350, 352, 362-364 Two of the 
articles, between them, provided sufficient information to enable a post hoc analysis of 
three of the phase III RCTs of alosetron, which reported efficacy according to FDA-
recommended endpoints only in women with severe IBS-D. 363, 364  
 These 10 trials included a total of 5517 patients, 3156 of whom were 
randomised to active treatment, and 2361 to placebo. The network plot is provided in 
Figure 4-2. When data were pooled there was no global statistical heterogeneity (I2 = 
2.3%), and no evidence of publication bias, or other small study effects (Figure 4-3). All 
treatments were significantly more effective than placebo, but alosetron 1mg b.i.d. was 
ranked as the most effective (P-score 0.97), in three RCTs (RR 0.69; 95% CI 0.60 to 
0.80) (Figure 4-4). This means that the probability of alosetron being the most effective 
when all treatments, including placebo, were compared with each other was 97%. After 
indirect comparison of active treatments, significant differences were seen with 
alosetron 1mg b.i.d., compared with all other treatments except ramosetron 2.5mcg o.d. 
(Table 4-4).  
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Figure 4-2. Network Plot for Failure to Achieve the FDA-recommended Endpoint 
to Define Treatment Response. 




Placebo A 10 2,361 
Alosetron 1mg b.i.d. B 3 391 
Ramosetron 2.5mcg o.d. C 1 173 
Rifaximin 550mg t.i.d. D 2 625 
Eluxadoline 100mg b.i.d. E 4 1,157 






Figure 4-3. Funnel Plot for Failure to Achieve the FDA-recommended Endpoint to 




Note: The horizontal axis represents the difference between the comparison-specific and 
study-specific effect sizes.  
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Figure 4-4. Forest Plot of the Indirect Evidence for Failure to Achieve the FDA-
recommended Endpoint to Define Treatment Response. 
 
Note: The P-score is the probability of each treatment being ranked as best in the 






Table 4-4. League Table for Failure to Achieve the FDA-recommended Endpoint to Define Treatment Response. 
Alosetron 1mg b.i.d. 
     
0.89 (0.72; 1.10) Ramosetron 2.5mcg o.d. 
    
0.80 (0.69; 0.93) 0.90 (0.77; 1.05) Eluxadoline 100mg b.i.d. 
   
0.78 (0.67; 0.91) 0.88 (0.75; 1.03) 0.98 (0.91; 1.05) Eluxadoline 75mg b.i.d. 
  
0.75 (0.64; 0.89) 0.85 (0.72; 1.00) 0.94 (0.87; 1.02) 0.97 (0.89; 1.05) Rifaximin 550mg b.i.d. 
 
0.69 (0.60; 0.80) 0.78 (0.67; 0.91) 0.87 (0.83; 0.91) 0.89 (0.84; 0.94) 0.92 (0.86; 0.98) Placebo 
 
Relative risk with 95% confidence intervals in parentheses. Comparisons, column versus row, should be read from left to right, and are ordered relative 
to their overall efficacy. The treatment in the top left position is ranked as best after the network meta-analysis of indirect effects. Boxes shaded green 
denote a statistically significant difference.  
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4.3.1.2  Failure to Achieve a Global IBS Symptom Response 
When dichotomous data were pooled for failure to achieve relief of global 
symptoms of IBS, there were 13 RCTs, reported in 11 articles, recruiting 7464 patients. 
298, 299, 350, 352, 356-362 Of these, 4316 were randomised to active treatment and 3148 to 
placebo. When data were pooled there was moderate global statistical heterogeneity (I2 
= 67.4%), which was driven by the trials of alosetron 1mg b.i.d. The comparison 
adjusted funnel plot for publication bias, or other small study effects, showed no 
asymmetry around the zero line (Figure 4-5). All treatments were significantly more 
effective than placebo, with the exception of rifaximin 550mg three-times daily (t.i.d.), 
but alosetron 1mg b.i.d. was ranked as the most effective (P-score 0.96), in two RCTs 
(RR 0.62; 95% CI 0.51 to 0.76) (Figure 4-6). After indirect comparison of active 
treatments, significant differences were seen with alosetron 1mg b.i.d. compared with 
rifaximin 550mg t.i.d. (Table 4-5).  
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Figure 4-5. Funnel Plot for Failure to Achieve a Global IBS Symptom Response. 
 
 
Note: The horizontal axis represents the difference between the comparison-specific and 
study-specific effect sizes.  
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Figure 4-6. Forest Plot of the Indirect Evidence for Failure to Achieve a Global 
IBS Symptom Response. 
 
Note: The P-score is the probability of each treatment being ranked as best in the 






Table 4-5. League Table for Failure to Achieve a Global IBS Symptom Response. 
Alosetron 1mg b.i.d. 
    
  
0.84 (0.63; 1.12) Ramosetron 2.5mcg o.d. 
   
  
0.82 (0.65; 1.04) 0.97 (0.76; 1.24) Ramosetron 5mcg o.d. 
  
  
0.80 (0.63; 1.02) 0.95 (0.74; 1.22) 0.98 (0.80; 1.19) Eluxadoline 100mg b.i.d. 
 
0.77 (0.59; 1.00) 0.91 (0.69; 1.19) 0.93 (0.74; 1.18) 0.96 (0.76; 1.21) Eluxadoline 75mg b.i.d. 
0.69 (0.53; 0.89) 0.81 (0.63; 1.06) 0.84 (0.68; 1.04) 0.86 (0.69; 1.07) 0.90 (0.70; 1.15) Rifaximin 550mg t.i.d.  
0.62 (0.51; 0.76) 0.74 (0.60; 0.91) 0.76 (0.66; 0.88) 0.78 (0.68; 0.90) 0.81 (0.68; 0.98) 0.91 (0.77; 1.07) Placebo 
 
Relative risk with 95% confidence intervals in parentheses. Comparisons, column versus row, should be read from left to right, and are ordered relative 
to their overall efficacy. The treatment in the top left position is ranked as best after the network meta-analysis of indirect effects. Boxes shaded green 
denote a statistically significant difference.  
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4.3.1.3 Failure to Achieve an Abdominal Pain Response 
There were 17 trials recruiting 9043 patients, reported in 15 separate articles, 227, 
298, 299, 350-355, 357-362 that reported dichotomous data for failure to achieve an abdominal 
pain response. There were 5026 patients assigned to active therapy, and 4017 allocated 
to placebo. When data were pooled there was no global statistical heterogeneity (I2 = 
0%), and no evidence of publication bias, or other small study effects (Figure 4-7). 
Ramosetron 2.5mcg o.d., ramosetron 5mcg o.d., alosetron 1mg b.i.d., and eluxadoline 
100mg b.i.d. were all significantly more effective than placebo. Overall, ramosetron 
2.5mcg o.d. was ranked as the most effective treatment (P-score 0.94), in two RCTs 
(RR 0.75; 95% CI 0.65 to 0.85) (Figure 4-8). On indirect comparison of active 
treatments, significant differences were seen with ramosetron 2.5mcg o.d. compared 
with eluxadoline 75mg b.i.d., eluxadoline 100mg b.i.d., and rifaximin 550mg t.i.d., as 
well as for ramosetron 5mcg o.d. compared with eluxadoline 75mg b.i.d. and rifaximin 
550mg t.i.d. Significant differences were also seen for alosetron 1mg b.i.d. compared 
with eluxadoline 75mg b.i.d. and rifaximin 550mg t.i.d. (Table 4-6).  
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Figure 4-7. Funnel Plot for Failure to Achieve an Abdominal Pain Response. 
 
 
Note: The horizontal axis represents the difference between the comparison-specific and 
study-specific effect sizes.  
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Figure 4-8. Forest Plot of the Indirect Evidence for Failure to Achieve an 
Abdominal Pain Response. 
 
Note: The P-score is the probability of each treatment being ranked as best in the 






Table 4-6. League Table for Failure to Achieve an Abdominal Pain Response. 
Ramosetron 2.5mcg o.d.        
0.91 (0.78; 1.07) Ramosetron 5mcg o.d.       
0.90 (0.78; 1.04) 0.99 (0.89; 1.10) Alosetron 1mg b.i.d.      
0.88 (0.68; 1.13) 0.96 (0.76; 1.21) 0.97 (0.77; 1.22) Alosetron 0.5mg b.i.d.     
0.84 (0.72; 0.97) 0.91 (0.82; 1.02) 0.93 (0.84; 1.02) 0.95 (0.76; 1.20) Eluxadoline 100mg b.i.d.  
0.79 (0.68; 0.91) 0.86 (0.77; 0.96) 0.87 (0.80; 0.95) 0.90 (0.71; 1.13) 0.94 (0.86; 1.03) Rifaximin 550mg t.i.d. 
0.78 (0.67; 0.92) 0.86 (0.76; 0.97) 0.87 (0.78; 0.96) 0.89 (0.70; 1.13) 0.94 (0.84; 1.05) 1.00 (0.90; 1.11) Eluxadoline 75mg b.i.d.  
0.75 (0.65; 0.85) 0.82 (0.75; 0.89) 0.83 (0.78; 0.88) 0.85 (0.68; 1.06) 0.89 (0.83; 0.96) 0.95 (0.89; 1.01) 0.95 (0.88; 1.04) Placebo 
 
Relative risk with 95% confidence intervals in parentheses. Comparisons, column versus row, should be read from left to right, and are ordered relative 
to their overall efficacy. The treatment in the top left position is ranked as best after the network meta-analysis of indirect effects. Boxes shaded green 
denote a statistically significant difference. 
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4.3.1.4  Failure to Achieve a Stool Consistency Response 
Twelve RCTs reported dichotomous data for failure to achieve a stool 
consistency response, and these were reported in 10 separate articles, and included 6663 
patients. 298, 299, 350, 352, 357-362 There were 3784 patients assigned to active therapy, and 
2879 to placebo. When data were pooled, there was no global statistical heterogeneity 
(I2 = 18.4%). The comparison adjusted funnel plot for publication bias, or other small 
study effects, showed no asymmetry around the zero line (Figure 4-9). All treatments 
were significantly more effective than placebo, but alosetron 1mg b.i.d. ranked as the 
most effective treatment (P-score 0.93), although in only one RCT (RR 0.70; 95% CI 
0.60 to 0.81) (Figure 4-10). After indirect comparison of active treatments, significant 
differences were seen with alosetron 1mg b.i.d., compared with eluxadoline 75mg b.i.d. 
and eluxadoline 100mg b.i.d. (Table 4-7).  
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Figure 4-9. Funnel Plot for Failure to Achieve a Stool Consistency Response. 
 
 
Note: The horizontal axis represents the difference between the comparison-specific and 
study-specific effect sizes.  
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Figure 4-10. Forest Plot of the Indirect Evidence for Failure to Achieve a Stool 
Consistency Response. 
 
Note: The P-score is the probability of each treatment being ranked as best in the 






Table 4-7. League Table for Failure to Achieve a Stool Consistency Response. 
Alosetron 1mg b.i.d.        
0.90 (0.76; 1.07) Ramosetron 5mcg o.d.       
0.90 (0.73; 1.10) 1.00 (0.85; 1.18) Rifaximin 550mg t.i.d.      
0.90 (0.74; 1.08) 0.99 (0.86; 1.15) 1.00 (0.83; 1.20) Ramosetron 2.5mcg o.d.     
0.82 (0.69; 0.97) 0.91 (0.81; 1.02) 0.91 (0.78; 1.07) 0.92 (0.80; 1.05) Eluxadoline 75mg b.i.d.  
0.81 (0.69; 0.96) 0.90 (0.81; 1.00) 0.91 (0.78; 1.05) 0.91 (0.80; 1.03) 0.99 (0.90; 1.09) Eluxadoline 100mg b.i.d. 
0.70 (0.60; 0.81) 0.78 (0.71; 0.85) 0.78 (0.68; 0.89) 0.78 (0.69; 0.88) 0.85 (0.79; 0.92) 0.86 (0.81; 0.91) Placebo  
 
Relative risk with 95% confidence intervals in parentheses. Comparisons, column versus row, should be read from left to right, and are ordered relative 
to their overall efficacy. The treatment in the top left position is ranked as best after the network meta-analysis of indirect effects. Boxes shaded green 




4.3.2.1 Overall Adverse Events 
Sixteen trials, recruiting 9134 patients and reported in 14 articles, 227, 298, 299, 350-
352, 355-362 provided data for overall adverse events. There was moderate global statistical 
heterogeneity (I2 = 64.2%), but no evidence of publication bias, or other small study 
effects (Figure 4-11). Heterogeneity was driven by the trials of alosetron 1mg b.i.d. and 
ramosetron 5mcg o.d. When comparing pooled overall adverse events, alosetron 1mg 
b.i.d. (five RCTs, RR = 1.24; 95% CI 1.09 to 1.41), and ramosetron 2.5mcg o.d. (two 
RCTs, RR = 1.27; 95% CI 1.01 to 1.60) were associated with a significant increase in 
overall adverse events, compared with placebo (Figure 4-12). When ranked using a P-
score, rifaximin 550mg t.i.d. was the best, and ramosetron 2.5mcg o.d. the worst, in 
terms of overall adverse events (P-scores 0.80 and 0.18 respectively). Indirect 
comparison of active treatments revealed no significant differences between individual 
drugs and dosages.  
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Figure 4-11. Funnel Plot for Overall Adverse Events. 
 
 
Note: The horizontal axis represents the difference between the comparison-specific and 
study-specific effect sizes.  
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Figure 4-12. Forest Plot of the Indirect Evidence for Overall Adverse Events. 
 
 
Note: The P-score is the probability of each treatment being ranked as best in the 
network analysis. A higher score equates to a greater probability of being ranked first.  
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4.3.2.2 Adverse Events Leading to Dropout 
Adverse events leading to dropout were provided by 15 trials, reported in 13 
papers. 227, 298, 299, 350, 352, 353, 356-362 Eluxadoline 75mg b.i.d. (two RCTs, RR = 1.88; 95% 
CI 1.25 to 2.81), eluxadoline 100mg b.i.d. (four RCTs, RR = 1.88; 95% CI 1.31 to 
2.70), and alosetron 1mg b.i.d. (four RCTs, RR = 1.97; 95% CI 1.48 to 2.63) were all 
associated with significantly higher trial dropout rates due to adverse events, compared 
with placebo. When ranked using a P-score, ramosetron 2.5mcg o.d. was the best, and 
alosetron 1mg b.i.d. the worst, in terms of adverse events leading to dropout (P-scores 
0.92 and 0.16 respectively). On indirect comparison of active treatments, significant 
differences were seen with ramosetron 2.5mcg o.d. compared with eluxadoline 100mg 
b.i.d., eluxadoline 75mg b.i.d., and alosetron 1mg b.i.d. 
4.3.2.3 Individual Adverse Events 
In terms of individual adverse events, rates of constipation were provided by 16 
of the eligible trials, reported in 15 articles. 227, 298, 299, 350-353, 355-362 All drugs, with the 
exception of rifaximin 550mg t.i.d., were associated with an increased risk of 
constipation and, when ranked using a P-score, rifaximin 550mg t.i.d. was the best, and 
alosetron 0.5mg b.i.d. the worst (P-scores 0.99 and 0.06 respectively). Indirect 
comparison of active treatments revealed that both placebo and rifaximin 550mg t.i.d. 
were significantly less likely to cause constipation than all other individual drugs, and 
dosages, but there were no other differences. There were no significant differences 
between any of the active therapies and placebo, in terms of incidence of either nausea 
or headache. Nine RCTs, reported in seven articles, provided information concerning 
abdominal pain. 298, 350, 355-358, 362 Eluxadoline 100mg b.i.d. and alosetron 1mg b.i.d. were 
more likely than placebo to cause abdominal pain, with rifaximin 550mg t.i.d. the best, 
and alosetron 1mg b.i.d. the worst (P scores 0.89 and 0.18 respectively). Indirect 
comparison of active treatments revealed that both placebo and rifaximin 550mg t.i.d. 
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were significantly less likely to cause abdominal pain than either eluxadoline 100mg 
b.i.d. or alosetron 1mg b.i.d. 
4.4 Discussion 
It is widely accepted that the licensed pharmacological therapies studied in this 
systematic review and network meta-analysis are more effective than placebo for the 
treatment of IBS-D and IBS-M. Using the FDA-recommended composite endpoint, 
although all drugs were more effective than placebo, alosetron 1mg b.i.d. ranked first, 
according to the available evidence. The probability of alosetron being superior to 
another competing treatment, according to this endpoint, was 97%, which exceeds the 
90% to 95% threshold that the available literature suggests is desirable. 328 Alosetron 
1mg b.i.d. continued to be ranked first when efficacy was assessed in terms of 
improvement in global IBS symptoms and stool consistency. Ramosetron 2.5mcg and 
5mcg o.d. were ranked first and second when effect on abdominal pain was studied. 
Rifaximin 550mg t.i.d. was no better than placebo for global IBS symptoms, and 
rifaximin 550mg t.i.d., alosetron 0.5mg b.i.d., and eluxadoline 75mg b.i.d. were no 
more effective than placebo for abdominal pain. Alosetron 1mg b.i.d. and ramosetron 
2.5mcg o.d. were both associated with a significant increase in overall adverse events, 
compared with placebo. Constipation was significantly more likely with all drugs, 
except rifaximin 550mg t.i.d., which ranked first for safety overall. The latter 
observation may be consistent with the observation that rifaximin may actually 
accelerate colonic transit, 365 and improve symptoms of IBS-C. 366 Finally, more 
patients reported abdominal pain as an adverse event with eluxadoline and alosetron 
than with placebo, although whether this is due to the fluctuating natural history of IBS, 
an associated feature of drug-induced constipation, or a specific adverse event 
associated with both drugs is unclear.  
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 A contemporaneous and exhaustive literature search was undertaken. This was 
conducted independently by two reviewers, and included searching conference 
proceedings, the “grey” literature, and clinicaltrials.gov. Assessment of eligibility and 
data extraction was also performed independently, and in duplicate. Subsequently the 
authors of two trials of rifaximin, 350 and one trial of eluxadoline, 299 were contacted in 
order to obtain the necessary data for the study analyses, as these were not available in 
the original papers. This inclusive approach enabled analysis of data from 18 RCTs of 
pharmacological therapies for IBS-D and IBS-M, recruiting almost 10,000 patients, 
with data extracted at 12 weeks for all endpoints. An intention-to-treat analysis was 
used and data were pooled using a random effects model to minimise the risk that the 
efficacy of the drugs studied would be overestimated. Finally, adverse events were 
extracted and pooled, where reported, in order to provide summary safety data. 
 No head-to-head studies of one drug versus another were identified, meaning 
that all analyses were based on indirect comparisons, which are not protected by 
randomisation. This could lead to confounding due to underlying differences between 
individual RCTs, 339 although the use of very similar endpoints to define efficacy after 
12 weeks of treatment in all trials should minimise this. However, this means that the 
relative efficacy and safety of these drugs in the longer term are unknown. In addition, 
eight of the 18 trials were at unclear risk of bias, 227, 299, 353-356, 358, 359 which may mean 
the efficacy of some of the drugs has been overestimated. 340 It is likely that these 
deficiencies represent omissions of reporting, rather than true design flaws, given the 
oversight of national regulatory agencies for many of the included trials. There were 
moderate levels of global statistical heterogeneity in the analysis using an improvement 
in global IBS symptoms to define treatment response, and for total adverse events, but 
no heterogeneity in any of the other analyses. Of note, heterogeneity was absent in the 
analysis of the FDA-recommended composite endpoint to define treatment response. 
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This reflects that this is a standardised assessment of global symptom improvement in 
IBS compared with the other definitions of global symptom improvement which often 
differed between trials.  In addition, it is important to point out that, as in most trials of 
pharmacological therapies in IBS, adverse events were not reported according to 
standardised endpoints, unlike efficacy data, which may mean making comparisons 
between individual treatments is less valid. Finally, there may have been subtle 
differences in symptom severity among the populations studied in each of these trials, 
which mean the results are not directly comparable. However, this should have been 
minimised, as 16 of the trials used similar combinations of a minimum abdominal pain 
threshold and a minimum stool consistency threshold, during a run-in period, to confirm 
eligibility prior to study entry. Among the remaining two RCTs, one did not report these 
data, as it was in abstract form, 299 and one used a minimum urgency threshold. 356  
 Ranking of these pharmacological therapies provides useful information to aid 
clinical decision making, but it is important to acknowledge that not all of these drugs 
are available in all countries or, indeed, to all patients with IBS-D or IBS-M. Alosetron 
was withdrawn in the US because of adverse events, including ischemic colitis and 
severe constipation. It was re-introduced, via a risk evaluation and mitigation strategy, 
for women with severe IBS-D. In the first 9 years after re-introduction, 29 cases of 
probable ischemic colitis were reported; an incidence of 1 case per 1000 patient-years. 
367 This is similar to the background rate of ischemic colitis in female patients with IBS, 
which ranges from 0.40 cases/1000 patient-years to 1.79 cases/1000 patient-years. 368 
Whether alosetron is effective in men with IBS-D is unclear, as only one RCT recruited 
solely men, 355 and participants in the remaining trials were either predominantly, or 
exclusively, women. However, cilansetron, another 5-HT3 receptor antagonist, appeared 
to be effective in both men and women with IBS-D. 300 Although ramosetron can be 
prescribed for men with IBS-D, as well as women, it is only licensed in Japan and some 
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other South, and South-East, Asian countries, at a dose of 2.5mcg o.d. in women and 
5mcg o.d. in men. However, three of the trials conducted using 5mcg o.d. recruited 
women. 358, 359, 361 If this dose was either not as effective or less well-tolerated in 
women, one would have expected this to have diluted efficacy, or led to more adverse 
events, yet 5mcg o.d. was ranked second for its effect on both abdominal pain and stool 
consistency, and was by no means the lowest ranked drug in terms of safety. 
  Although both alosetron and ramosetron appeared to perform the best in this 
network meta-analysis, many patients with IBS will be unable to access these drugs. 
Two recent RCTs of ondansetron, another 5-HT3 receptor antagonist, which is widely 
available and has a robust safety profile, suggest that this drug is also of benefit in IBS. 
228, 303 Neither of these trials were eligible for inclusion in this network, as the drug is 
not licensed for IBS; one trial was a cross-over RCT with a treatment duration of 10 
weeks, 228 and the other was a parallel arm trial of only 8 weeks duration. 303 A 12-week 
trial has been undertaken in the UK; 369 however, it is yet to report its findings. Another 
issue is that all of the RCTs of ramosetron were conducted in Japan, and the majority of 
the trials of alosetron, eluxadoline, and rifaximin in North American populations, so the 
findings may not be generalisable to individuals with IBS-D or IBS-M in other 
countries. 
 Because these studies span the last 20 years of clinical practice, during which 
time the Rome criteria for IBS have undergone multiple revisions, 14, 30-32 there are 
variations between individual trial populations, in terms of how the diagnosis of IBS 
was determined. The majority of the alosetron trials and the earlier ramosetron RCTs 
used the Rome I or II criteria, 30, 31 which are arguably less restrictive than the Rome III 
criteria, 32 used in later trials of ramosetron, and all studies of rifaximin and eluxadoline. 
However, agreement between these criteria for the diagnosis of IBS is good, 34 and such 
differences are mitigated against, to some extent, by being able to compare all drugs 
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using the standardised FDA-recommended endpoint for trials in IBS-D. It is important 
to highlight that, because these endpoints had not been agreed at the time some of the 
earlier drug trials were conducted, the data for alosetron are based entirely on a post hoc 
analysis of three trials. 363, 364 Around 50% of patients in these trials were absent from 
the analysis, because they failed to meet the updated FDA-recommended symptom 
thresholds for inclusion in an IBS treatment trial. This may mean that the efficacy of 
alosetron has been overestimated for this endpoint, although as only patients with severe 
IBS-D were included in this analysis, this seems unlikely. In addition, the strength of 
the P-score for alosetron, together with the absence of global statistical heterogeneity, 
suggests that the treatment ranking reported in this network meta-analysis is likely to be 
accurate. 
 All of the drugs considered in this network meta-analysis are likely to be 
prescribed as second-line therapy, after failure of antidiarrhoeal and antispasmodic 
drugs. It would therefore be important to understand how they perform relative to these 
first-line therapies, particularly as loperamide is available over the counter in many 
countries, and has evidence of short-term efficacy for reducing diarrhoea. 278 
Unfortunately, there are few trials examining this issue. One RCT demonstrated that 12 
weeks of alosetron 1mg b.i.d. was superior to mebeverine 135mg t.i.d., in terms of 
adequate relief of abdominal pain, in a mixed population of patients with IBS of all 
stool subgroups, 370 but a trial of 4 weeks of ramosetron 5mcg o.d. versus mebeverine 
135mg t.i.d. demonstrated no significant differences. 371  
 There have also been no head-to-head trials of these drugs against other second-
line therapies, such as tricyclic antidepressants. Additionally, there are no RCTs of 
tricyclic antidepressants, or other pharmacological therapies used off-license for IBS, 
that have been conducted solely in patients with IBS-D or IBS-M over 12 weeks 
reporting identical endpoints to the ones used in these trials, 278 and which could 
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therefore have been included in this network meta-analysis. Pregabalin has been shown 
to improve abdominal pain in IBS, 372, 373 and a recent trial found significant 
improvements in diarrhoea and bloating scores compared with placebo, 374 suggesting 
that this drug might be beneficial for treating IBS-D. However, the trial recruited a 
mixed IBS population that included people with IBS-C and so was ineligible for 
inclusion in this network meta-analysis. Another RCT has compared 24 weeks of 
alosetron 1mg b.i.d. with traditional pharmacotherapy, which in some patients consisted 
of tricyclic antidepressants, in almost 2000 female patients with severe IBS-D. 301 In 
this trial, treatment with alosetron 1mg b.i.d. resulted in significantly greater relief of 
global IBS symptoms. There were also significant reductions in number of visits to see 
a physician for IBS, use of over the counter medications, and days of lost work 
productivity. However, this beneficial effect was accompanied by non-serious 
constipation, occurring in one-third of patients, compared with constipation in <1% of 
those allocated to traditional pharmacotherapy. Initiating alosetron at a dose of 0.5mg 
b.i.d., and increasing the dose subsequently if there is inadequate clinical improvement, 
as is currently recommended, may minimise this. Finally, the two large, phase III trials 
of eluxadoline have reported efficacy of the drug in a subset of patients who had 
previously failed loperamide, 298 with similar efficacy demonstrated in this post hoc 
analysis. 282 The most recent RCT of eluxadoline that was identified had recruited only 
patients with IBS-D who reported, subjectively, that they had previously failed 
loperamide, again with similar results. 299 
 Given the lack of head-to-head trials, performing a network meta-analysis could 
be criticised, because all of the conclusions are derived from data based on indirect 
treatment comparisons. However, as discussed previously, it is unlikely that 
pharmaceutical companies will ever conduct such studies, or even undertake a trial of 
one of these drugs against an antidiarrhoeal or tricyclic antidepressant. Network meta-
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analyses circumvent this problem to some extent, allowing credible ranking systems of 
the likely efficacy and safety of different treatments to be developed, even in the 
absence of trials making direct comparisons. The results of this study are therefore still 
likely to be important for both patients and policy makers, in order to help inform 
treatment decisions for IBS-D and IBS-M.  
 Although all drugs were superior to placebo, according to the FDA-
recommended composite endpoint for trials in IBS, alosetron 1mg b.i.d. ranked first in 
terms of efficacy in this network meta-analysis. It was also the top ranked treatment 
when either global relief of symptoms or improvement in stool consistency were used to 
define treatment response, but ramosetron 2.5mcg o.d. was ranked first in terms of 
improving abdominal pain. With regard to safety, rifaximin 550mg t.i.d. was least likely 
to cause adverse events, and was the only drug that did not significantly increase the 
risk of constipation. However, it demonstrated relatively poor efficacy across many of 
the treatment endpoints that were studied. Eluxadoline 100mg b.i.d., meanwhile, was 
significantly better than placebo across all endpoints, but its overall performance was 
modest. This information will hopefully assist clinicians in choosing a second-line 
treatment for IBS-D, and to a lesser extent IBS-M, based on the patient’s most 
troublesome symptom, prioritising both efficacy and safety. Alosetron and ramosetron 
remain unavailable in many countries, including the UK. Given the chronic and 
frequently debilitating nature of IBS, this lack of availability may need to be 
reconsidered, in order to widen access to potentially effective second-line treatments for 
those patients with IBS-D or IBS-M when conventional first-line therapies fail. 
 Overall, the results reported here and in the preceding chapter provide valuable 
insights into the relative efficacy of second-line drugs targeting abnormal stool pattern 
in IBS, and could help physicians and patients to make better informed treatment 
choices. These drugs exemplify the principle that patients with IBS should be 
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categorised according to their predominant stool pattern, be that IBS-C, IBS-D, or IBS-
M, and that these subgroups should be used to guide treatment.  However, despite 
having been developed with this aim in mind, it is notable that, overall, only 20% to 
30% of patients might expect to experience symptom-improvement with these drugs, 
290, 291, 293, 335, 349, 350 and there is little to choose between many individual drugs, in terms 
of efficacy.  
The reasons underlying this relatively modest performance are unclear; however, 
one hypothesis is that, due to the complex nature of IBS, even though all trial 
participants across both network meta-analyses met the Rome criteria for either IBS-C, 
or IBS-D or IBS-M, based on their gastrointestinal symptoms, they were differentiated 
by other factors that were not evaluated.  Indeed, just as no study of secretagogues for 
IBS-C included any evaluation of psychological health, the same applies to all the trials 
included in this network meta-analysis of treatments for IBS-D and IBS-M. However, 
as already outlined, psychological health may be an important determinant of IBS 
symptom severity and impact on quality of life, and together with other 
pathophysiological factors, may be responsible for shaping an individual’s clinical 
response to certain treatments. For example, with respect to alosetron, which acts via 
serotoninergic pathways, it has been shown that genetic polymorphisms in the promoter 
for synthesis of SERT influence response to the drug. 375 Similarly, there are differences 
in mucosal serotonin metabolism in people with IBS-D, and those with the lowest 
concentrations in rectal biopsies have been shown to be the most responsive to 
treatment with ondansetron, another 5-HT3-receptor antagonist. 
226 Studies have also 
highlighted the role that certain CNS pathways may play in determining clinical 
response to drugs. In one placebo-controlled trial of alosetron, there was an association 
between subjective symptom improvement and reduced activity in the amygdala, 376 
which is a component of the limbic system that is more active during visceral 
188 
 
stimulation in people with non-constipated IBS compared with healthy controls. 377 
Patients who exhibited less activity in the orbitofrontal cortex bilaterally, and in the left 
medial temporal gyrus, in response to rectal distension using a barostat at baseline also 
appear to respond better to treatment with alosetron, and these alterations in CNS 
activity seem to correlate with lower levels of psychological distress. 378 Consequently, 
novel approaches to subgrouping people with IBS that include factors other than stool 
pattern might reveal who is more likely to respond to a peripherally acting drug in 
isolation, and who is liable to need additional treatments, such as centrally acting 
neuromodulators or psychological therapies. This will be the focus of the work 
presented in Chapters 6 and 7, using mathematical modelling to derive new IBS 
subgroups in a large cohort of people who identify as having IBS. However, prior to 
conducting this analysis, it is first necessary to examine the epidemiological, clinical, 
and psychological characteristics of the study cohort, and this is the aim of the study 
reported in Chapter 5.
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CHAPTER 5  
Describing the Epidemiological, Clinical, and Psychological 
Characteristics of Individuals with Self-reported Irritable Bowel 
Syndrome and Exploring Differences Based on the Rome IV Versus 




This chapter describes the recruitment of a large cohort of people who self-
identify as having IBS. Their data will be used to examine new approaches to 
subgrouping individuals with IBS, as detailed in Chapter 6. However, this data also 
provides a valuable opportunity to examine whether demographic and clinical 
differences exist between people with IBS dependent on whether the Rome IV or Rome 
III criteria are used to define IBS, because both sets of criteria were applied 
simultaneously. As will be discussed, understanding this is important in its own right, 
being relevant to both treatment and research in IBS.  However, it also has implications 
for subgrouping people with IBS, as it may be that mathematical modelling derives 
subgroups that differ both in number and characteristics, dependent on how IBS is 
defined in the model.   
The role of symptom-based diagnostic criteria for making a diagnosis of IBS has 
already been described in detail. The aim of these criteria is to reduce unnecessary and 
exhaustive investigation before a diagnosis of IBS is reached, as well as to facilitate the 
recruitment of homogeneous groups of patients into research studies that examine either 
underlying pathophysiological mechanisms in IBS, or the efficacy of therapies, such as 
the trials included in the network meta-analyses reported in Chapters 3 and 4. The 
current gold standard for diagnosing IBS are the Rome IV criteria. These were 
described in 2016, 14 and were modified from the previous Rome III criteria. 32 As 
discussed already, there were three main changes made in moving from the Rome III 
criteria to Rome IV, which are summarised again here. Firstly, abdominal discomfort 
was removed from the definition of IBS, as this was felt to be an ambiguous term, with 
no equivalent in some languages. It was hypothesised that, regardless of whether the 
term abdominal pain or abdominal discomfort was used, the same individuals would 
meet criteria for IBS. 33 Second, the threshold for the frequency of abdominal pain 
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required to meet criteria for IBS was increased from 3 days per month, to one day per 
week, based on a normative survey of the frequency of the occurrence of abdominal 
pain in the general population. 33 Finally, there was an appreciation that abdominal pain 
in IBS is related to, rather than just relieved by, defaecation.  
The aim of these changes was to increase the specificity of the Rome IV criteria, 
over prior iterations, which have performed only modestly in diagnosing IBS in 
previous studies conducted among unselected patients with lower gastrointestinal 
symptoms. 23, 34 A recent validation study suggests that this aim has been achieved; 37 
however, due to their more restrictive nature, the prevalence of symptoms compatible 
with IBS among individuals in population-based surveys is likely to fall when using the 
Rome IV criteria. Other investigators have suggested that among patients with IBS in 
secondary or tertiary care, implementation of these criteria, in preference to Rome III, 
has few implications, other than an increase in the severity of symptoms among those 
with Rome IV IBS. Most patients with Rome III-defined IBS still meet the Rome IV 
criteria for IBS, 40, 41 and there are little in the way of demographic differences between 
individuals when the different criteria are used. 42  
Unfortunately, most of these studies did not actually apply the Rome III and 
Rome IV criteria simultaneously in their study design, but rather used a retrospective 
surrogate set of criteria approximating Rome IV. In addition, as the spectrum of patients 
in secondary and tertiary care is likely to be relatively narrow, there may be other 
consequences for individuals with IBS in the community when moving from Rome III 
to Rome IV, which were not uncovered by the design of these studies. This study 
therefore applied the Rome III and Rome IV criteria simultaneously to people who were 
not recruited from a referral population.  
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There were several hypotheses. First, despite believing they have IBS, many of 
these individuals would not meet Rome IV criteria for IBS. Second, the degree of 
agreement between Rome III and Rome IV would be only modest. Third, many of those 
with Rome III-defined IBS, but who did not meet the Rome IV criteria for IBS, would 
instead be classified as suffering from one of the other functional bowel disorders, and 
that this may have implications in terms of available treatment options. Fourth, there 
may be substantial implications for clinical trials of novel therapies for IBS, in terms of 
symptom severity, mood, and psychological health among individuals now defined as 
having IBS according to the Rome IV criteria.  
5.2 Methods 
5.2.1 Participants and Setting 
The study was conducted among individuals who self-identified as having IBS, 
and who were registered with three organisations in the UK. The first was the IBS 
network, the registered charity for people living with the condition. The second was 
TalkHealth, an online social health community providing information about various 
medical conditions. The third was ContactMe-IBS, a dedicated register allowing 
individuals with IBS not receiving specialist care currently to participate in research. 
There were no exclusion criteria, other than an inability to understand written English. 
All individuals registered with these organisations were contacted via a postal and 
electronic mailshot, between December 2017 and December 2018. This correspondence 
directed them to a website, where they were able to access further information about the 
study. Those who wanted to participate could complete a questionnaire online, with 
their responses stored in an online database. The University of Leeds School of 




5.2.2 Data Collection and Synthesis 
5.2.2.1 Demographic Data 
Basic demographic data, including age, gender, ethnicity, marital status, 
educational level, lifestyle (tobacco and alcohol use), height (in metres), and weight (in 
kilograms), which were used to calculate body mass index (BMI), were collected using 
the questionnaire. Respondents were also asked to state whether their IBS symptoms 
commenced after an acute enteric infection, and whether they had seen a GP or a 
gastroenterologist with their symptoms. 
5.2.2.2 Definitions of Functional Bowel Disorders 
Lower gastrointestinal symptom data were captured using the Rome III and 
Rome IV questionnaires. 379, 380 The presence or absence of either Rome III or Rome 
IV-defined IBS among all individuals was assigned according to the scoring algorithms 
proposed for use with the Rome III and Rome IV questionnaires, 14, 32 which are 
detailed in Table 1.1.The study then examined whether using the Rome IV criteria to 
define IBS led to individuals who would previously have met the Rome III criteria for 
IBS being reclassified as suffering from another functional bowel disorder, including 
functional constipation, functional diarrhoea, functional abdominal bloating or 
distension, and unspecified functional bowel disorder. The proportion of participants 
with other lower gastrointestinal symptoms, such as urgency and faecal incontinence, 
was also assessed.  
5.2.2.3 Assessment of Symptom Severity and Impact on Activities of Daily Living 
The severity of IBS symptoms was assessed using the IBS severity scoring 
system (IBS-SSS). 381 This is a seven-item self-administered questionnaire measuring 
presence, severity, and frequency of abdominal pain, presence and severity of 
abdominal distension, satisfaction with bowel habit, and degree to which IBS symptoms 
194 
 
are affecting, or interfering with, the person’s life in general. The maximum score is 500 
points: <75 points indicates remission of symptoms; 75-174 points mild symptoms; 
175-299 points moderate symptoms; and 300-500 points severe symptoms. It was also 
possible to assess the degree to which IBS symptoms were impacting on activities of 
daily living using some of the items in the Rome IV questionnaire.  
5.2.2.4 Assessment of Mood and Somatoform-type Behaviour 
Anxiety and depression data were collected using the hospital anxiety and 
depression scale (HADS). 382 The total HADS score ranges from a minimum of 0 to a 
maximum of 21 for either anxiety or depression. Severity for each was categorised into 
normal (total HADS depression or anxiety score 0-7), borderline normal (8-10), or 
abnormal (≥11). 382 Somatisation data were collected using the patient health 
questionnaire-15 (PHQ-15), 383 which is derived from the validated full PHQ. 384 The 
total PHQ-15 score ranges from a minimum of 0 to a maximum of 30. Somatisation 
severity was categorised, as previously recommended, 383 using the total PHQ-15 score, 
into high (total PHQ-15 ≥15), medium (10-14), low (5-9) or minimal (≤4) levels. 
5.2.2.5 Assessment of Perceived Stress 
The 10-item version of the Cohen perceived stress scale (CPSS) was used to 
assess perceived stress. This is derived from the original 14-item instrument, 385 has 
been used widely, and is considered to be psychometrically reliable and comparable 
with its predecessor. 386 It measures the degree to which the individual feels he or she 
has experienced stress in the previous month. It has been used widely in research on 
stress and immune function. High CPSS scores appear to be associated with poor 
quality of life and poor coping in other gastrointestinal diseases, including inflammatory 
bowel disease. 387 As there are no validated cut offs to define low, medium, or high 
levels of perceived stress, these data were divided into tertiles of equal size. 
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5.2.2.6 Assessment of Gastrointestinal Symptom-specific Anxiety 
Gastrointestinal Symptom-specific Anxiety was assessed using the visceral 
sensitivity index (VSI), 115 which is a 15-item instrument measuring gastrointestinal 
symptom-specific anxiety. Replies to each of the questions are provided on a six-point 
scale from “strongly disagree” (scored as 0) to “strongly agree” (scored as 5). Again, as 
there are no validated cut offs to define low, medium, or high levels of visceral 
sensitivity, these data were divided into tertiles of equal size. 
5.2.3 Statistical Analysis 
The proportions of individuals who self-identified as having IBS and who met 
either the Rome III or Rome IV criteria for IBS were calculated. Agreement between 
the Rome III and Rome IV criteria for the presence of IBS was measured using the 
modified Kappa statistic, where a value <0.2 indicates poor agreement and a value >0.8 
indicates excellent agreement beyond chance. The study then examined whether 
individuals with Rome III-defined IBS were classified into another functional bowel 
disorder, based on the Rome IV criteria. Finally, the characteristics of individuals 
meeting the Rome III and Rome IV criteria were compared. Categorical variables, such 
as sex, ethnicity, impact on activities of daily living, presence of other lower 
gastrointestinal symptoms, and presence or absence of abnormal anxiety scores, 
abnormal depression scores, high somatisation scores, high perceived stress scores, and 
high levels of gastrointestinal symptom-specific anxiety were compared between 
individuals with Rome III and Rome IV IBS using a χ2 test, and continuous data such as 
age, BMI, and scores for IBS-SSS, HADS, PHQ-15, CPSS, and VSI were compared 
using an independent samples t-test. Due to multiple comparisons a 2-tailed p value of 
<0.01 was considered statistically significant for all analyses. All statistical analyses 




In total, 1375 individuals who self-identified as having IBS were recruited into 
the study between December 2017 and December 2018. The mean age of recruited 
subjects was 49.2 years (range 18 to 86 years), 1157 (84.1%) were female, and 1293 
(94.0%) of the respondents were White Caucasian. There were 180 (13.1%) individuals 
who stated that their IBS symptoms commenced after an acute enteric infection. 
Overall, 1048 (95.5%) of participants stated that they had previously seen their GP with 
their IBS, and 633 (57.7%) had seen a gastroenterologist.  
5.3.1 Proportion of Individuals with IBS Meeting the Rome III and Rome IV 
Criteria and Level of Agreement 
In total, 1368 individuals with IBS provided complete Rome III data, and 1080 
(78.9%) of these met the Rome III criteria for IBS. Overall, 1373 individuals provided 
complete Rome IV data, of whom 811 (59.1%) met the Rome IV criteria for IBS (Table 
5-1). Of those 1080 individuals who met Rome III criteria for IBS, 794 (73.5%) also 
met Rome IV criteria. Among 811 individuals meeting the Rome IV criteria for IBS, 
only 17 (2.1%) did not also meet the Rome III criteria.  The Kappa statistic for the level 
of agreement between the Rome III and Rome IV was 0.50, indicating only moderate 
agreement. When the analysis was restricted to only those who had seen a 
gastroenterologist, the Kappa statistic for agreement between Rome III and Rome IV 
was very similar at 0.54.  
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Table 5-1. Agreement Between the Rome III and Rome IV Criteria for IBS. 
 Met Rome IV criteria for IBS  
(n = 811) 
Did not Meet Rome IV 
criteria for IBS (n = 557) 
Met Rome III criteria for IBS  
(n = 1080) 
794 (97.9%) 286 (51.3%) 
Did not Meet Rome III 
criteria for IBS (n = 288) 





5.3.2 Other Functional Bowel Disorder Diagnoses Among Individuals Not 
Meeting the Rome IV Criteria for IBS 
This study examined whether the 286 individuals who met the Rome III criteria 
for IBS, but who did not meet Rome IV, satisfied the Rome IV criteria for another 
functional bowel disorder. Overall, 33 (11.5%) subjects met the Rome IV criteria for 
functional constipation, 118 (41.3%) functional diarrhoea, 68 (23.8%) functional 
abdominal bloating or distension, and 67 (23.4%) an unspecified functional bowel 
disorder. This meant that of those individuals with Rome III IBS who did not meet the 
Rome IV criteria for IBS, only 11.5% were reclassified into another functional bowel 
disorder where licensed and evidence-based therapies are available.  Reasons for not 
meeting the Rome IV criteria among those with Rome III IBS overall, and according to 
other Rome IV-defined functional bowel disorders, are provided in Table 5-2. The 





Table 5-2. Reasons for not Meeting the Rome IV Criteria for IBS Among those 
Meeting the Rome III Criteria. 
 Reported abdominal 
discomfort, rather 
than abdominal pain 
(%) 
Reported abdominal 
pain, but not at the 
required frequency 
(%) 
Other reasons (%) 
Met Rome III criteria, 
but not Rome IV 
criteria, for IBS  
(n = 286) 
Rome IV functional 
constipation (n = 33) 
Rome IV functional 
diarrhoea  
(n = 118) 
Rome IV functional 
abdominal bloating  
(n = 68) 
Rome IV unspecified 
functional bowel 











































5.3.3 Characteristics of Individuals with Rome III and Rome IV IBS 
The characteristics of the 286 individuals who met the Rome III criteria, but not 
the Rome IV criteria, for IBS were examined and compared with those of the 811 who 
met the Rome IV criteria (Table 5-3). Individuals with Rome IV IBS were significantly 
younger (p < 0.001) and less likely to use alcohol (p = 0.005), but there were no other 
differences in demographic characteristics. There was no difference in the proportion of 
people who had seen a GP with their IBS symptoms, but significantly more of those 
with Rome IV IBS had seen a gastroenterologist (p = 0.001). Those with Rome III IBS 
were more likely to meet criteria for IBS-M, and those with Rome IV IBS were more 
likely to have IBS-D or IBS-C (p < 0.001). Symptoms were significantly more severe 
among those with Rome IV IBS, and were more likely to interfere with activities of 
daily living (p < 0.001). Debilitating urgency occurring on most days and faecal 
incontinence on at least a weekly basis were significantly more frequent, mood and 
psychological health were significantly worse, and perceived stress levels and 
gastrointestinal symptom-specific anxiety were higher among those with Rome IV IBS 




Table 5-3. Characteristics of Individuals Meeting Rome III Criteria, but not Rome 
IV Criteria for IBS, Compared with those Meeting Rome IV Criteria for IBS. 
 Met Rome III Criteria, but not 
Rome IV Criteria, for IBS 
(n = 286) 
Met Rome IV 




Mean age (SD) 51.5 (15.5) 47.4 (15.2) <0.001 
Mean body mass index (SD) 26.9 (8.5) 28.4 (8.3) 0.03 
Female gender (%) 231 (80.8) 697 (85.9) 0.04 
Tobacco user (%) 12 (4.2) 79 (9.7) 0.01 
Alcohol user (%) 187 (65.4) 442 (54.5) 0.005 
Married or co-habiting (%) 186 (65.0) 526 (64.9) 1.00 
University or postgraduate level 
of education (%) 
72 (25.2) 164 (20.3) 0.10 
White Caucasian ethnicity (%) 273 (95.5) 763 (94.3) 0.47 
IBS after acute enteric infection 
(%) 
44 (15.4) 106 (13.1) 0.38 
Seen a GP with IBS (%) 270 (94.4) 778 (95.9) 0.24 
Seen a gastroenterologist with 
IBS (%) 
141 (49.3) 492 (60.7) 0.001 










































Mean IBS-SSS score (SD) 188.2 (79.2) 292.0 (95.8) <0.001 
IBS limits activities ≥50% of the 
time (%) 
136 (47.6) 573 (70.7) <0.001 
Urgency at least most days (%) 44 (15.4) 233 (28.7) <0.001 
Faecal incontinence at least 
once a week (%) 
26 (9.1) 157 (19.4) <0.001 
















Mean HADS-A score (SD) 8.7 (4.4) 11.0 (4.7) <0.001 
















Mean HADS-D score (SD) 5.6 (4.1) 7.7 (4.5) <0.001 
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Mean PHQ-15 score (SD) 11.8 (4.0) 15.4 (4.9) <0.001 
















Mean CPSS score (SD) 17.6 (7.8) 21.6 (8.2) <0.001 
















Mean VSI score (SD) 39.5 (16.9) 50.7 (16.8) <0.001 
CPSS, Cohen perceived stress score; HADS, hospital anxiety and depression scale; IBS-
SSS, IBS severity scoring system; PHQ-15, patient health questionnaire-15; SD, 
standard deviation; VSI, visceral sensitivity index. 
*p value for independent samples t-test for continuous data and Pearson χ2 for 





This study has examined the impact of moving from the Rome III criteria for the 
diagnosis of IBS to Rome IV, in a large cohort of individuals who self-identify as 
having the condition in the UK. Among more than 1300 participants, almost 80% met 
the Rome III criteria, but when the Rome IV criteria were used less than 60% still met 
criteria for IBS. The level of agreement between Rome III and Rome IV criteria for 
diagnosing IBS was moderate, with almost one-quarter of those meeting the Rome III 
criteria no longer classed as having IBS when the Rome IV criteria were used. 
Importantly, among these 286 individuals, almost 90% were reclassified by the Rome 
IV questionnaire as having functional diarrhoea, functional abdominal bloating or 
distension, or an unspecified functional bowel disorder. None of these conditions has 
any licensed or evidence-based therapies available to treat them. Finally, when 
comparing the characteristics of the 811 individuals with Rome IV-defined IBS with the 
286 subjects who met Rome III criteria, there were significantly more individuals with 
severe symptoms, which had a greater impact on activities of daily living, and higher 
proportions of participants with low mood, poor psychological health, and high levels of 
stress and gastrointestinal symptom-specific anxiety among those meeting the Rome IV 
criteria for IBS. As will be discussed, the findings of this study have implications for 
future research. 
A large number of individuals were recruited into this study, all of whom were in 
the community and self-identified as having IBS. Some individuals had consulted a GP, 
some a gastroenterologist, and some had never consulted a physician, meaning the 
participants are likely to be generalisable to many individuals living with IBS in the 
UK. This is further supported by the proportion of individuals in the study who stated 
that their IBS symptoms commenced after an acute enteric infection, which at 13.1% is 
almost identical to that reported in another recent, large internet survey of subjects with 
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IBS, 159 and the fact that the proportion with each IBS stool subgroup is similar to other 
community based surveys. 61, 102 Due to the use of an online questionnaire, data 
collection was near complete for many of the variables of interest. It is believed that this 
is the first study to examine the implications of moving from the Rome III to Rome IV 
criteria for IBS in individuals living with the condition that has actually used the 
validated Rome III and Rome IV questionnaires side by side in the same study.  
Weaknesses of the study include the fact that the diagnosis of IBS was not 
confirmed in all individuals in this study by looking at their medical records. This 
means that the study relied on the fact that the people who took part believed that they 
had IBS as a means of confirming a diagnosis. This may have led to a reduction in 
performance of both the Rome III and Rome IV criteria. However, given that almost 
80% of those who responded did meet the Rome III criteria for IBS, more than 95% had 
previously seen a GP with their IBS, and almost 60% had seen a gastroenterologist, this 
is unlikely to have affected the results to any great degree. As the questionnaire was 
completed online, after visiting a website, it was not possible to assess how many 
individuals chose not to complete the questionnaire, or whether those who responded 
are broadly representative of all the people with IBS registered with these three 
organisations. In addition, because of the setting in which this study was conducted, and 
the fact that participants had to have internet access and be motivated to participate, the 
individuals taking part may not be generalisable to patients consulting with a 
gastroenterologist in secondary or tertiary care. However, this is probably unlikely, as 
57.7% had previously consulted in this setting. Finally, there may have been an over-
representation of White Caucasians in this study, meaning that the results cannot be 
extrapolated to individuals with IBS of other ethnicities.  
As discussed, previous studies have suggested there may be few implications of 
moving from the Rome III to the Rome IV criteria for IBS. 40-42 In a study conducted in 
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a tertiary referral population in Sweden, 40 Aziz et al. reported that 85% of patients with 
Rome III-defined IBS met the Rome IV criteria, but that quality of life was impaired to 
a greater degree, and symptoms were more severe, among those with Rome IV IBS. 
Another study, conducted in secondary and tertiary care in the Netherlands 
demonstrated almost identical findings. 41 More than 85% of individuals meeting Rome 
III criteria for IBS still met the Rome IV criteria, although symptoms were more severe, 
and quality of life worse, in those with Rome IV IBS. However, neither of these studies 
applied the Rome III and IV criteria for IBS simultaneously, but instead used a 
surrogate for Rome IV, consisting of reporting abdominal pain on ≥2 days in the last 10 
days in one study, 40 or reporting abdominal pain once a week in a diary in the other 
study. 41 In addition, the consequences of moving from Rome III to Rome IV-defined 
IBS in those who did not meet Rome IV criteria, in terms of reclassification to another 
functional bowel disorder, were only examined in one of these studies, with 
approximately one-third of patients meeting criteria for each of functional constipation, 
functional diarrhoea, and functional abdominal bloating or distension. 41 A third tertiary 
care study showed less diagnostic agreement between Rome III and IV criteria, with a 
Kappa of 0.45, and only 46.5% of those with Rome III-defined IBS meeting the Rome 
IV criteria. 42 Symptom severity was greater among those with Rome IV IBS, but there 
were few other differences.  
There are likely to be several implications of this study for research and clinical 
practice. Firstly, moving from the Rome III criteria for IBS to Rome IV means that 
approximately one-in-four individuals who believe that they have IBS will no longer 
meet criteria for the condition. Although all these individuals can be reclassified as 
suffering from another functional bowel disorder according to Rome IV, in almost 90% 
of individuals in this study this was not one that was treatable. Functional constipation 
is the only other functional bowel disorder with evidence-based licensed therapies 
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available to treat it. 283, 388 It is unlikely that those with troublesome gastrointestinal 
symptoms will be particularly happy to be labelled as having a poorly understood 
condition, such as functional abdominal bloating or distension, or an unspecified 
functional bowel disorder, with little in the way of effective therapies. In addition, 
unlike in IBS where a positive diagnosis is encouraged, 212, 269, 278 functional diarrhoea is 
a diagnosis of exclusion, due to the higher likelihood that organic conditions, such as 
bile acid diarrhoea or microscopic colitis may present with similar symptoms. This is 
likely to have implications for the health service, in terms of costs of investigation. 
Secondly, the degree of agreement between Rome III and IV criteria for IBS was only 
modest, and worse than for any other iterations of the Rome criteria. A previous study 
demonstrated Kappa values of between 0.74 to 0.95 for the Rome I, II, and III criteria 
for diagnosing IBS. 34 The main reason for the lack of agreement between Rome III and 
Rome IV was the increase in the frequency threshold for abdominal pain required to 
meet Rome IV criteria. This study shows that applying this threshold leads to a 
substantial number of individuals who believe they have IBS no longer meeting 
diagnostic criteria for the condition. Finally, the increased severity of symptoms, and 
higher levels of mood disorder, poor psychological health, perceived stress, and visceral 
sensitivity seen among those with Rome IV IBS demonstrate that this is the more severe 
end of the disease spectrum. This is likely to have huge implications for treatment trials 
in the disorder. Placebo response rates in IBS are high, 318 and most drugs that have 
been tested in patients with Rome III IBS only have modest efficacy, 292, 293, 297, 298, 335 as 
has been discussed in the network meta-analyses presented in Chapters 3 and 4. It is 
therefore possible that moving from Rome III to Rome IV IBS will reduce the 
likelihood of novel pharmacological therapies demonstrating efficacy in the condition in 
future RCTs; however, placebo response rates may be lower among a patient cohort 
with more severe IBS.   
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In summary, moving from the Rome III to the Rome IV criteria for IBS led to a 
reclassification of one-in-four individuals who believe they have IBS to another 
functional bowel disorder. Almost 90% instead met criteria for disorders that are even 
more poorly understood than IBS and have little in the way of available evidence-based 
therapies. Most of this reclassification occurred due to the change in the frequency 
threshold for abdominal pain required by Rome IV. Agreement between Rome III and 
Rome IV was modest at best. Individuals meeting Rome IV criteria for IBS had more 
severe symptoms, which impacted more on activities of daily living, and had higher 
prevalence of abnormal mood, psychological comorbidity, perceived stress, and 
gastrointestinal symptom-specific anxiety. Understanding the impact of these changes 
to the diagnostic classification system for IBS on the efficacy of novel therapies for the 
disorder in future RCTs will be important. The findings of this study, therefore, have 
important implications for the work presented in Chapters 6 and 7, in which data from 
the same cohort of individuals will be used to explore novel approaches to subgrouping 
people with IBS. The clinical and psychological characteristics of people with IBS 
differ significantly dependent on whether the diagnosis is made using the Rome III or 
Rome IV criteria, so it will be necessary to evaluate whether different subgrouping 
models are derived depending on which iteration of the Rome criteria is used to define 
IBS. In addition, this study highlights that reclassification to another functional bowel 
disorder occurs in people who no longer meet criteria for IBS, and that this has 
potentially important clinical ramifications. This will need to be a consideration when 
evaluating the natural history of the novel subgrouping models in Chapter 7. 
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CHAPTER 6  
Using Latent Class Analysis to Identify Distinct and Reproducible 
Subgroups of People with Irritable Bowel Syndrome Based on 




Earlier discussion has already detailed how people with IBS are subgrouped 
according to their predominant stool pattern into one of four groups: IBS-C, IBS-D, 
IBS-M, or IBS-U. These groups are defined by the Rome criteria and have been 
described in Table 1.3. Although the aims of this classification system are laudable, 
using it to direct therapy is problematic for several reasons. First, even when people 
with IBS with these stool subgroups are treated with novel drugs, which have more 
precise modes of action, only 20% to 30% report symptom improvement, 290, 291, 293, 298, 
335, 350 and, as has already been shown in Chapters 3 and 4, there is little to choose 
between many of the available drugs, in terms of efficacy. Second, predominant stool 
type in IBS fluctuates over time. 44, 47 Third, almost 50% of patients have IBS-M or 
IBS-U, 61, 389-391 but most new drugs are tested only in IBS-D or IBS-C, so treatment 
options for patients with these two subgroups are limited. Finally, and perhaps most 
importantly, because IBS is a brain-gut disorder, mood and psychological health play an 
important role in the development and persistence of symptoms. 50-54 Mood disorders 
are much more common in people with IBS than among healthy individuals. 55 Earlier 
use of psychological therapies in patients exhibiting substantial psychological 
comorbidity might change the natural history of IBS. However, access to these is 
limited and, often, their use is advocated only in patients whose symptoms do not 
respond adequately to pharmacological treatment, 269 so they tend to be used only as a 
last resort. Indeed, recent studies have bolstered interest in the use of psychological 
therapies, such as CBT, as effective treatments for IBS with long-lasting benefits. 308-310 
Unfortunately, current approaches to subgrouping patients with IBS offer no clinical 
guidance regarding who might derive the most benefit from these therapies. 
 A classification system based on stool pattern alone does not, therefore, reflect 
the complex composite nature of IBS adequately, nor does it allow equitable access of 
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patients to either clinical trials of novel drugs, or existing drugs or psychological 
therapies with an evidence base for efficacy. In acknowledgment of the fact that IBS is a 
disorder of gut-brain interaction, with biopsychosocial influences, the Rome Foundation 
developed the MDCP, which has already been described in detail in Table 1.4. To recap, 
this is a framework that, in addition to clinical symptoms, includes the assessment of 
psychological factors, and impact of the illness, in order to build a unique clinical 
profile for each patient. 57 Although intended to help guide treatment, this approach has 
yet to be utilised in routine clinical practice, and is not incorporated into current 
diagnostic criteria. If it were possible to classify patients, not only by clinical 
symptoms, but also by psychological profiles, this may help optimise treatment 
selection, resulting in better outcomes, and reduced health service and societal costs of 
IBS. 392  
 To date, only a few studies have examined this issue. 26, 27, 59 In two of these 
studies, conducted by the same group of investigators, distinct subgroups, or clusters, of 
patients appeared to exist. These subgroups consisted of those whose symptoms were 
predominantly intestinal, and who had only minimal psychological distress, and those 
for whom IBS symptoms were part of a broader picture, which included anxiety, 
depression, or extra-intestinal symptoms. 26, 27 These subgroups were not, however, 
reproducible across different patient cohorts or different iterations of the Rome criteria, 
and one study was conducted in only 172 patients in tertiary care. 26 A third study 
demonstrated clusters distinguished by low or high severity of intestinal and non-
intestinal symptoms, which were further differentiated by the extent of impairment in 
IBS-related quality of life, but combined patients meeting either the Rome II or Rome 
III criteria together. 59 However, the study reported in Chapter 5 has shown that there 
are important differences in the clinical and psychological characteristics of people with 
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IBS depending on how it is defined. Comparing subgroups between different iterations 
of the Rome criteria is, therefore, important. 
 In this study, it was hypothesised that it would be possible to derive subgroups 
of people with IBS that were distinct and reproducible, irrespective of setting or 
diagnostic criteria. If feasible, these subgroups could change both the classification of, 
and management strategies for, IBS. For instance, those with predominantly 
gastrointestinal symptoms may respond best to a drug acting peripherally on the 
intestine, those with predominantly psychological or extra-intestinal symptoms to a 
centrally acting drug or psychological therapy, and those with both gastrointestinal and 
extra-intestinal symptoms to a combination of therapies. 
6.2 Methods 
6.2.1 Participants and Setting 
The study recruited individuals who self-identified as having IBS registered with 
three UK organisations. Full details of the recruitment methodology have already been 
discussed in Chapter 5. 
6.2.2 Data Collection and Synthesis 
6.2.2.1 Demographic and Symptom Data 
Basic demographic data were collected, and respondents were asked to state 
whether they had seen a GP or a gastroenterologist about their IBS symptoms. Lower 
gastrointestinal symptom data was captured using the Rome III and Rome IV 
questionnaires. 379, 380 The severity of IBS symptoms was assessed using the IBS-SSS. 
381 Full details of demographic and symptom data collection have already been 




6.2.2.2 Assessment of Mood and Extra-Intestinal Symptoms 
Anxiety and depression data was collected using the HADS. 382 The total HADS 
score ranges from a minimum of 0 to a maximum of 21 for either anxiety or depression. 
Data regarding extra-intestinal symptoms was collected using the PHQ-12, 113 derived 
from the validated PHQ-15. 383 The total PHQ-12 score ranges from a minimum of 0 to 
a maximum of 24. Full details of the assessment of mood and extra-intestinal symptoms 
have already been discussed in Chapter 5. 
6.2.2.3 Assessment of Gastrointestinal Symptom-specific Anxiety and Perceived 
Stress 
The 15-item VSI 115 was used to measure gastrointestinal symptom-specific 
anxiety. Perceived stress was assessed using the 10-item version of the CPSS, which is 
derived from the original 14-item instrument. 385 Full details of the assessment of 
gastrointestinal symptom-specific anxiety and perceived stress have already been 
discussed in Chapter 5. 
6.2.3 Statistical Analysis 
6.2.3.1 Rome III and Rome IV Cohorts 
Two cohorts of individuals, who self-identified as having IBS and who met 
either the Rome III or Rome IV criteria for IBS, were identified. Many participants met 
both iterations of the diagnostic criteria and were therefore represented in both cohorts. 
Consequently, the baseline characteristics of these two cohorts were compared using a 
partially overlapping t-test for continuous data, and a partially overlapping z-test for 
comparison of proportions, 393 with the “partiallyoverlapping” package in R (version 





6.2.3.2 Latent Class Analysis 
Latent class analysis (LCA) was performed in each cohort using LatentGOLD (version 
5.1 Statistical Innovations, Belmont, MA, USA). 395 LCA is a method of structural 
equation modelling used to identify unobserved groups, or latent classes, within 
observed multivariate data. 396 A statistical model is postulated for the population from 
which the data sample is obtained, and it is assumed that a mixture of underlying 
probability distributions generates the data. 397 The use of LCA for this purpose is 
referred to as model-based clustering (Figure 6-1). LCA is a flexible technique, enabling 
inclusion of a range of variable types within the same model. Analysis is iterative, 
whereby, for any given number of clusters, multiple solutions are evaluated to 
determine the best output. 397 Finally, robust statistical criteria can be used to determine 
the best fit of the model, and the optimum number of clusters. 398 The Bayesian 
information criterion of the log-likelihood (BIC(LL)) was used for this purpose, and the 
cluster solution with the lowest BIC(LL) value was selected as the one that best fit the 


















The observed indictor variables are chosen directly from the dataset to be used in the model. The unobserved categorical variables are the latent 
classes, the number of which can be specified. The estimated measurement parameters describe the relationship between the unobserved categorical 
variables and the observed data. Interpretation of these parameters enables identification and characterisation of clusters, or subgroups, within the 
dataset that would otherwise be unknown.   
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Frequency of abdominal pain (or discomfort*) 
anywhere in the abdomen in past 3 months 
Ordinal 
9-point scale from “Never” (0) to “Multiple 
times per day or all the time” (8) 
All of these variables for 
quantifying gastrointestinal 
symptoms were taken from 
Rome Foundation 
questionnaires. These are the 
recognised “gold standard” for 
diagnosing IBS, and are widely 
used. 
Frequency of abdominal pain being closely related 
to a bowel movement 
Ordinal 
11-point scale from “0%” (never) to “100%” 
(always) 
Frequency with which abdominal pain improved or 
resolved following a bowel movement 
Ordinal 
11-point scale from “0%” (never) to “100%” 
(always) 
Frequency with which stools became softer or 
harder than usual in association with abdominal 
pain 
Ordinal 
11-point scale from “0%” (never) to “100%” 
(always) 
Frequency with which stools became more or less 
frequent than usual in association with abdominal 
pain 
Ordinal 
11-point scale from “0%” (never) to “100%” 
(always) 
Frequency with which abdominal pain started or 
got worse after a meal 
Ordinal 
11-point scale from “0%” (never) to “100%” 
(always) 
Frequency with which abdominal pain restricted 
usual activities 
Ordinal 
11-point scale from “0%” (never) to “100%” 
(always) 
Frequency of hard or lumpy stools in last 3 months Ordinal 
5-point scale from “0%” (never or rarely) to 
“100%” (always) 
Frequency of loose, mushy, or watery stools in the 
last 3 months 
Ordinal 
5-point scale from “0%” (never o rarely) to 
“100%” (always) 
Frequency of faecal urgency over last 3 months Ordinal 
9-point scale from “Never” (0) to “Multiple 
times per day or all the time” (8) 
Frequency of faecal incontinence over last 3 
months 
Ordinal 
9-point scale from “Never” (0) to “Multiple 






Frequency of abdominal bloating or distension over 
last 3 months 
Ordinal 
9-point scale from “Never” (0) to “Multiple 



















All individual items of the PHQ-12 and the 
frequency experienced in the last 4 weeks: 
Back pain 
Arm, leg, joint pain 






Shortness of breath 
Pain/problems during sex 




3-point scale: “Never” (0), “A little” (1), or 
“A lot” (2) 
Reporting symptoms referable to 
multiple body systems, also 
referred to as somatisation, is 
recognised as being associated 
with IBS and other functional 
gastrointestinal disorders. The 
PHQ-12 questionnaire is a 
widely used and validated 






Presence of anxiety, as measured by the total score 
of the HADS-Anxiety questionnaire 
Ordinal 
3-point scale: normal (0), borderline (1), or 
abnormal (2) 
Abnormal mood is well-
recognised as being an important 
factor in IBS. The HADS 
questionnaire for quantifying the 
presence of anxiety and/or 
depression are widely used and 
validated for this purpose. 
Presence of depression, as measured by the total 
score of HADS-Depression questionnaire 
Ordinal 
3-point scale: normal (0), borderline (1), or 
abnormal (2) 
HADS, hospital anxiety and depression scale; PHQ-12, patient health questionnaire-12. 
* Discomfort was included, in addition to pain, for the Rome III definition of IBS, as per Rome III criteria.  
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6.2.3.3 Description of Cluster Characteristics 
For each cluster, a radar plot was drawn using z-values for each variable. These 
were calculated by adjusting the cluster mean for each variable to the cohort mean and 
standard deviation (SD) for that variable. The radar plots were compared by visual 
inspection and the particular characteristics of each cluster were described.  
6.2.3.4 Validation of Rome III and IV Latent Class Models 
In order to internally validate the analyses, 10-fold cross-validation was 
performed, 399 for both the Rome III and Rome IV models, using the n-validation 
capability of LatentGOLD. The misclassification statistic for the original model 
derivation was compared with that obtained from cross-validation, in order to 
understand how the model would perform if applied to a different dataset.  
10-fold cross-validation was also performed manually, by splitting the data 
randomly into 10 equally-sized groups, or folds. These folds were recombined in all 10 
possible permutations, omitting a different fold each time, and LCA was undertaken in 
each recombined dataset, using the same variables as were included in the original 
model. The clusters for each derivation were drawn out using radar plots and it was 
determined, by visual inspection, whether the subgroups appeared similar to those of the 
original model. Each derivation model was validated by applying it to the fold that had 
been omitted each time, averaging the misclassification statistic across all 10 validation 
cycles to determine the overall misclassification statistic for the cross-validation process 
















The dataset is split randomly into 10 equally-sized folds. In each iteration, the model is derived in the combined training folds and evaluated in the 
validation fold in order to calculate a performance metric, in this case the misclassification statistic (M). The misclassification statistic is averaged 
across all 10 iterations in order to calculate the misclassification statistic for the 10-fold cross-validation process as a whole. 
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6.2.3.5 Comparison of Characteristics of Individuals Between Clusters 
The characteristics of individuals in each cluster were compared for both the 
Rome III and Rome IV cohorts. Categorical variables, such as sex, consultation with a 
gastroenterologist, high levels of gastrointestinal symptom-specific anxiety or perceived 
stress, high symptom severity scores, IBS stool subgroup according to the BSFS, and 
whether IBS onset followed an acute enteric infection, were compared between 
individuals in each cluster using a χ2 test. Differences in continuous variables between 
clusters were compared using a one-way analysis of variance (ANOVA) test. Due to 
multiple comparisons, a 2-tailed p value of <0.01 was considered as statistically 
significant for these analyses, which were performed using SPSS for Windows (version 
24.0 SPSS Inc., Chicago, IL, USA). 
6.3 Results 
In total, and as reported in Chapter 5, 1375 individuals who self-identified as 
having IBS were recruited into the study. The mean age of subjects was 49.2 years 
(range 18 to 86 years) 1157 (84.1%) were female, and 1293 (94.0%) were White 
Caucasian. Overall, 180 (13.1%) individuals stated their IBS symptoms commenced 
after an acute enteric infection, 1048 (95.5%) had previously seen their GP with their 
IBS, and 633 (57.7%) had seen a gastroenterologist.  
6.3.1 Characteristics of the Rome IV and Rome III Cohorts 
There were 1373 individuals providing complete Rome IV data, of whom 811 
(59.0%) met the Rome IV criteria for IBS. In total, 1368 individuals with IBS provided 
complete Rome III data, and 1080 (78.9%) met the Rome III criteria for IBS. The two 
cohorts overlapped, such that of the 1080 individuals who met Rome III criteria for IBS, 
794 (73.5%) also met Rome IV criteria. Therefore, among 811 individuals meeting the 
Rome IV criteria for IBS, only 17 (2.1%) did not also meet Rome III criteria. The Rome 
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IV cohort were significantly younger (p < 0.001), but there was no difference in the 
proportion of female participants between groups (Table 6-2). In both cohorts, over 
95% of individuals had seen a GP with IBS; however, those in the Rome IV cohort were 
significantly more likely to have seen a gastroenterologist (p < 0.001). IBS symptoms 
were significantly more severe in the Rome IV cohort (p < 0.001), and mood and 
psychological health were significantly worse (p <0.001). CPSS and VSI scores were 




Table 6-2. Comparison of Demographic Data, IBS Symptom Severity, and 
Psychological Comorbidity Between the Rome III and Rome IV Cohorts. 
 
Rome III cohort* 
(n = 1080) 
Rome IV cohort† 
(n = 811) 
p value‡ 
Mean age (SD) 48.4 (15.3) 47.4 (15.2) <0.001 
Female (%) 915 (84.7) 697 (85.9) 0.06 
IBS after acute enteric infection (%) 147 (13.6) 106 (13.1) 0.40 
Seen a GP with IBS (%) 1031 (95.5) 778 (95.9) 0.22 
Seen a gastroenterologist with IBS (%) 620 (57.4) 492 (60.7) <0.001 
Mean IBS-SSS score (SD) 265 (102) 292 (96) <0.001 
Mean PHQ-12 score (SD) 9.6 (4.3) 10.3 (4.3) <0.001 
Mean HADS-Anxiety score (SD) 10.4 (4.7) 11.0 (4.7) <0.001 
Mean HADS-Depression score (SD) 7.1 (4.5) 7.6 (4.5) <0.001 
Mean CPSS score (SD) 20.5 (8.3) 21.6 (8.2) <0.001 
Mean VSI score (SD) 47.6 (17.5) 50.7 (16.8) <0.001 
CPSS, Cohen perceived stress scale; HADS, hospital anxiety and depression scale; IBS-
SSS, IBS severity scoring system; PHQ-12, patient health questionnaire-12; VSI, 
visceral sensitivity index; SD, standard deviation. 
*Includes 794 individuals who also met the Rome IV criteria for IBS. 
†Includes 17 individuals who did not meet Rome III criteria for IBS.  
‡p value for overlapping samples t-test for continuous data and overlapping samples z-




6.3.2 Latent Class Analysis in the Rome IV Cohort 
The best LCA solution was achieved with seven clusters, as indicated by the 
lowest value of the BIC(LL) (Figure 6-3). An overview of the seven-cluster result is 
provided in Figure 6-4, with descriptions of the clusters and their relative proportions. 
Each cluster was characterised by specific symptom profiles. Radar plots for each of 
these clusters are presented in Figure 6-5.  
 Two clusters were characterised by above-average scores for loose and watery 
stools and urgency, but were differentiated by the presence of below-average or above-
average scores for abdominal pain that was not relieved by defaecation, and for extra-
intestinal and mood-related symptoms. Similarly, another two of the clusters were 
characterised by above-average scores for hard and lumpy stools and bloating, and were 
again differentiated by the presence of below-average or above-average scores for 
abdominal pain that was not relieved by defaecation, and for extra-intestinal and mood-
related symptoms. These clusters were described as diarrhoea and urgency with low 
psychological burden (Figure 6-5A), diarrhoea, abdominal pain, and urgency with high 
psychological burden (Figure 6-5D), constipation and bloating with low psychological 
burden (Figure 6-5G), and constipation, abdominal pain, and bloating with high 
psychological burden (Figure 6-5E). 
 Two clusters were characterised by below-average scores for all gastrointestinal 
symptoms, and were differentiated by the presence of below-average or above-average 
scores for extra-intestinal and mood-related symptoms. These clusters were described as 
low overall gastrointestinal symptom severity with low psychological burden (Figure 
6-5C) and low overall gastrointestinal symptom severity with high psychological 
burden (Figure 6-5B), respectively. The remaining cluster was characterised by a mixed 
profile of well above-average scores for gastrointestinal symptoms, including diarrhoea, 
constipation, and abdominal pain, as well as well above-average scores for extra-
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intestinal and mood-related symptoms. This cluster was described as high overall 




Figure 6-3. Values of BIC(LL) Plotted for Each Specification of the Number of 
Clusters in the Rome IV Cohort. 
 
Lowest value of BIC(LL) indicates the optimum number of clusters. The model 
converges on a 7-cluster solution being the best fit for the model. 
































































A. Cluster 1: Diarrhoea and urgency with low psychological burden. 
B. Cluster 2: Low overall gastrointestinal symptom severity with high psychological burden. 
C. Cluster 3: Low overall gastrointestinal symptom severity with low psychological burden. 
D. Cluster 4: Diarrhoea, abdominal pain, and urgency with high psychological burden. 
E. Cluster 5: Constipation, abdominal pain, and bloating with high psychological burden. 
F. Cluster 6: High overall gastrointestinal symptom severity with high psychological burden. 
G. Cluster 7: Constipation and bloating with low psychological burden. 
 





6.3.3 Latent Class Analysis in the Rome III Cohort 
In the Rome III cohort, the best LCA solution was again achieved with seven 
clusters (Figure 6-6). Overall, these clusters were almost identical to those identified in 
the Rome IV cohort analysis, as shown in Figure 6-7. The symptom profiles that 
characterised each cluster were essentially identical, and radar plots for each of these 
clusters are presented in (Figure 6-8).  
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Figure 6-6. Values of BIC(LL) Plotted for Each Specification of the Number of 
Clusters in the Rome III Cohort. 
 
 
Lowest value of BIC indicates the optimum number of clusters. The model converges 
on a 7-cluster solution being the best fit for the model. 







































































A. Cluster 1: Diarrhoea and urgency with low psychological burden. 
B. Cluster 2: Low overall gastrointestinal symptom severity with high psychological burden. 
C. Cluster 3: Low overall gastrointestinal symptom severity with low psychological burden. 
D. Cluster 4: Diarrhoea, abdominal pain, and urgency with high psychological burden. 
E. Cluster 5: Constipation, abdominal pain, and bloating with high psychological burden. 
F. Cluster 6: High overall gastrointestinal symptom severity with high psychological burden. 
G. Cluster 7: Constipation and bloating with low psychological burden. 
 




6.3.4 Cluster Assignment Among Those Individuals Not Meeting Rome III 
or IV Criteria for IBS 
There were 271 individuals who, although they identified as having IBS, met 
neither the Rome III nor Rome IV criteria for IBS. In the case of Rome IV, this was 
because, in 235 people (86.7%), their GI symptoms were mild, although 89 (37.9%) of 
these reported psychological symptoms. When the Rome IV-derived model was applied 
to these 271 people, 146 (53.9%) were assigned to cluster 3, with low overall 
gastrointestinal symptoms and low psychological burden, and 89 (32.8%) to cluster 2, 
with low overall gastrointestinal symptoms and high psychological burden. The findings 
for the Rome III criteria, and applying the Rome III-derived model, were similar. 
6.3.5 10-fold Cross-validation for the Rome IV and Rome III Latent Class 
Analyses 
The misclassification statistic for the Rome IV cohort seven-cluster LCA was 
12.2%, compared with 14.8% when 10-fold cross-validation was carried out. This 
suggests that the model could be expected to perform similarly if applied to a different 
dataset containing the same variables. When the cross-validation process was 
undertaken manually and radar plots characterising the clusters resulting from each 
iteration were drawn out, seven clusters of very similar appearance occurred each time, 
matching the characteristics of the seven clusters described in the original model 
analysis. The results from 10-fold cross-validation in the Rome III cohort were broadly 
similar; the misclassification statistic for the Rome III cohort seven-cluster LCA was 




6.3.6 Characteristics of the Different Clusters in the Rome IV and Rome III 
Cohorts  
The characteristics of the seven clusters in the Rome IV cohort are shown in 
Table 6-3. There was a difference in mean age between clusters, with those in cluster 1, 
defined as diarrhoea, urgency and low psychological burden, being significantly older, 
and those in cluster 5, defined as constipation, abdominal pain, and high psychological 
burden, being significantly younger (p < 0.001). There was also a difference in sex 
distribution between clusters, with a significantly higher proportion of men in cluster 3, 
with low overall gastrointestinal symptoms and low psychological burden (p = 0.003). 
There were no significant differences in terms of the proportion of individuals who had 
seen a gastroenterologist, or the proportion who reported that their IBS symptoms 
started after an acute enteric infection. The proportion of participants with high CPSS 
scores and VSI scores, and the proportion of individuals with severe symptoms were 
significantly higher in clusters 2, 4, 5, and 6; those characterised by higher 
psychological burden (p < 0.001). Stool subgroup according to the BSFS reflected the 
symptom-based characteristics of each cluster, and this trend was significant (p < 
0.001). Clusters 1 and 4, which were those groups with above-average scores for 
diarrhoea, had the largest proportions of subjects with IBS-D according to the BSFS, 
with very few having IBS-C, and approximately one-third having IBS-M. Conversely, 
clusters 5 and 7, which had above-average scores for constipation, had the highest 
proportion of participants with IBS-C, and contained very few individuals with either 
IBS-D or IBS-M. The proportion of individuals with IBS-M was highest in clusters 2, 3, 
and 6; those characterised by a more mixed profile of gastrointestinal symptoms of 
varying severity. An identical analysis comparing clusters in the Rome III cohort 














(n = 161) 
Cluster 2 






(n = 170) 
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(n = 59) 
p value* 
Mean age (SD) 51.7 (15.5) 44.6 (15.2) 49.3 (16.7) 45.3 (13.1) 40.7 (12.9) 46.9 (13.8) 47.6 (14.3) <0.001 
Female (%) 140 (87.0) 141 (82.9) 129 (78.2) 139 (90.3) 31 (100.0) 62 (87.3) 55 (93.2) 0.003 
Seen a 
gastroenterologist 
with IBS (%) 
92 (57.1) 104 (61.2) 97 (58.8) 98 (63.6) 18 (58.1) 48 (68.6) 35 (59.3) 0.726 
High VSI scores (%) 46 (28.6) 80 (47.3) 32 (19.5) 87 (56.5) 23 (74.2) 53 (75.7) 10 (16.9) <0.001 
High CPSS scores 
(%) 
18 (11.2) 81 (47.6) 20 (12.1) 86 (56.2) 18 (58.1) 57 (80.3) 10 (16.9) <0.001 
Severe symptoms on 
IBS-SSS (%) 








Subgroup on BSFS         
IBS-C (%) 6 (3.7) 37 (21.9) 20 (12.1) 3 (1.9) 26 (83.9) 2 (2.8) 48 (81.4)  
IBS-D (%) 101 (62.7) 40 (23.7) 58 (35.2) 88 (57.1) 2 (6.5) 19 (26.8) 3 (5.1)  
IBS-M (%) 50 (31.1) 87 (51.5) 77 (46.7) 61 (39.6) 3 (9.7) 46 (64.8) 7 (11.9)  
IBS-U (%) 4 (2.5) 5 (3.0) 10 (6.1) 2 (1.3) 0 (0.0) 4 (5.6) 1 (1.7) <0.001 
IBS after acute 
enteric infection (%) 
21 (13.0) 19 (11.2) 30 (18.2) 15 (9.7) 6 (19.4) 12 (17.1) 3 (5.1) 0.083 
BSFS: Bristol stool form scale;  CPSS: Cohen perceived stress scale; GI: gastrointestinal; IBS-SSS: IBS severity scoring system; 
SD, standard deviation; VSI: visceral sensitivity index. 















(n = 236) 
Cluster 2 
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(n = 61) 
p value* 
Mean age (SD) 53.3 (15.4) 48.6 (15.2) 48.3 (16.4) 46.8 (14.1) 40.0 (13.5) 46.4 (13.6) 47.66 (13.6) <0.001 
Female (%) 202 (85.6) 181 (80.4) 167 (78.8) 161 (87.0) 78 (96.3) 70 (87.5) 56 (91.8) 0.002 
Seen a 
gastroenterologist 
with IBS (%) 
132 (55.9) 136 (60.4) 104 (49.1) 119 (64.3) 40 (49.4) 53 (67.1) 62 (59.0) 0.014 
High VSI scores (%) 53 (22.5) 73 (32.6) 27 (12.7) 97 (52.4) 47 (58.8) 60 (75.9) 15 (24.6) <0.001 
High CPSS scores 
(%) 
31 (13.1) 72 (32.0) 21 (9.9) 92 (50.0) 43 (53.1) 66 (82.5) 14 (23.0) <0.001 
Severe symptoms on 
IBS-SSS (%) 






BSFS: Bristol stool form scale; CPSS: Cohen perceived stress scale; GI: gastrointestinal; IBS-SSS: IBS severity scoring system; SD, standard 
deviation; VSI: visceral sensitivity index. 
* p value for Pearson χ2 for comparison of categorical data and one-way ANOVA for comparison of means. 
 
Subgroup on BSFS         
IBS-C (%) 10 (4.2) 38 (17.0) 49 (23.1) 4 (2.2) 46 (56.8) 3 (3.8) 45 (73.8)  
IBS-D (%) 149 (63.1) 61 (27.2) 70 (33.0) 105 (56.8) 2 (2.5) 26 (32.5) 5 (8.2)  
IBS-M (%) 65 (27.5) 116 (51.8) 81 (38.2) 74 (40.0) 32 (39.5) 47 (58.8) 10 (16.4)  
IBS-U (%) 12 (5.1) 9 (4.0) 12 (5.7) 2 (1.1) 1 (1.2) 4 (5.0) 1 (1.6) <0.001 
IBS after acute 
enteric infection (%) 




This study investigated whether it is possible to subgroup people with IBS using 
factors beyond stool pattern. The analysis found seven unique clusters of individuals 
with IBS, distinguished by the pattern of gastrointestinal symptoms, extra-intestinal 
symptoms, and mood. Two of these were characterised by diarrhoea and were 
differentiated based on the presence of abdominal pain that was not relieved by 
defaecation, and high or low psychological burden (Figure 6-5A/6-8A vs. Figure 6-
5D/6-8D). Two clusters were characterised by constipation and were again 
differentiated based on the presence of abdominal pain that was not relieved by 
defaecation, and high or low psychological burden (Figure 6-5E/6-8E vs. Figure 6-
5G/6-8G). A further two clusters exhibited mixed gastrointestinal symptoms of low 
overall intensity but were differentiated by the presence of high or low psychological 
burden (Figure 6-5B/6-8B vs. Figure 6-5C/6-8C). The final cluster was characterised by 
mixed gastrointestinal symptoms of high overall intensity with high psychological 
burden (Figure 6-5F/6-8F). These seven clusters were reproducible, irrespective of 
whether IBS was defined according to the Rome III or Rome IV criteria. These models 
were validated, demonstrating that they would be expected to perform similarly if 
applied to a different dataset. Comparing additional characteristics between clusters 
found a significantly higher proportion of men in the cluster with low overall symptoms 
and low psychological comorbidity. It was also found that groups characterised by high 
psychological comorbidity had a significantly greater proportion of people with high 
scores using other measures of psychological health, such as the VSI and CPSS, which 
were not included in the model itself. Finally, stool subgroup, as defined according to 
the BSFS, correlated significantly with the gastrointestinal symptom profile of each 
cluster. These results have the potential to change classification and treatment of IBS.  
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This study has several strengths. A large number of individuals were recruited, 
all of whom were in the community and self-identified as having IBS. Some individuals 
had consulted a GP, some a gastroenterologist, and some had never consulted a 
physician, meaning the participants are likely to be generalisable to many individuals 
living with IBS. This is further supported by the proportion of individuals with each IBS 
stool subgroup, which is similar to other community based surveys. 61, 102 The study 
used an online questionnaire, meaning data collection was near complete for many of 
the variables of interest. External validation of the Rome III and Rome IV latent class 
models in a different cohort of patients was not possible because no suitable data were 
available. In lieu of this, it was possible to internally validate both models instead, in 
order to understand how they might apply to other groups of patients with IBS. 
Weaknesses of the study include the fact that it was not possible to confirm the 
diagnosis of IBS in all individuals in this study by looking at their medical records. This 
means it was necessary to rely on the fact that the people who took part believed that 
they had IBS as a means of confirming a diagnosis. This may have led to the inclusion 
of some people with disorders other than IBS, which may have different symptom 
profiles, and this may have affected the extent to which the results of this LCA are 
indicative of true IBS subgroups. However, given that almost 80% of those who 
responded did meet the Rome III criteria for IBS, more than 95% had previously seen a 
GP with their IBS, and almost 60% had seen a gastroenterologist, it is unlikely that this 
will have affected the results to any great degree. As the questionnaire was completed 
online, after visiting a website, it was not possible to assess how many individuals 
visited the website but chose not to complete the questionnaire, or whether those who 
responded are broadly representative of all the people with IBS registered with these 
three organisations. In addition, because of the setting in which the study was 
conducted, and the fact that participants had to have internet access and be motivated to 
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participate, they may not be generalisable to patients consulting with a 
gastroenterologist in secondary or tertiary care. However, given that almost 60% had 
previously consulted in this setting, this is unlikely.  
 To date, there have been only four previous studies examining approaches other 
than stool pattern to subgrouping people with IBS. 26, 27, 59, 60 In the first of these studies, 
there appeared to be six distinct subgroups of people with Rome III-defined IBS; those 
whose symptoms were predominantly intestinal, including diarrhoea, constipation, or 
abdominal pain, and who had only minimal psychological distress, and those for whom 
IBS symptoms were part of a broader picture, which included anxiety, depression, and 
extra-intestinal symptom reporting. 26 This Swedish study, however, included only 172 
patients in tertiary care, so the findings may not be generalisable to the majority of 
people with IBS, who are seen in a primary or secondary care setting. In a second study 
conducted by the same group, again IBS subgroups characterised by a combination of 
gastrointestinal and extra-intestinal symptoms were identified, but these were not 
consistent between Rome III and Rome IV criteria. 27 The authors identified seven 
subgroups for Rome III-defined IBS, but only five with Rome IV. The latter were less 
distinct, with a preponderance of mixed-symptom profiles. Moreover, and in contrast to 
this study, it was a population-based cross-sectional survey, which classified 
participants as having IBS solely based on whether their responses fulfilled the Rome 
criteria, rather being included because they reported having IBS, or had received a 
diagnosis of IBS. A third study included 107 patients diagnosed with IBS using the 
Rome I criteria and conducted a K means cluster analysis using intestinal symptoms, 
psychological health, and rectal distension thresholds. 60 Three distinct subgroups of 
patients were observed. Two of these were defined by low rectal distension thresholds 
and were distinguished by low or high psychological co-morbidity. In contrast, the third 
subgroup had high rectal distension thresholds, low disease impact, and low 
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psychological co-morbidity overall. The final study used an advertisement to recruit 332 
patients who had received a diagnosis of IBS, and analysis of data concerning 
gastrointestinal symptoms, extra-intestinal symptoms, and IBS-related quality of life 
identified four subgroups. 59 Two subgroups had low overall symptoms and were 
differentiated based on having either good or moderate quality of life. The other two 
subgroups had high overall symptoms, with or without diarrhoea, and were further 
differentiated based on having poor or moderate quality of life. This study defined IBS 
according to either the Rome II or Rome III criteria, but combined all participants 
together for analysis, so it is unclear how use of these different symptom-based 
definitions of IBS might have affected the characteristics of the subgroups.  
Despite differences in their patient populations, and the variables used to define 
symptoms, all the studies conducted thus far have demonstrated that people with IBS 
appear to separate into distinct subgroups based on more than just stool pattern. The 
number of subgroups, however, and their precise characteristics, differs between 
studies. In part, this reflects differences in the choice of variables to be included in the 
model. Choosing different variables will change the results, a limitation of any such 
modelling analysis, which is why it is important to select relevant variables with a clear 
rationale. Although distinct IBS subgroups constructed using clinical symptoms, 
symptom severity, and psychological symptoms appear to exist, whether they are 
reproducible in other patient cohorts is unknown. This study is the first to demonstrate 
that the same IBS subgroups are reproducible irrespective of whether IBS is defined 
according to the Rome III or Rome IV criteria. This might partly reflect the overlap 
between the Rome III and Rome IV cohorts. However, previous studies, which also had 
similarly overlapping groups, failed to demonstrate this consistency. 27 Moreover, the 
subgrouping model was validated, demonstrating it could be expected to perform 
similarly if it were applied to a different cohort of patients with IBS. This is important 
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because it suggests that the analysis has not derived a model that is too specific and 
“overfitted” to the data, a risk in previous studies where model validation has not been 
undertaken. 26, 27, 59  
As all of these studies are cross-sectional in design, and in the absence of 
follow-up data, whether these subgroups can be used to guide treatment for the 
individual patient with IBS is uncertain. 58 Nonetheless, examining the diverse 
characteristics of the individuals within the seven clusters identified in this study, which 
look beyond gastrointestinal symptoms, it becomes easier to understand why response 
to a drug targeted against a predominant stool pattern is so variable in clinical practice. 
It also supports the MDCP approach proposed by the Rome Foundation, but indicates 
that, rather than simply acting as a guide to clinicians for managing an individual 
patient, it could be more effective if incorporated formally into the stratification of all 
patients with IBS. This view is supported by a recent discussion paper, suggesting that 
conditions such as IBS should be classified as “functional somatic disorders”, 
occupying a neutral territory between being considered purely somatic or purely mental. 
400 Such a classification system aligns with the aetiological construct that these 
disorders reflect the complex interaction between brain and body. Indeed, the results of 
this study indicate that some people are likely to respond well to drugs targeting their 
most troublesome gastrointestinal symptom, some may benefit from instituting a 
psychological therapy early on in their disease course and, in others, a combined 
approach targeting both physical and psychological symptoms may be more effective. 
People in cluster 3 could be provided with education about the condition and lifestyle 
advice, 401 cluster 1 or 7 treated with a drug targeting diarrhoea or constipation, 
respectively, cluster 2 a psychological therapy, such as CBT, cluster 4 or 5 a drug 
targeting diarrhoea or constipation, in combination with a central neuromodulator or 
psychological therapy to address pain and mood, 402 and cluster 6 augmentation of a 
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central neuromodulator with a psychological therapy, a successful strategy in other 
functional somatic disorders, such as chronic headache and fibromyalgia. 403 This is 
supported by a recent observational study, which suggested that female patients with 
high somatisation and depression should be prioritised for gut-brain psychological 
therapies. 404 
Overall, therefore, stratifying patients into these clusters has the potential to 
change the management paradigm for IBS, facilitating a more personalised approach to 
treatment, by allowing clinicians to select the best treatment, or treatments, at the 
earliest opportunity for any individual patient.  There is therefore a need to understand 
whether these clusters predict underlying pathophysiological mechanisms in IBS and, 
more importantly, whether they can be used to tailor treatment. The latter could be 
achieved in collaboration with other investigators by examining clinical trial datasets 
retrospectively to assess whether these subgroups predict response to a particular drug 
or psychological therapy. This study also provides guidance for a minimum dataset that 
future treatment trials in IBS could collect, to identify subgroups of patients who will 
respond best to a particular treatment. 
 In summary, this study shows that, irrespective of whether IBS is defined 
according to the Rome III or Rome IV criteria, people with IBS could be divided into 
seven distinct and reproducible clusters. These were differentiated according to the 
presence of certain gastrointestinal symptoms, including stool form or frequency, and 
abdominal pain that was not relieved by defaecation, as well as by the presence of extra-
intestinal symptoms and abnormal mood. If these novel subgroups are reproducible in 
other settings, and are shown to predict response to specific therapies that are available 
to treat IBS, they could then be utilised to personalise treatment. This has the potential 
to change clinical practice by allowing gastroenterologists and patients to select the 
right therapy based on these subgroups, leading to improved symptom control, higher 
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levels of patient satisfaction, better quality of life, and reduced health service and 
societal costs of managing IBS. In addition, for people whose IBS symptoms form part 
of a broader picture that includes substantial psychological comorbidity, the subgroups 
could be used to prioritise access to psychological therapies, or to make the decision to 
institute combined therapy with both a drug and a psychological therapy. Earlier use of 
psychological therapies in these particular subgroups of people, rather than after 
pharmacological therapies have failed, as is currently recommended, 269 may alter the 
clinical course of the condition. To better understand whether these subgroups could be 
used to personalise the treatment of IBS and change outcomes as described, longitudinal 
follow-up exploring their natural history and prognostic value is needed, and this is the 
focus of the study presented in Chapter 7.
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CHAPTER 7  
Examining the Natural History and Prognostic Value of a Novel 




In Chapter 6 it has been demonstrated that, irrespective of whether IBS is 
defined according to the Rome III or Rome IV criteria, people with IBS can be divided 
into seven distinct and reproducible clusters using latent class analysis. These were 
characterised by a pattern of gastrointestinal symptoms (predominantly diarrhoea-
related, predominantly constipation-related, or mixed symptoms) further differentiated 
by the presence or absence of abdominal pain not relieved by defaecation, and by the 
presence of high or low levels of both extra-intestinal symptom reporting and 
psychological comorbidity. This reflects the principles of the Rome Foundation MDCP 
framework, which looks beyond the cardinal gastrointestinal symptoms needed to make 
a diagnosis of IBS and subgrouping patients according to their predominant stool 
pattern, instead recommending the assessment of additional clinical features, 
psychological factors, and impact of the illness, in order to build a unique clinical 
profile for each patient. 57 Nevertheless, directing treatment according to predominant 
stool pattern alone remains the mainstay of IBS management, even though longitudinal 
studies demonstrate that IBS stool subgroups are not stable over time, 44, 45, 47-49 with a 
change in subgroup occurring in up to one-third of people during follow-up. 49 
Moreover, in a recent study, fluctuation between IBS stool subgroups did not depend 
solely on whether a new treatment was initiated, or whether the choice of treatment was 
deemed appropriate based on IBS stool subgroup at baseline. 49 If, as discussed, 
gastroenterologists and patients were to personalise their treatment choices based on 
these novel subgroups instead, for example making earlier use of psychological 
therapies in clusters with high psychological comorbidity, this has the potential to 
improve outcomes. To explore this theory further, a longitudinal follow-up study was 
conducted in order to understand the evolution of IBS according to this novel 
classification system, and to assess whether these clusters were predictive of differing 
251 
 
disease courses. This study also examined if commencing new treatments was 
associated with a change in cluster membership. 
7.2 Methods 
7.2.1 Participants and Setting 
This was a 12-month follow-up study of individuals who self-identified as 
having IBS registered with three organisations in the UK, and who agreed to participate 
in the previous studies detailed in Chapters 5 and 6. Briefly, participants were contacted 
via email and post, inviting them to complete an online questionnaire. The questionnaire 
collected demographic data, and data about lower gastrointestinal symptoms, extra-
intestinal symptoms, and psychological health. Invitations were sent out to complete a 
follow-up questionnaire a minimum of 12 months later, using the same methods. All 
non-responders were sent a reminder. Although all participants self-identified as having 
IBS, the baseline data were used to identify two cohorts of people meeting the Rome IV 
and Rome III diagnostic criteria for IBS. In both cohorts, latent class analysis, a method 
of model-based clustering, was used to derive novel subgroups of people with IBS, and 
these models were validated internally. Comprehensive details regarding this 
methodology are provided in Chapter 6.  
 The latent class modelling using baseline data identified seven distinct IBS 
clusters, which were almost identical, in both the Rome IV and Rome III cohorts, and 
which are detailed in Figure 6-5 and Figure 6-8. To examine the natural history of these 
clusters, the same model was applied to participant follow-up data, and cluster 
membership at baseline was compared with that at 12-month follow-up. The University 





7.2.2 Data Collection and Synthesis 
7.2.2.1 Demographic and Treatment Data 
Demographic data was collected at baseline. At 12 months, participants were 
asked to record any new treatments (dietary, drugs, and/or psychological, but not 
complementary or alternative medicines) that they commenced, as well as GP visits, or 
consultations with a gastroenterologist, after the baseline questionnaire. The 
questionnaires were otherwise identical at baseline and 12-month follow-up.  
7.2.2.2 Lower Gastrointestinal Symptom and Psychological Health Data 
Lower gastrointestinal symptom data at baseline and follow-up were captured 
using both the Rome IV and Rome III questionnaires. 379, 380 The presence or absence of 
either Rome IV or Rome III-defined IBS was assigned among all individuals according 
to the scoring algorithms proposed for these questionnaires. 14, 32 Participants who no 
longer met either Rome IV or Rome III criteria for IBS at 12 months were classified 
into one of the other functional bowel disorders, including functional constipation, 
functional diarrhoea, functional abdominal bloating or distension, or unspecified 
functional bowel disorder. 14 Individuals with the latter diagnosis have lower 
gastrointestinal symptoms that do not meet criteria for any of the other four functional 
bowel disorders. Symptom severity was measured using the validated IBS-SSS, 381 and 
the impact of symptoms, in terms of the proportion of time that they limited normal 
daily activities, was measured as per the Rome questionnaire. Anxiety and depression 
data were collected using the HADS, 382 and extra-intestinal symptom data using the 
PHQ-12, 113 derived from the validated PHQ-15. 383 These same measures were used to 
assess psychological burden at baseline. Full details of these questionnaires and 




7.2.3 Statistical Analysis 
Categorical variables were compared between individuals responding to the 12-
month questionnaire, and those who did not, using a χ2 test. An independent samples t-
test was used to compare mean age. IBS cluster at baseline was compared with IBS 
cluster at follow-up in those still meeting criteria for Rome IV-defined IBS and Rome 
III-defined IBS, respectively. In addition, IBS cluster membership was compared 
between the two time points stratified according to predominant stool pattern, and level 
of psychological burden, at baseline. The proportions of individuals with Rome IV or 
Rome III IBS at baseline who fluctuated to another functional bowel disorder at 12 
months was also compared, analysed according to their IBS cluster at baseline. Due to 
multiple comparisons a 2-tailed p value of <0.01 was considered statistically significant 
for all analyses. The study also examined whether baseline cluster influenced 
subsequent disease behaviour by comparing proportions of people in each cluster who 
reported symptoms limiting their activities ≥50% of the time, commenced a new 
treatment, saw their GP, or consulted a gastroenterologist, using a χ2 test, and the mean 
number of new treatments commenced using a one-way ANOVA. Finally, the study 
examined what treatments participants received, according to their baseline cluster, and 
whether commencing new treatment(s) was associated with changing to a different 
cluster at follow-up. All analyses were performed using SPSS for Windows (version 
24.0 SPSS Inc., Chicago, IL, USA).  
7.3 Results 
As detailed in Chapter 6, 1375 individuals who self-identified as having IBS 
were recruited into the study at baseline with a mean age of 49.2 years (range 18 to 86 
years). 1157 (84.1%) were female, and 1293 (94.0%) were White Caucasian. 784 
participants (57.0%) were successfully followed up and provided complete data at 12 
months. The differences between responders and non-responders related to demographic 
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characteristics (Table 7-1). There were no differences in the proportion who met either 
the Rome IV or Rome III criteria at baseline, IBS symptom severity, or psychological 
comorbidity between those successfully followed up, and those who were not. There 
was also no difference in the proportion of individuals in each baseline cluster between 
responders and non-responders. There were 811 participants who met Rome IV criteria 
for IBS at baseline, of whom 452 (55.7%) responded to the 12-month questionnaire, and 
319 (70.6%) of these individuals still met Rome IV criteria for IBS at follow-up. In 
total, 631 (58.4%) of 1080 participants who met Rome III criteria for IBS at baseline 
responded to the 12-month questionnaire, and 527 (83.5%) still met the Rome III 
criteria for IBS at follow-up. Overall, results for the cohort of participants meeting 




Table 7-1. Characteristics of Individuals Responding to the 12-month 
Questionnaire Compared with Non-responders. 
 Responded to 
Questionnaire at 12 
months 
(n=784) 
Did not Respond to 
Questionnaire at 
12 months 
(n = 591) 
p 
value* 
Mean age (SD) 50.7 (14.4) 47.1 (16.4) <0.001 
Female gender (%) 660 (84.2) 497 (84.1) 0.96 
Married or co-habiting (%) 535 (68.2) 363 (61.4) 0.009 
University or postgraduate level of 
education (%) 
369 (47.1) 218 (37.2) <0.001 
White Caucasian ethnicity (%) 754 (96.2) 539 (91.7) <0.001 
IBS after acute enteric infection (%) 102 (13.0) 78 (13.2) 0.90 
Previously seen a GP regarding IBS at 
study entry (%) 
754 (96.2) 548 (92.9) 0.007 
Previously seen a gastroenterologist 
regarding IBS at study entry (%) 
475 (60.6) 314 (53.2) 0.006 
Rome IV criteria for IBS met (%) 452 (57.7) 359 (60.8) 0.24 
Rome III criteria for IBS met (%) 631 (80.7) 449 (76.6) 0.07 










































































PHQ-12 severity high (%) 166 (21.2) 142 (24.0) 0.21 
Rome IV latent class baseline cluster (%) † ‡    
Cluster 1 135 (17.2) 109 (18.4)  
Cluster 2 167 (21.3) 127 (21.5)  
Cluster 3 277 (35.3) 188 (31.8)  
Cluster 4 105 (13.4) 70 (11.8)  
Cluster 5 14 (1.8) 20 (3.4)  
Cluster 6 34 (4.3) 40 (6.8)  
Cluster 7 52 (6.6) 37 (6.3) 0.15 
HADS, hospital anxiety and depression scale; IBS-SSS, IBS severity scoring system; 
PHQ-12, patient health questionnaire-12; SD, standard deviation. 
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*p value for independent samples t-test for continuous data and Pearson χ2 for 
comparison of categorical data. 
†Based on applying Rome IV model to all participants, not only those with Rome IV 
IBS. 
‡Analysis comparing Rome III Latent Class Baseline Cluster also showed no significant 





7.3.1 Natural History of IBS Clusters Among Individuals Continuing to 
Meet Rome IV Criteria for IBS at Follow-up 
Of the 319 individuals still meeting Rome IV criteria for IBS at follow-up, 172 
(53.9%) remained in the same IBS cluster as at baseline and 147 (46.1%) changed 
cluster. Fluctuation in each individual cluster is detailed in Figure 7-1. The proportion 
of people who remained in the same cluster between baseline and follow-up varied from 
47.5% for cluster 4 (diarrhoea, abdominal pain, and urgency with high psychological 
burden) to 72.2% for cluster 7 (constipation and bloating with low psychological 




Figure 7-1. Comparison of IBS Cluster Membership Between Baseline and Follow-
up Among 319 Individuals with Rome IV IBS. 
 
Cluster 1: Diarrhoea and urgency with low psychological burden. 
Cluster 2: Low overall gastrointestinal symptom severity with high psychological 
burden. 
Cluster 3: Low overall gastrointestinal symptom severity with low psychological 
burden. 
Cluster 4: Diarrhoea, abdominal pain, and urgency with high psychological burden. 
Cluster 5: Constipation, abdominal pain, and bloating with high psychological burden. 
Cluster 6: High overall gastrointestinal symptom severity with high psychological 
burden. 








































































Cluster 1 FU Cluster 2 FU Cluster 3 FU Cluster 4 FU
Cluster 5 FU Cluster 6 FU Cluster 7 FU
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Of the 140 people who were in a diarrhoea-related cluster (clusters 1 or 4) at 
baseline, 87 (62.1%) remained in a diarrhoea-related cluster at follow-up and 50 
(35.7%) moved to a mixed gastrointestinal symptom cluster (clusters 2, 3, or 6), whilst 
only three individuals (2.1%) moved to a constipation-related cluster (clusters 5 or 7) 
(Figure 7-2). Similarly, although the number of people was smaller, of 28 individuals in 
a constipation-related cluster at baseline, 19 (67.9%) remained in a constipation-related 
cluster at follow-up, seven (25.0%) moved to a mixed gastrointestinal symptom cluster, 
and only two individuals (7.1%) moved to a diarrhoea-related cluster. Lastly, of the 151 
individuals in a mixed gastrointestinal symptom cluster at baseline, 115 (76.2%) 
remained in a mixed gastrointestinal symptom cluster at follow-up. The proportion of 
individuals who remained in a mixed gastrointestinal symptom cluster at follow-up was 
significantly higher than the proportion who remained in either a diarrhoea-related 




Figure 7-2. Comparison of IBS Cluster Membership According to Pattern of 
Gastrointestinal Symptoms Between Baseline and Follow-up Among 319 















































Diarrhoea-related cluster FU Constipation-related Cluster FU Mixed GI Symptom Cluster FU
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Of the 131 people who were in a cluster with low psychological burden at 
baseline (clusters 1, 3, or 7), 104 (79.4%) remained in a cluster with low psychological 
burden at follow-up (Figure 7-3). Similarly, of the 188 people who were in a cluster 
with high psychological burden at baseline (clusters 2, 4, 5, or 6), only 30 individuals 
(16.0%) moved to a cluster with low psychological burden at follow-up. Mean IBS-SSS 
scores at follow-up were significantly higher in clusters with high psychological burden 




Figure 7-3. Comparison of Cluster Membership According to Degree of 
Psychological Burden Between Baseline and Follow-up Among 319 Individuals 
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Table 7-2. Symptom Severity, Consultation Behaviour, and Commencement of New Treatment According to Baseline IBS Cluster Assignment 
Among 319 Individuals with Rome IV IBS. 
 Rome IV IBS latent class cluster at baseline   
 
p value 























































(n = 18) 
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41 (68.3) 50 (72.5) 32 (60.4) 72 (90.0) 9 (90.0) 23 (79.3) 16 (88.9) 243 (76.2) 0.002 











7 (11.7) 19 (27.5) 7 (13.2) 18 (22.5) 6 (60.0) 10 (34.5) 9 (50.0) 76 (23.8) <0.001 








3 (5.0) 7 (10.1) 3 (5.7) 4 (5.0) 3 (30.0) 3 (10.3) 2 (11.1) 25 (7.8) 0.14 
Secretagogue (%) 0 (0.0) 3 (4.3) 1 (1.9) 3 (3.8) 1 (10.0) 3 (10.3) 2 (11.1) 13 (4.1) 0.16 






28 (46.7) 17 (24.6) 14 (26.4) 41 (51.2) 1 (10.0) 10 (34.5) 0 (0.0) 111 (34.8) <0.001 
Anti-diarrhoeal 
(%) 
28 (46.7) 14 (20.3) 14 (26.4) 37 (46.3) 1 (10.0) 9 (31.0) 0 (0.0) 103 (32.3) <0.001 













28 (46.7) 38 (55.1) 24 (45.3) 62 (77.5) 8 (80.0) 20 (69.0) 13 (72.2) 193 (60.5) 0.001 
Anti-spasmodic 
e.g. hyoscine (%) 
20 (33.3) 21 (30.4) 17 (32.1) 40 (50.0) 5 (50.0) 11 (37.9) 8 (44.4) 122 (38.2) 0.19 
Mebeverine or 
alverine (%) 
10 (16.7) 19 (27.5) 4 (7.5) 21 (26.3) 1 (10.0) 7 (24.1) 2 (11.1) 64 (20.1) 0.07 
TCA (%) 2 (3.3) 9 (13.0) 5 (9.4) 12 (15.0) 3 (30.0) 5 (17.2) 3 (16.7) 39 (12.2) 0.15 
SSRI (%) 5 (8.3) 14 (20.3) 3 (5.7) 21 (26.3) 2 (20.0) 7 (24.1) 3 (16.7) 55 (17.2) 0.03 











8 (13.3) 4 (5.8) 4 (7.5) 4 (5.0) 0 (0.0) 4 (13.8) 1 (5.6) 25 (7.8) 0.40 
CBT (%) 6 (10.0) 3 (4.3) 3 (5.7) 3 (3.8) 0 (0.0) 3 (10.3) 1 (5.6) 19 (6.0) 0.62 
Hypnotherapy 
(%) 
2 (3.3) 1 (1.4) 2 (3.8) 1 (1.3) 0 (0.0) 1 (3.4) 0 (0.0) 7 (2.2) 0.89 
*Adds up to >100%, as some people commenced more than one treatment during 12-month follow-up. 
CBT, cognitive behavioural therapy; IBS-SSS, IBS severity scoring system; GI, gastrointestinal; SD, standard deviation; SNRI; serotonin 
norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant. 
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7.3.2 Change in Functional Bowel Disorder Diagnosis and IBS Cluster 
Membership Among Those No Longer Meeting Rome IV Criteria for 
IBS at Follow-up. 
Among the 133 (29.4%) individuals with Rome IV IBS at baseline who no 
longer met Rome IV criteria for IBS at 12-month follow-up, 48 (36.1%) met Rome IV 
criteria for functional diarrhoea, 39 (29.3%) functional abdominal bloating or 
distension, 32 (24.1%) unspecified functional bowel disorder, and 14 (10.5%) 
functional constipation. Change in functional bowel disorder diagnosis at 12 months 
according to baseline IBS cluster is shown in Figure 7-4. Although these individuals no 
longer met Rome IV criteria for IBS, when the baseline Rome IV cluster model was 
applied to these individuals at 12 months, 93 (69.9%) were assigned to clusters with low 
overall gastrointestinal symptoms (clusters 2 or 3), compared with 68 (51.1%) at 
baseline, reflecting a greater proportion fluctuating to having milder symptoms that, 




Figure 7-4. Change in Functional Bowel Disorder Diagnosis at Follow-up 




Cluster 1: Diarrhoea and urgency with low psychological burden. 
Cluster 2: Low overall gastrointestinal symptom severity with high psychological 
burden. 
Cluster 3: Low overall gastrointestinal symptom severity with low psychological 
burden. 
Cluster 4: Diarrhoea, abdominal pain, and urgency with high psychological burden. 
Cluster 5: Constipation, abdominal pain, and bloating with high psychological burden. 
Cluster 6: High overall gastrointestinal symptom severity with high psychological 
burden. 
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7.3.3 Commencement of New Treatment and Consultation Behaviour 
According to Baseline IBS Cluster Among Those with Rome IV IBS at 
Baseline and Follow-up. 
Overall, of the 319 individuals who continued to have Rome IV IBS at follow-
up, 243 (76.2%) had commenced at least one new treatment during the 12-month 
follow-up period, of whom 112 (46.1%) changed IBS cluster at follow-up. Similarly, of 
the 76 people who did not commence any new treatment, 35 (46.1%) changed IBS 
cluster at follow-up. There was no significant association between commencing a new 
treatment and changing IBS cluster at follow-up (p = 1.00). This remained the case 
when subcategories of treatment were examined, including commencing any medication 
for diarrhoea (p =0.23), any medication for constipation (p = 1.00), any medication for 
pain, including a central neuromodulator (p = 0.35), or any psychological therapy (p = 
0.84). 
 New treatments commenced by baseline IBS cluster are shown in Table 7-2. 
Only 25 individuals with Rome IV IBS at baseline and follow-up reported receiving any 
form of psychological therapy, of whom 13 (52%) were in baseline clusters 
characterised by low psychological burden (clusters 1, 3, or 7). Overall, the mean 
number of treatments commenced was significantly higher in clusters with a high 
psychological burden (clusters 2, 4, 5, or 6) (p<0.001), and these clusters also had 
significantly higher rates of consultation with both GPs and gastroenterologists 
(p<0.001 and p = 0.007, respectively). The impact of symptoms at follow-up, in terms 
of patients reporting that they limited activities at least 50% of the time, was also 
significantly greater in clusters with high psychological burden at baseline (p<0.001). 
Although it was the combination of troublesome gastrointestinal symptoms and high 
psychological burden that was the most debilitating (clusters 4, 5, and 6), it should be 
noted that the proportion of individuals with diarrhoea and urgency with low 
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psychological burden (cluster 1) reporting marked limitation of activities was slightly 
greater than the proportion of those with low overall gastrointestinal symptom severity 
and high psychological burden (cluster 2), and much greater than the proportion of 
people with low psychological burden in association with constipation and bloating 
(cluster 7). Diarrhoea and urgency therefore appear to be important symptoms with 
respect to the impact they can have on daily life.  
As would be expected, a significantly higher proportion of people in clusters 
with diarrhoea-related symptoms (clusters 1 or 4) commenced medication for diarrhoea 
(p<0.001) and, similarly, a significantly higher proportion of people in clusters with 
constipation-related symptoms (clusters 5 or 7) commenced medication for constipation 
(p<0.001). Finally, a significantly higher proportion of people in clusters characterised 
by high psychological burden (clusters 2, 4, 5, or 6) commenced medication for pain, 
including prescription of central neuromodulators (p = 0.001). 
7.3.4 Natural History of IBS Clusters Among Individuals Continuing to 
Meet Rome III Criteria for IBS at Follow-up 
Of the 527 individuals still meeting Rome III criteria for IBS at follow-up, 275 
(52.2%) remained in the same IBS cluster as at baseline and 252 (47.8%) changed 
cluster. Fluctuation in each individual cluster is detailed in Figure 7-5. The proportion 
of people who remained in the same cluster between baseline and follow-up varied from 
40.6% for cluster 5 (constipation, abdominal pain, and bloating with high psychological 
burden) to 58.3% for cluster 6 (high overall gastrointestinal symptom severity with high 




Figure 7-5. Comparison of IBS Cluster Membership Between Baseline and Follow-
up Among 527 Individuals with Rome III IBS. 
 
 
Cluster 1: Diarrhoea and urgency with low psychological burden. 
Cluster 2: Low overall gastrointestinal symptom severity with high psychological 
burden. 
Cluster 3: Low overall gastrointestinal symptom severity with low psychological 
burden. 
Cluster 4: Diarrhoea, abdominal pain, and urgency with high psychological burden. 
Cluster 5: Constipation, abdominal pain, and bloating with high psychological burden. 
Cluster 6: High overall gastrointestinal symptom severity with high psychological 
burden. 
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Of the 217 people who were in a diarrhoea-related cluster (1 or 4) at baseline, 
138 (63.6%) remained in a diarrhoea-related cluster at follow-up and 72 (33.2%) moved 
to a mixed gastrointestinal symptom cluster (2, 3, or 6), whilst only seven individuals 
(3.2%) moved to a constipation-related cluster (5 or 7) (Figure 7-6). Similarly, although 
the number of people was smaller, of 62 individuals in a constipation-related cluster at 
baseline, 31 (50.0%) remained in a constipation-related cluster at follow-up and 24 
(38.7%) moved to a mixed gastrointestinal symptom cluster, with only seven 
individuals (11.3%) moving to a diarrhoea-related cluster. Lastly, of the 248 individuals 
in a mixed gastrointestinal symptom cluster at baseline, 170 (68.5%) remained in a 
mixed gastrointestinal symptom cluster at follow-up. The proportion of individuals who 
remained in a constipation-related cluster at follow-up was significantly lower than the 
proportion who remained in either a diarrhoea-related cluster or a mixed gastrointestinal 




Figure 7-6. Comparison of IBS Cluster Membership According to Pattern of 
Gastrointestinal Symptoms Between Baseline and Follow-up Among 527 
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Of the 250 people who were in a cluster with low psychological burden at 
baseline (clusters 1, 3, or 7), 199 (79.6%) remained in a cluster with low psychological 
burden at follow-up (Figure 7-7). Similarly, of the 277 people who were in a cluster 
with high psychological burden at baseline (clusters 2, 4, 5, or 6), only 59 individuals 
(21.3%) moved to a cluster with low psychological burden at follow-up. Mean IBS-SSS 
scores at follow-up were significantly higher in clusters with high psychological burden 






Table 7-3. Symptom Severity, Consultation Behaviour, and Commencement of New Treatment According to Baseline IBS Cluster Assignment 
Among 527 Individuals with Rome III IBS. 
 Rome III IBS latent class cluster at baseline   
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Seen a GP regarding 
IBS during follow-up 
(%) 
40 (33.3) 41 (36.6) 29 (29.0) 51 (52.6) 25 (78.1) 27 (75.0) 10 (33.3) 223 (42.3) <0.001 
Seen a 
gastroenterologist 
regarding IBS during 
follow-up (%) 
19 (15.8) 22 (19.6) 17 (17.0) 29 (29.9) 10 (31.3) 20 (55.6) 3 (10.0) 120 (22.8) <0.001 
Any new treatment 
commenced during 
follow-up (%) 
77 (64.2) 76 (67.9) 61 (61.0) 78 (80.4) 28 (87.5) 29 (80.6) 23 (76.7) 372 (70.6) 0.005 
Mean number of new 
treatments commenced 
during follow-up (SD) 
(%) 










11 (9.2) 23 (20.5) 14 (14.0) 21 (21.6) 15 (46.9) 11 (30.6) 17 (56.7) 112 (21.3) <0.001 
Laxative (%) 10 (8.3) 20 (17.9) 9 (9.0) 18 (18.6) 12 (37.5) 10 (27.8) 15 (50.0) 94 (17.8) <0.001 
Suppositories or 
enemas (%) 
4 (3.3) 9 (8.0) 4 (4.0) 6 (6.2) 5 (15.6) 3 (8.3) 5 (16.7) 36 (6.8) 0.052 
Secretagogue (%)  1 (0.8) 0 (0.0) 1 (1.0) 2 (2.1) 3 (9.4) 4 (11.1) 2 (6.7) 13 (2.5) <0.001 
Prucalopride (%) 2 (1.7) 3 (2.7) 2 (2.0) 3 (3.1) 2 (6.3) 2 (5.6) 3 (10.0) 17 (3.2) 0.28 
Any medication for 
diarrhoea commenced 
during follow-up (%) 
54 (45.0) 26 (23.2) 26 (26.0) 47 (48.5) 7 (21.9) 12 (33.3) 1 (3.3) 173 (32.8) <0.001 
Anti-diarrhoeal (%) 54 (45.0) 25 (22.3) 26 (26.0) 43 (44.3) 5 (15.6) 11 (30.6) 1 (3.3) 165 (31.3) <0.001 
Ondansetron (%) 0 (0.0) 2 (1.8) 0 (0.0) 4 (4.1) 2 (6.3) 1 (2.8) 0 (0.0) 9 (1.7) 0.064 
Any medication for 
pain and central 











35 (29.2) 30 (26.8) 34 (34.0) 40 (41.2) 13 (40.6) 14 (38.9) 9 (30.0) 175 (33.2) 0.30 
Mebeverine or alverine 
(%) 
20 (16.7) 23 (20.5) 13 (13.0) 17 (17.5) 9 (28.1) 10 (27.8) 3 (10.0) 95 (18.0) 0.23 
TCA (%) 4 (3.3) 15 (13.4) 7 (7.0) 15 (15.5) 5 (15.6) 6 (16.7) 4 (13.3) 56 (10.6) 0.031 
SSRI (%) 7 (5.8) 22 (19.6) 5 (5.0) 21 (21.6) 7 (21.9) 9 (25.0) 2 (6.7) 73 (13.9) <0.001 
SNRI (%) 0 (0.0) 4 (3.6) 0 (0.0) 5 (5.2) 2 (6.3) 4 (11.1) 1 (3.3) 16 (3.0) 0.007 
Any psychological 
therapy commenced 
during follow-up (%) 
6 (5.0) 11 (9.8) 7 (7.0) 5 (5.2) 0 (0.0) 5 (13.9) 0 (0.0) 34 (6.5) 0.11 
CBT (%) 4 (3.3) 10 (8.9) 7 (7.0) 4 (4.1) 0 (0.0) 3 (8.3) 0 (0.0) 28 (5.3) 0.18 
Hypnotherapy (%) 2 (1.7) 2 (1.8) 1 (1.0) 1 (1.0) 0 (0.0) 2 (5.6) 0 (0.0) 8 (1.5) 0.51 






CBT, cognitive behavioural therapy; GI, gastrointestinal; IBS-SSS, IBS severity scoring system; SD, standard deviation; SNRI; serotonin 
norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant
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Figure 7-7. Comparison of IBS Cluster Membership According to Degree of 
Psychological Burden Between Baseline and Follow-up Among 527 Individuals 
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7.3.5 Change in Functional Bowel Disorder Diagnosis and IBS Cluster 
Membership Among Those No Longer Meeting Rome Criteria for IBS 
at Follow-up. 
Among the 104 individuals (16.5%) with Rome III IBS at baseline who no 
longer met Rome III criteria for IBS at 12-month follow-up, 34 (32.7%) met criteria for 
an unspecified functional bowel disorder, 31 (29.8%) functional abdominal bloating or 
distension, 28 (26.9%) functional diarrhoea, and 11 (10.6%) functional constipation. A 
comparison of change in functional bowel disorder diagnosis according to baseline IBS 
cluster is shown in Figure 7-8. When the baseline Rome III cluster model was applied to 
these individuals at 12-month follow-up, 87 (83.7%) were assigned to clusters with low 






Figure 7-8. Change in Functional Bowel Disorder Diagnosis at Follow-up 




Cluster 1: Diarrhoea and urgency with low psychological burden. 
Cluster 2: Low overall gastrointestinal symptom severity with high psychological 
burden. 
Cluster 3: Low overall gastrointestinal symptom severity with low psychological 
burden. 
Cluster 4: Diarrhoea, abdominal pain, and urgency with high psychological burden. 
Cluster 5: Constipation, abdominal pain, and bloating with high psychological burden. 
Cluster 6: High overall gastrointestinal symptom severity with high psychological 
burden. 
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7.3.6 Commencement of New Treatment and Consultation Behaviour 
According to Baseline IBS Cluster Among Those with Rome III IBS at 
Baseline and Follow-up. 
Overall, of the 527 individuals who continued to have Rome III IBS at follow-
up, 372 (70.6%) had commenced at least one new treatment during the 12-month 
follow-up period, of whom 174 (46.8%) changed IBS cluster at follow-up. Similarly, of 
the 155 people who did not commence any new treatment, 78 (50.3%) also changed IBS 
cluster at follow-up. Overall, there was no significant association between commencing 
a new treatment and changing IBS cluster at follow-up (p = 0.46). This remained the 
case when subcategories of treatment were examined, including commencing any 
medication for diarrhoea (p =0.61), any medication for constipation (p = 0.93), any 
medication for pain, including a central neuromodulator (p = 0.40), or any 
psychological therapy (p = 0.93). 
New treatments commenced by baseline IBS cluster are shown in Table 7-3. 
Only 34 individuals with Rome III IBS at baseline and follow-up reported receiving any 
form of psychological therapy, of whom 13 (38.2%) were in baseline clusters 
characterised by low psychological burden (clusters 1, 3, or 7). Overall, the mean 
number of treatments commenced was significantly higher in clusters with a high 
psychological burden (clusters 2, 4, 5, or 6) (p<0.001), and these clusters also had 
significantly higher rates of consultation with both GPs and gastroenterologists 
(p<0.001). The impact of symptoms at follow-up, in terms of patients reporting that 
they limited activities at least 50% of the time, was also significantly greater in clusters 
with high psychological burden at baseline (p<0.001). 
A significantly higher proportion of people in clusters with diarrhoea-related 
symptoms (clusters 1 or 4) commenced medication for diarrhoea (p<0.001), and, 
similarly, a significantly higher proportion of people in clusters with constipation-
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related symptoms (clusters 5 or 7) commenced medication for constipation (p<0.001). 
Finally, a significantly higher proportion of people in clusters characterised by high 
psychological burden (clusters 2, 4, 5, or 6) commenced medication for pain, including 
prescription of central neuromodulators (p = 0.013). 
7.4 Discussion 
The study reported in Chapter 6 used LCA to derive and validate a model to 
classify people with IBS into seven novel subgroups, or clusters, based on their pattern 
of gastrointestinal symptoms, extra-intestinal symptoms, and psychological profiles. 
The current longitudinal follow-up study has examined the natural history of these 
subgroups, investigating whether they are of prognostic value, and explored changes in 
cluster membership, by applying the baseline model to longitudinal data, collected after 
12-months, in the same cohort of people. Of those who provided follow-up data, 46% 
changed cluster at 12 months. Commencing a new treatment was not associated with a 
change in cluster membership. When cluster membership was stratified according to 
gastrointestinal symptoms, of those in a diarrhoea-predominant or constipation-
predominant cluster at baseline, around two-thirds remained in such a cluster at follow-
up. Of those who changed cluster, this was almost exclusively to a mixed-
gastrointestinal symptom cluster; transition between diarrhoea-predominant and 
constipation-predominant clusters, or vice versa, was rare. Of those in a mixed 
gastrointestinal symptoms cluster at baseline, three-quarters remained in such a cluster 
at follow-up. Cluster membership stratified according to psychological comorbidity was 
more stable; of those in a cluster with high psychological comorbidity at baseline, 84% 
remained in a cluster with high psychological comorbidity at follow-up. Findings with 
respect to those in a cluster with low psychological comorbidity at baseline were 
similar. This stratification was useful from a prognostic perspective; people in clusters 
with high psychological burden had more severe symptoms at follow-up, which had a 
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significantly greater impact on daily activities, commenced a higher mean number of 
treatments, and were more likely to consult with a doctor about their IBS compared with 
people in clusters with low psychological burden, irrespective of whether the Rome IV 
or III criteria were used to define IBS. 
This study recruited a large number of individuals in a community setting who 
self-identified as having IBS. Most had consulted a GP, some a gastroenterologist, and a 
small proportion had never sought medical advice for their symptoms. This implies that 
the participants, and the model that was derived from their data, will be generalisable to 
many individuals living with IBS. Moreover, and in contrast to other subgroup 
modelling studies in IBS, 26, 27, 59 the model has been validated, as described in Chapter 
6,  showing that it was likely to perform similarly if applied to other cohorts of patients 
with IBS. In addition, the questionnaire was completed using a web-based portal 
meaning that, for most variables of interest, data collection at baseline and 12-months 
was complete.  
Weaknesses include the fact that it was not possible to confirm the diagnosis of 
IBS in all individuals in this study using medical records. Consequently, because those 
participating believed that they had IBS, and met diagnostic criteria, it was assumed that 
they had the condition. It is important to acknowledge that some organic gastrointestinal 
disorders, such as coeliac disease or inflammatory bowel disease, can mimic IBS; 304, 
405-407 however, the community prevalence of these disorders in comparison to IBS is 
considerably lower. Moreover, over 95% of study subjects had consulted with a doctor 
regarding their symptoms. It is likely, therefore, that the majority of participants had 
undergone some investigation, in addition to clinical assessment, to rule out organic 
disease and did, therefore, genuinely have IBS. The response rate to the 12-month 
questionnaire was 57%, which is similar to other longitudinal follow-up studies of 
gastrointestinal disorders conducted over a similar time frame. 408-412 Responders were 
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older, less likely to smoke, more likely to be married or co-habiting, to have attained a 
university or postgraduate level of education, to be White Caucasian, and to have seen a 
doctor about their IBS symptoms. This indicates that the population that was studied at 
follow-up may not be representative of the original cohort of people that were recruited. 
However, comparison between responders and the original study participants in terms 
of symptoms, symptom severity, psychological comorbidity, and baseline cluster 
membership revealed no significant differences. Moreover, absolute differences in 
demographic data observed were relatively modest.  
Other investigators have also examined the possibility of subgrouping people 
with IBS using factors beyond stool pattern.26, 27, 59, 60 Although there is a consensus that 
people with IBS can be separated into distinct groups using a combination of 
gastrointestinal symptoms and psychological factors, the specific characteristics and 
number of subgroups varies between studies. The current treatment paradigm for IBS 
advocates targeting therapy according to predominant gastrointestinal symptom; 
however, extra-intestinal symptoms and psychological comorbidity, which are 
recognised as playing an important role in IBS symptomatology, are not considered as 
part of the current classification system for the condition. Consequently, knowing how 
best to tailor multimodal treatment, including use of psychological therapies, to the 
needs of the individual patient is difficult, and yet it seems likely that the pursuit of 
more personalised treatment in the care of those with IBS will be increasingly desirable. 
Crucially, no previous study investigating novel IBS subgroups has examined their 
natural history, in order to understand the clinical evolution of IBS, or whether they can 
be used to identify those with a worse disease course. If alternative approaches to 
subgrouping IBS, such as have been proposed, are to be incorporated into clinical 
practice and used to guide treatment, understanding these issues is key. 
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Overall, the findings of this study show that cluster membership changes over 
time; however, rather than being a disadvantage, this flexibility is a desirable feature of 
a classification system that could be used to direct treatment. Indeed, one would hope 
that patients could transition from clusters with a high symptom burden to those with a 
lower symptom burden, a trend that was observed among those individuals no longer 
meeting criteria for IBS at follow-up. Nevertheless, the reasons for changes in cluster 
membership are unclear. There was no association with commencing a new treatment 
and changes may, therefore, reflect natural fluctuations of symptoms over time. 
However, it is also important to consider that, due to experiencing improvements in 
their symptoms, some participants may not have responded to the follow-up 
questionnaire, and this will have affected assessment of natural history of the clusters. 
In contrast to studies investigating the stability of IBS stool subgroups alone, which 
have suggested that IBS-M is the least stable subgroup, 44-46 this study found that the 
proportion of individuals who remained in a mixed gastrointestinal symptoms cluster 
between baseline and follow-up was higher than the proportion remaining in either a 
diarrhoea-predominant or constipation-predominant group, respectively. However, in 
keeping with the findings of these previous stool subgroup stability studies, 44-46 very 
few participants transitioned from a diarrhoea-predominant cluster to a constipation-
predominant cluster, or vice versa.  
Changes in cluster membership might have been the consequence of alterations 
in underlying pathophysiological mechanisms which were not measured in this study. 
With respect to visceral sensitivity, it has been shown that, although patients with IBS 
are viscerally hypersensitive at baseline compared with healthy controls, repeated 
exposure to visceral stimuli over a 12-month period resulted in normalisation of visceral 
perception. 413 This was accompanied by a reduction in CNS arousal, despite continued 
activation of neural networks involved in processing visceral nociception. Crucially, 
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however, these changes notwithstanding, there was no accompanying change in either 
IBS symptom severity or psychological profiles. Overall, therefore, these findings 
suggest that changes in visceral sensitivity are unlikely to have a played a major role in 
determining changes in cluster membership and, furthermore, they emphasise that pain 
perception not only depends on neural nociceptive pathways between gut and brain, but 
also on psychological factors. 414 Another study conducted an integrated longitudinal 
analysis of the gut microbiome, metabolome, host epigenome, and transcriptome in 
patients with IBS compared with healthy controls. 415 Changes in the gut microbiome, 
and in microbial metabolites, appeared to underlie symptom flares in people with IBS 
and, therefore, these factors might have been drivers of transition from clusters with less 
severe gastrointestinal symptoms to those with more severe symptom profiles. 
Similarly, changes in immune function may also have played a role; symptom flares in 
people with IBS-D have been shown to be associated with significant reductions in both 
T-helper cell proliferation and concentrations of interferon gamma in peripheral blood 
samples. 416 
Treatments commenced appeared broadly appropriate for each cluster, but, 
interestingly, were not associated with a change in cluster membership. It is important 
to emphasise, however, that, although it is possible to examine treatment according to 
cluster, it was not directed in this way. Instead it was prescribed by the participants own 
clinicians, or obtained over the counter, presumably according to predominant 
gastrointestinal symptoms. Of note, a previous study investigating the effect of 
treatment on IBS stool subgroup stability specifically, in the same cohort, found that 
there was no association. 49 Moreover, because this study only collected data at two 
distinct time points, it is not possible to assess the temporal relationship between 
treatment and symptoms, or cluster membership. It is also difficult to assess the 
appropriateness of treatment for any individual, and whether this influences a change in 
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cluster membership. Some participants who were in a baseline cluster with diarrhoea, 
for example, received secretagogue drugs for constipation. This seems an inappropriate 
choice of drug therapy, but an individual’s symptoms might have changed from baseline 
to the point of commencing this treatment. In addition, it is difficult to assess the effects 
of different combinations of treatment.  
Regarding psychological comorbidity, it is interesting to note that those 
individuals in a cluster characterised by high psychological comorbidity at baseline 
largely remained in such a cluster at follow-up. Compared with a change in cluster 
membership stratified by gastrointestinal symptoms, cluster membership stratified by 
level of psychological comorbidity was more stable, and predicted higher numbers of 
subsequent treatments, as well as consultation behaviour and disease impact. Of note, 
despite there being 188 people in a cluster with high psychological comorbidity at 
baseline, the number of people receiving psychological therapies was very low, the 
emphasis being mainly on first line drug therapies, such as antidiarrhoeals and laxatives. 
This might partly reflect difficulties accessing these therapies, particularly for those 
individuals managed solely in a primary care setting. Nevertheless, these findings raise 
the question of whether addressing psychological health needs earlier, in conjunction 
with physical symptoms, might prove to be a more effective approach, which could 
have resulted in changes to cluster membership and reduced consumption of medical 
resources. 
In summary, this study has explored the natural history and prognostic value of a 
novel method of subgrouping people with IBS, described in Chapter 6, which uses a 
combination of gastrointestinal symptoms, extra-intestinal symptoms, and psychological 
comorbidity. Overall, although approximately half of those responding to the follow-up 
questionnaire changed cluster, further analysis revealed that there was little transition 
with respect to psychological comorbidity. Most people who were in a cluster with high 
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psychological burden at baseline remained in such as cluster at follow-up, and these 
appeared to predict disease course. Despite this, very few people reported receiving 
psychological therapies. To better understand whether formal approaches to 
subgrouping patients with IBS using factors beyond stool are helpful in directing 
treatment, a prospective study is needed. Such a study would allocate patients to a 
cluster at baseline using the model, which is a mathematical equation that can be easily 
applied in clinical practice, and then randomise them to receive targeted treatment 
according to cluster, or conventional physician-directed management according to the 
patient’s predominant symptoms, with symptoms, quality of life, and resource use 
compared between groups. Clusters with low gastrointestinal symptoms and high 
psychological burden would likely receive a psychological therapy, clusters with high 
gastrointestinal symptoms and low psychological burden a peripherally acting drug, and 
clusters with high gastrointestinal symptoms and high psychological burden a 
combination of psychological therapy and drugs, including centrally acting 
neuromodulators. Further investigation of this potential approach for the management of 
IBS is warranted as clinicians strive for ways to deliver high-quality and high-value 
personalised care, with the potential to improve outcomes, for people suffering with this 
chronic, and frequently debilitating, condition.
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Over the last 30 years, the Rome Foundation have sought to standardise and 
refine the definition of IBS used in clinical and research practice by creating symptom-
based diagnostic criteria called the Rome criteria. The most recent iteration, Rome IV, 
were published in 2016 and characterise IBS as the presence of abdominal pain in 
association with a change in stool frequency, stool form, or both. 14 In addition to 
making a diagnosis of IBS, the Rome criteria also stipulate that patients should be 
subgrouped according to their predominant stool pattern, be that IBS-C, IBS-D, or IBS-
M, as a means of directing symptom-specific treatments, such as dietary modifications, 
antidiarrhoeal drugs, or laxatives. 
Although gastrointestinal symptoms are central to making a diagnosis of IBS, 
they are not the only important consideration. Indeed, the Rome IV process reclassified 
IBS, and all other functional gastrointestinal disorders, as disorders of gut-brain 
interaction. This was in recognition of the complex interplay of biological, 
psychological, and social factors underpinning these disorders. 417 However, although a 
broad range of pathophysiological mechanisms and risk factors have been identified in 
IBS, including psychological comorbidities, alterations in visceral sensitivity, genetic 
factors, and changes in the gut microbiome, no single factor is universal to all patients. 
Moreover, it is likely that even among people with identical gastrointestinal symptoms, 
the underlying pathophysiology responsible for causing them varies, and this may be 
important for determining an individual’s response to certain drug therapies, or for 
predicting prognosis. Unfortunately, however, with the exception of psychological 
health, which can be assessed relatively easily using validated questionnaires, 
measurement of other factors is complicated both by the need for invasive testing, such 
as that required to evaluate visceral sensitivity, and by uncertainty regarding the clinical 
interpretation of results, a problem with respect to profiling the gut microbiome in IBS, 
for example. Nevertheless, whatever the deficits in current knowledge, subgrouping 
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patients and directing treatment according to gastrointestinal symptoms in isolation is 
almost certainly too simplistic, ignoring both the evidently multifaceted nature of IBS 
and failing to highlight patients liable to benefit from psychological therapies, for 
example.  
These issues are addressed to some extent by the Rome Foundation MDCP, a 
framework that encourages physician-led appraisal of a broader range of factors, 
including psychological health and the impact of illness, in addition to gastrointestinal 
symptoms during the assessment and treatment of anyone with IBS. 57 However, the 
MDCP is intended for use on a case-by-case basis only, and is not currently 
incorporated into diagnostic criteria for IBS. This thesis has therefore firstly examined 
the merits of directing treatment according to predominant stool pattern in isolation, by 
investigating the relative efficacy of drugs specifically designed for treating stool 
pattern abnormalities, among patients who were subgrouped in this way using the Rome 
criteria. It has subsequently investigated whether it is possible to subgroup people with 
IBS by including factors other than stool pattern alone, and whether differences exist 
depending on which iteration of the Rome criteria is used to define IBS. Finally, it has 
explored the natural history of these novel subgroups, including whether they are of 
prognostic value, in order to evaluate if this approach could lead to more personalised 
management of the condition.  
Over the past 15 years, a number of second-line drugs have been developed 
specifically for the treatment of IBS-C. These so-called secretagogues, such as 
lubiprostone, linaclotide, plecanatide, and tenapanor, which share common mechanisms 
of action, have all been shown to be effective in placebo-controlled trials. Likewise, for 
the treatment of IBS-D and IBS-M, a range of drug therapies have been developed with 
proven efficacy, and, although they differ in their pharmacology, they are all usually 
reserved as second-line treatments. Examples of these include alosetron, ramosetron, 
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eluxadoline, and rifaximin. Overall, the relative efficacy of these treatments remains 
unknown due to a lack of head-to-head trials and therefore two network meta-analyses 
were undertaken, one for treatments in IBS-C, and one for treatments in IBS-D or IBS-
M, to resolve this uncertainty. Both of these studies showed that the efficacy of these 
drugs is modest overall, with little to choose between individual treatments. This is 
despite them having been developed specifically to target stool pattern abnormalities in 
IBS and tested in patient populations that are homogeneous with respect to 
gastrointestinal symptoms, having been recruited using the Rome criteria. One possible 
explanation for these findings is that trial participants were differentiated by other 
factors, such as psychological comorbidities, which were not measured, but which 
might have had a bearing on clinical response to a peripherally acting drug. These two 
studies therefore reinforced the hypothesis that novel approaches to subgrouping people 
with IBS, which include these additional factors, may better reflect the complexities of 
the condition, and enable a more targeted approach to treatment, which might predict 
clinical response. 
In order to explore this further, a study was undertaken to recruit a large cohort 
of people in the community who self-identified as having IBS, and whose data were 
used to conduct cluster modelling to derive new IBS subgroups. Participants were 
evaluated according to both the Rome III and Rome IV criteria for IBS 
simultaneously.14, 32 This provided an opportunity to investigate whether there were 
differences in the clinical and psychological characteristics of people with IBS 
depending on how the disorder was defined. Indeed, the Rome IV criteria for IBS were 
made more restrictive than Rome III in order to increase their diagnostic specificity. 
Previous studies suggested that these changes had few implications; 40-42 however, two 
studies were unable to apply the full criteria simultaneously, and instead used a 
retrospective surrogate measure to approximate the Rome IV criteria. 40, 41 In contrast, 
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the study conducted as part of this thesis used both the Rome IV and III questionnaire 
side-by-side, and showed that people with Rome IV-defined IBS had more severe 
symptoms, which had a greater impact on daily life, and higher levels of psychological 
comorbidity, compared with people with Rome III-defined IBS. These findings 
highlighted that it would be necessary to evaluate whether different subgrouping models 
would be derived depending on which iteration of the Rome criteria was used to define 
IBS. 
Subsequently, LCA was used in the same cohort to investigate novel approaches 
to subgrouping people with IBS using factors beyond stool pattern alone. Only three 
studies had examined this issue previously, 26, 27, 59 and these had important limitations 
which this new study aimed to address. One study had included only a small number of 
patients recruited in a tertiary care setting thereby limiting generalisability, 26 and 
another used outdated definitions of IBS. 59 The third study recruited people who met 
Rome criteria for IBS in a population-based cross-sectional survey, rather than 
including them because they reported having IBS, or had received a diagnosis of IBS. 27 
Crucially, no study validated the subgrouping models they proposed, meaning it was 
unclear whether the models were applicable to other people with IBS, or were specific 
only to the cohorts in which they were derived.  
The LCA study reported in this thesis found that people with IBS could be 
divided into seven unique subgroups, or clusters. These were differentiated according to 
the presence of certain gastrointestinal symptoms, including stool pattern, and 
abdominal pain that was not relieved by defaecation, as well as by the presence of extra-
intestinal symptoms and abnormal mood. Despite the aforementioned differences in 
diagnostic criteria, these seven clusters were reproducible, irrespective of whether IBS 
was defined according to the Rome III or Rome IV criteria. The subgrouping models 
were validated internally, demonstrating that they would be expected to perform 
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similarly if applied to a different dataset. Moreover, a large number of individuals were 
included in the LCA, all of whom were in the community and self-identified as having 
IBS. Some individuals had consulted in primary care, some in secondary care, and some 
had never seen a doctor, meaning that the clusters were likely to be generalisable to 
many individuals living with IBS. 
The characteristics of the seven IBS clusters were diverse. These differences 
might explain why response to a drug targeted at predominant stool pattern in IBS is so 
variable in clinical practice. A more personalised approach to management, which 
addresses psychological health needs in conjunction with gastrointestinal symptoms, 
may therefore be needed. In order to explore this further, a longitudinal follow-up study 
was undertaken, examining the natural history of these novel subgroups and assessing 
their prognostic value. Overall, this showed that, of those who responded to the request 
for follow-up data at 12-months, around half changed cluster; however, cluster 
membership stratified according to psychological burden was more stable. Indeed, of 
those in a cluster with high psychological burden at baseline, over 80% remained in 
such a cluster at follow-up. Moreover, from a prognostic perspective, people in clusters 
with high psychological burden at baseline had more severe symptoms at follow-up, 
which had a significantly greater impact on daily activities, commenced a higher mean 
number of treatments, and were more likely to consult with a doctor about their IBS, 
compared with people in clusters with low psychological burden, irrespective of 
whether the Rome IV or III criteria were used to define IBS. Theoretically, directing 
treatment according to these clusters, including earlier use of psychological therapies, 
might alter disease course and improve outcomes in IBS. 
The work undertaken in this thesis has highlighted several areas that could be 
the focus of further research. Firstly, although it can be speculated that using these new 
subgrouping models to personalise the management of IBS may improve outcomes, 
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additional studies are needed to test this hypothesis. As discussed, a prospective study 
could allocate people with IBS to a cluster at baseline using the model, and then 
randomise them to receive targeted treatment according to cluster using a predefined 
algorithm, or conventional physician-directed management according to the patient’s 
predominant symptoms. Clinical outcomes, in terms of improvements in gastrointestinal 
symptoms, psychological health, and quality of life, could be compared between groups, 
as could use of healthcare resources. Second, if future treatment trials are able to collect 
the data necessary to enable the application of these models for subgrouping 
participants, secondary analyses could be conducted to examine whether there is any 
difference in clinical outcomes between clusters with individual treatments tested. 
Third, although the subgrouping model in this thesis has included measures of 
psychological health in addition to gastrointestinal symptoms, if it were also possible to 
incorporate data regarding other pathophysiologies or risk factors, this might improve 
the ability of the model to describe the complex nature of IBS, and provide further 
insights into factors responsible for governing treatment response and prognosis. 
Gathering pathophysiological data from large cohorts of people is likely to be 
logistically challenging; however, smaller hypothesis-generating pilot studies could be 
conducted, which start by cross-tabulating pathophysiological data using the existing 
seven subgroup model in order to explore possible trends and associations. Finally, 
although IBS is among the most prevalent of the functional gastrointestinal disorders, it 
is one of over 30 such conditions that have been categorised by the Rome Foundation. 
Like IBS, these other conditions, such as functional dyspepsia or functional 
constipation, are also defined using symptom-based criteria, and are considered to be 
disorders of gut-brain interaction, with a complex pathophysiology. 417 Exploration of 
novel approaches to subgrouping people with these other disorders should be 
considered, and may reveal common themes, such as the relevance of psychological 
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health, which may change, fundamentally, the way these disorders are categorised and 
managed in the future.  
In summary, this thesis has investigated new approaches to subgrouping people 
with IBS that look beyond stool pattern alone. It has been demonstrated that people with 
IBS can be divided into seven unique subgroups based on a combination of 
gastrointestinal symptoms, extra-intestinal symptoms, and mood. The diversity of these 
subgroups highlight the complex nature of IBS, and might partly explain why the 
clinical response to drugs targeted at predominant stool form in isolation is relatively 
modest, as has been summarised in two complementary network meta-analyses. These 
novel subgroups were reproducible, irrespective of whether IBS is defined according to 
the Rome III or Rome IV criteria. This is despite analysis showing that gastrointestinal 
symptoms are more severe, and psychological health is poorer, among individuals with 
Rome IV-defined IBS compared with those with Rome III-defined IBS. Longitudinal 
follow-up over 12 months demonstrated little transition between subgroups with respect 
to psychological burden, and these appeared to predict a more severe disease course. 
Directing treatment according to these novel subgroups, including earlier use of 
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